Cellular nanoparticle delivery by G-protein coupled receptors by Hild, Wolfgang
  
 
- 1 - 
 
 
Cellular Nanoparticle Delivery by  
G-Protein Coupled Receptors  
 
 
 
 
 
Dissertation to obtain the Degree of Doctor of Natural Sciences  
(Dr. rer. nat.)  
from the Faculty of Chemistry and Pharmacy  
University of Regensburg  
 
 
 
 
 
 
Presented by  
Wolfgang Hild 
from Landshut  
 
March 2010 
This work was carried out from May 2005 until April 2009 at the Department of 
Pharmaceutical Technology of the University of Regensburg.  
 
 
 
The thesis was prepared under supervision of Prof. Dr. Achim Göpferich.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submission of the PhD application:    19.03.2010  
Date of examination:      07.05.2010  
Examination board:   Chairman:   Prof. Dr. S. Elz  
1. Expert:   Prof. Dr. A. Göpferich  
2. Expert:   Prof. Dr. J. Heilmann 
3. Examiner:  Prof. Dr. F.-M. Matysik 
 
  
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A pessimist sees the difficulty in every opportunity, an optimist sees the opportunity 
in every difficulty           - Winston Churchill 
Winston Churchill 
Cellular Nanoparticle Delivery by G-Protein Coupled Receptors 
- 5 - 
Table of contents 
 
Chapter 1 Introduction ....................................................................................7  
Chapter 2 Goals of the Thesis .....................................................................51 
Chapter 3 Synthesis of Quantum Dots – Comparison Between 
 Non-coordinating and Coordinating Solvents...............................55 
Chapter 4 Solubilization and Characterization of  
 Quantum Dots for Biological Applications ....................................79 
Chapter 5 Characterization of Aqueous Quantum Dot  
 Dispersions using Asymmetrical Flow  
 Field-flow Fractionation (AF4) ....................................................105 
Chapter 6 Cell-culture Characterization of Quantum Dots..........................121 
Chapter 7 G-Protein Coupled Receptor Targeted Micelles.........................137 
Chapter 8 G-protein Coupled Receptor Targeted Nanoparticles  
 Allow for Choosing between Membrane Binding 
 and Cellular Uptake ...................................................................155 
 Supporting Information...............................................................175 
Chapter 9 Towards the Characterization of the Mechanism of Internali- 
 zation of QDs Targeted to Neuropeptide Y Y1 -receptors .........185 
Chapter 10 Summary and Conclusions .......................................................203 
 
Appendix Abbreviations .............................................................................211 
 Curriculum Vitae ........................................................................215 
 List of Publications .....................................................................216 
 Acknowledgements....................................................................218 
  
 
Cellular Nanoparticle Delivery by G-Protein Coupled Receptors 
 
 
 
 
Chapter 1 
 
 
Introduction: 
Quantum dots – Nano-sized Probes for the 
Exploration of Cellular and Intracellular Targeting 
 
 
W. A. Hild,  M. Breunig, A. Göpferich 
Department of Pharmaceutical Technology, University of Regensburg, 
Universitätsstraße 31, 93040 Regensburg, Germany 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
European Journal of Pharmaceutics and Biopharmaceutics 68 (2008) 153–168 
Chapter 1 Introduction 
 
- 8 - 
Abstract 
Nanoparticles emerged as promising tool in drug targeting, since, after appropriate 
modification, they are able to deliver their payload to specific sites, like tissues, cells, 
or even certain cellular organelles. In this context, the delivery of nanoparticles from 
the circulation into the target cells represents a crucial step. Here, model drug 
delivery systems such as quantum dots are ideal candidates to elucidate this process 
in more detail, since they provide outstanding features like a small and uniform size, 
unique optical properties for most sensitive detection and modifiable surfaces.    
Recent progress in the surface chemistry of quantum dots expanded their use in 
biological applications, reduced their cytotoxicity and rendered quantum dots a 
powerful tool for the investigation of distinct cellular processes, like uptake, receptor 
trafficking and intracellular delivery.  
In this review, we will not only describe the ideal attributes of QDs for biological 
applications and imaging but also their distinct specific and non-specific pathways 
into the cells as well as their intracellular fate.  
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1. Introduction 
In contemporary drug therapy, most drugs are designed to bind to specific receptors 
or receptor subtypes. However, these drugs still lack selectivity for specific sites in 
the human body, namely specific cells, tissues or organs since the receptors may be 
expressed at various sites of the body. In addition, modern drugs tend to have 
unfavorable pharmacokinetic properties. As a consequence, the dose of the drug has 
to be increased. However, this raises the cost of the therapy as well as side-effects. 
In some cases, the design of prodrugs can improve this situation but, so far, we are 
far from a general solution. 
A more promising solution to this problem can be expected by targeted nanoparticles 
for site-specific drug delivery [1]. Under ideal circumstances, these drug carriers, 
mediated by a targeting sequence, should deliver their payload only to specific target 
cells, tissues or organs [2].  
Nanoparticles are tools that can compensate for unfavorable physico-chemical 
properties of the drug and therefore may optimize the bioavailability and the 
biodistribution of the drug. However, after their application to the circulation such 
particles face several obstacles until they are able to reach their destination. First, the 
particles have to escape from the reticulo endothelial system (RES) consisting of 
phagocytosing cells. These are mainly located in the liver, the spleen and the bone 
marrow, which rapidly remove “foreign” particles from the circulation. The recognition 
of nanoparticles by the RES can be reduced by modifying the surface of the particles 
with “protein repulsive” molecules, such as polyethylene glycol (PEG) [3,4]. Apart 
from that, the particles will have to pass biological barriers like the endothelium or 
they will have to penetrate tissues. Both processes, however, require small, 
nanoparticulate drug delivery systems of optimal size. Additionally, targeting 
sequences on the particle surfaces are needed to address the drug carrier to specific 
cells [5]. Last but not least, when the nanoparticles have reached the target cell, the 
final question still remains unanswered: How can the drug be delivered into the cell, 
in case of an intracellular site of action?  
To obtain detailed information on the particle design for optimized intracellular drug 
delivery, well-defined model colloids are necessary, since the pathways for 
nanoparticles into cells strongly depend on the properties of the colloid itself like its 
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size. The importance of this is emphasized by the fact that the different pathways for 
the cellular uptake of a colloid already determine its fate inside the cell [6]. Another 
crucial parameter is the surface composition of the nanoparticles. As an example, 
protein repulsive molecules on the surface of the colloid, like PEGs, can mask the 
particles for cells. As a consequence, non-specific cellular particle uptake [7] beyond 
specific mechanisms, like receptor-mediated endocytosis, can be reduced. This fact 
is crucial to obtain specific targeting to the desired cell type. A last, obvious 
requirement for the model colloid is that it must be easily detectable, e.g. by 
fluorescence, in order to follow its cellular uptake and intracellular accumulation in 
certain organelles.  
Unfortunately, conventional nanoparticles, like polymer-based ones, often possess 
quite broad size distributions, which limit the use of these particles for the 
examination of the cellular uptake and intracellular distribution. When these particles 
are tagged with fluorescent dyes, this can also change the physico-chemical 
properties of the particles significantly. 
Quantum dots (QDs), fluorescent, semiconductor nanoparticles, overcome these 
problems due to their small size, narrow size distribution, and unique optical 
properties. This enables the investigation of size-dependence of cellular uptake and 
the detection of the particles due to their fluorescence. Furthermore, these 
nanoparticles can be modified with a number of targeting ligands. Taken together, 
these properties render QDs ideal model colloids to study the cellular uptake and 
intracellular targeting of nanoparticles.  
In this review, we show that QDs are used to answer particular questions in the realm 
of cellular nanoparticle delivery, like what is the optimal size of a particle for 
endocytosis [8], how can non-specific uptake of particles be reduced by surface 
PEGylation [9], or which receptors can mediate specific uptake of colloids [10,11]? 
Other approaches focus on how specific organelles can be targeted by QDs, once 
the particles have arrived inside a cell [12,13]. Dividing the complex field of drug 
targeting with nanoparticles into such distinct questions, which can be answered by 
using well-defined, QD-based colloids, will promote the progress in this research 
area.   
The review is structured as follows: after a short overview of the properties and 
advantages of QDs, we will show how these particles can be modified in order to use 
them for the analysis of specific cellular uptake. This will be followed by a 
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presentation of the distinct pathways for cellular uptake and intracellular delivery of 
nanoparticles. In the next section, an overview of approaches of cellular uptake 
studies as well as of organelle targeting with QDs will be given. Finally, possibilities 
for further developments in intracellular drug targeting using QDs will be presented.         
2. Non-invasive imaging using nanoparticles 
For the development of drug targeting systems, non-invasive imaging technologies 
play a key-role, since they allow for following the fate of nanoparticles inside 
biological systems, like cells, tissues or whole organisms.   
Non-invasive imaging of nanoparticles includes a number of techniques, like positron 
emission tomography (PET), single photon emission computed tomography 
(SPECT), magnetic resonance imaging (MRI) and optical imaging. These techniques 
differ concerning their sensitivity, resolution complexity and demands on personnel 
and equipment (for more detailed information see [14, 19]) 
In order to investigate the interactions between nanoparticles and biological systems,  
particles of well-defined size and size distribution are required, as presented above. 
Three widely used systems provide these properties: colloidal gold [14], 
superparamagnetic iron oxide particles (SPIONs) [15] and semiconductor 
nanocrystals (QDs) [10]. However, these particles show great differences in their 
detectability, which is the second, important demand on a model colloid. All of these 
particles can be detected by transmission electron microscopy. Yet, this technique 
requires the fixation of the cells which does not allow for studies of dynamic 
processes in living cells. SPIONs can additionally be detected by MRI. This 
technique proves especially favorable in deep-tissue and in vivo imaging. Though, 
the resolution of this technique is not suitable for the investigation of processes on 
the cellular level (see table 1). 
QDs, on the other hand, offer some advantages in imaging cell-particle interactions. 
They can be detected easily by (confocal) fluorescence microscopy which is most 
preferable for the observation of distinct cellular processes, like endocytosis and 
intracellular trafficking. The high resolution, sensitivity and versatility of fluorescence 
detection render QDs the most suitable of these three systems for the described 
application.  
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 Transmission electron 
microscopy (TEM) 
Magnetic resonance 
imaging (MRI) 
Fluorescence laser 
scanning  microscopy 
(CLSM) 
applications in vitro imaging 
(cell fixation required) 
deep-tissue in vivo- 
imaging [16] 
 
intracellular imaging 
In vivo imaging [17] 
resolution visualization of  sub-
cellular distribution [18]  
sensitivity and resolution 
(10-100µm) not for sub-
cellular processes [19] 
high resolution (to the 
single molecule level) 
[11,20] 
imaged 
nanoparticles 
gold, superparamagnetic 
iron oxide, quantum dots   
superparamagnetic iron 
oxide 
quantum dots 
Table 1: Comparison of imaging technologies for different types of nanocrystals 
3. Properties of QDs for optical imaging 
QDs -small (1-10 nm) semiconductor nanocrystals- have attracted increasing 
attention due to their unique optical properties as compared to conventional organic 
fluorescent dyes. QDs possess a bright fluorescence, which means that they can 
absorb light efficiently due to their large extinction coefficient together with high 
quantum yields (up to 85% [21]), which is the ratio of the number of photons emitted 
to the number of photons absorbed. Together with their high stability with regard to 
photobleaching as compared to conventional fluorophores, QDs enable high 
sensitive detection and long observation times in fluorescence microscopy [22]. What 
is more, QDs have a large stokes shift, which is the difference between the 
wavelength of absorbed and emitted light. They also exhibit narrow emission spectra 
[23] as compared to conventional organic fluorescent dyes. As a consequence, the 
fluorescence signal of QDs can easily be separated from the light of the excitation 
source. In addition, these unique optical properties allow for multiple-color imaging 
without crosstalk between different detection channels in fluorescence microscopes. 
Additionally, QDs of different emission maxima can be excited by one single 
wavelength [24], which eliminates the need for numerous excitation sources in the 
instrumental setup. The relatively long fluorescence lifetime (20-50 ns [25]) enables 
time-resolved detection of the QD-fluorescence which can significantly increase the 
signal-to-background ratio (factor of 15) relative to cell auto-fluorescence [26]. 
The range of the fluorescence maxima of QDs is determined by their elemental 
composition and extends over the whole visible spectrum (e.g. CdS and CdSe) to the 
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near infrared (NIR; e.g. CdTe). Furthermore, within the emission range given by the 
elemental composition, the emission maximum of QDs can be tuned precisely by 
adjusting the size of the QDs. Smaller QDs emit light of lower wavelengths than 
larger particles. For example, the emission maxima of CdSe nanocrystals of 3 and 7 
nm in diameter are approximately 550 and 650 nm, respectively [27]. The so-called 
QD cores then usually are covered by a shell of another semiconductor, mostly ZnS 
[21,28,29] (figure 1). The thus generated core-shell QDs provide enhanced quantum 
yields as compared to the blank cores [30]. An interesting phenomenon is the so-
called “blinking”, an on-off behaviour of the luminescence signal of the QDs. This 
phenomenon is caused by charge trapping and un-trapping at surface defects during 
excitation and results in an alternation of bright and dark states during which no 
photons are emitted [31]. Blinking can be a limiting factor for detection but can also 
represent a useful fingerprint, for example to follow trafficking of receptors labeled 
with QDs [20].  
Antibody
QD core
Passivation shell
Peptide
Small ligand
Hydrophilic
coating
 
Figure 1: Scheme of a QD for biological application. The nanocrystal core (e.g. 
CdSe) is passivated by another semiconductor shell (e.g. ZnS). The QD-surface is 
covered by a hydrophilic coating which enables conjugation to biological active 
compounds (e.g. antibodies, peptides or small ligands, here depicted for folic acid). 
Recent developments in QD technology also expanded the applicability in the field of 
in vivo imaging, especially of small animals. Important advances in this field have 
been achieved by the use of NIR emitting QDs [32] since the penetration of NIR light 
into tissues is significantly higher than light of lower wavelengths, which is scattered 
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and absorbed by the tissue [33; 34]. An increase in detectability can also be achieved 
by combining the unique optical properties of the QDs with MRI traceability 
[35,36,37], which further enhances the possibility of tissue imaging. Another 
approach to improve the detectability of QDs in-vivo is given by so-called self-
illuminating QDs. Here, no excitation source is needed since using the phenomenon 
of bioluminescence resonance energy transfer (BRET), a bioluminescent molecule 
coupled to QDs serves for the excitation of the QDs. As a consequence, the 
sensitivity of detection and the signal-to-background ratio in vivo is enhanced [38]. 
4. Surface modifications and bioconjugation of QDs 
Unmodified QDs cannot be used for cellular studies since, after most of the QD 
synthesis strategies, the particles are water-insoluble. Therefore, to make use of their 
unique properties, the particles have to be modified on the surface. Additionally, the 
particles have to be conjugated with cell-specific biomolecules like proteins or 
peptides, in order to investigate specific uptake mechanisms and intracellular 
targeting. 
QDs are mostly synthesized in non-polar organic solvents and are solubilized in 
these solvents by hydrophobic surface ligands like aliphatic phosphines and 
phosphine oxides, fatty acids and aliphatic amines. For solubilisation in aqueous 
buffers, the hydrophobic QD-surface needs to be modified by a hydrophilic coating 
(figure 1). This coating additionally has to prevent aggregation of the QDs, e.g. by 
electrostatic stabilization or by steric repulsion between the particles mediated by a 
polymer coating. The hydrophobic surface ligands can be exchanged by thiol-
containing molecules [10,39], oligomeric phosphines [40], dendrons [41], or peptides 
[42,43]. Other approaches encapsulate the QDs in a silica shell [44] or use 
hydrophobic interactions between the QDs and amphiphilic polymers [45,46] or 
phospholipids [47] for modification (for a more detailed review, see [48]).  
Since the QDs are supposed to be used for the investigation of distinct cellular 
uptake processes, the particles have to be connected to biomolecules like peptides 
or proteins, which can address the colloid to certain structures on the cell surface, 
like receptors. Therefore, the surface of the QD colloid must also provide functional 
groups or other reactive sites which can react with the biomolecules (figure 1).  
There are several possibilities for the attachment of biomolecules to QDs. A 
commonly used strategy is the use of QDs containing streptavidin because they can 
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easily be linked to biotin-tagged biomolecules [11,20,24,49] (figure 2A). Yet, since 
streptavidin is quite bulky (~ 60 kDa) and can bind four biotin molecules, steric and 
size aspects have to be considered. Hence, small covalent linkages are often 
preferred when the particle size of the QD bioconjugate is critical for the application, 
for example when intracellular pores have to be crossed or cellular transport proteins 
are targeted. Such covalent bonds can be formed by carboxylic acids, for instance 
provided by a mercapto acid coating of the QDs. The mercapto groups of such acids 
can bind to the QDs while the carboxylic acid functions can form stable amide bonds 
with amines in presence of coupling reagents, like carbodiimides and N-
hydroxysuccinimides (NHS) [10,50] (figure 2B).  
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Figure 2: Examples for bioconjugation of differently functionalized QDs to 
biomolecules by various strategies. For details, please see text. 
Stable, covalent bonds can also be formed between maleimides and thiols, resulting 
in a thioether between QDs and biomolecules [47,49,51] (figure 2C). 
Heterobifunctional crosslinkers, like sulfosuccinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (sulfo-SMCC), can be used to couple thiol-containing 
biomolecules with amine-coated QDs [47], or vice versa [52]. Thiol groups in proteins 
or peptides are provided by cystein residues or, after thiolation, e.g. by iminothiolane 
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[53]. Functionalization of QDs stabilized with thiols can also be achieved by a thiol-
exchange with biomolecules containing a sulfhydryl group [53]. After incubation, 
equilibrium of the thiols on the QD surface is achieved resulting in partial substitution 
of the initial coating molecules by the biomolecules. Electrostatic interactions 
between the QD-surface and peptides or proteins (figure 2D) can also be used for 
coating and linkage [54,55] (for reviews see [56,57]). 
5. Cytotoxicity of QDs 
Since QDs are supposed to be used for studies at living cells and organisms, these 
particles have to be characterized concerning their biocompatibility. As compared to 
other nanoparticles, like gold or iron nanoparticles, which have been used for several 
decades and which proved to be biocompatible [58,59], QDs are quite new materials 
and have not been completely characterized with regard to their toxicity. Most of the 
QDs used for biological applications contain the heavy metal cadmium, known to 
cause toxic effects, when in contact with cells. Derfus et al. showed for hepatocytes 
that oxidation of Cd on the QD surface and subsequent Cd2+ release, e.g. mediated 
by air or UV light, is one possible mechanism responsible for QD cytotoxicity [60]. 
Consequently, the next step was to protect the QD core, as described above, by a 
shell of much lower toxicity, in most cases ZnS, which resulted in a significant 
reduction of cytotoxic effects [60,61]. As this layer also improves the optical 
properties, core-shell systems have become standard in most biological applications. 
But the introduction of capping layers was still not sufficient to solve the problem of 
cytotoxicity completely. Various other factors, like the aggregation of particles on the 
cell surface [62] and even the stabilizing QD surface ligands were shown to impair 
cell viability [63]. Hence, choosing an appropriate surface coating is also important, 
since simple coatings, like thiol containing carboxylic acids, present a minor diffusion 
barrier for Cd2+. Additionally, thiol-coated QDs, in addition, are known for their poor 
colloidal stability [44,64], and therefore, the introduction of inert and stable, 
macromolecular or cross-linked surface coatings was an important improvement. 
This concept has been realized by several workgroups. For instance, Dubertret et al. 
integrated QDs in PEG-containing phospholipid micelles and microinjected them into 
early-stage Xenopus embryos [47]. The development of the embryos was observed 
and it did not show toxic effects when 2 x 109 QDs per cell were injected. However, at 
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higher concentrations (>5 x 109 QDs per cell) abnormalities (cell size, cell death, cell 
movement and axis elongation) became apparent. Other coatings, like silica 
encapsulation or polymer coating [62], can also serve for fairly non-toxic 
modifications. Finally, the recent replacement of the toxic elements of the 
semiconductors by more biocompatible ones is a next step towards low-toxic QDs 
[61,69].  
Besides the toxic effects of the elemental building blocks, cell death can be induced 
by the formation of reactive oxygen species (ROS) [70-72], since QDs can transfer 
absorbed optical energy to oxygen molecules. Free radicals can cause damage to 
DNA [73] and other cellular components and as a consequence induce apoptosis 
and necrosis.   
Surprisingly, in most of the studies of QDs in live cells there was no significant 
influence on cell viability, morphology, function or development in the used 
concentrations (ranging from nM to µM) [24,51,54,65-68]. So far, few data on the 
toxicity of QDs, especially for in vivo applications, are available. Therefore, this 
toxicity remains the main limitation for the use of QDs. Several questions remain 
unanswered, like the clearance of the particles from the circulation and tissues and if 
there are long-term effects on gene expression. First gene arrays after the incubation 
of fibroblasts with silanized, PEGylated QDs, however, indicate low cytotoxicity when 
the QDs have an appropriate surface modification [74].  
6. Cellular particle uptake – a decisive step for intracellular particle 
delivery 
When nanoparticles in general or QDs as model colloids have to be delivered into 
specific cells, two aspects have to be considered: first, specific cell-surface structures 
have to be addressed and, second, an appropriate pathway into the cell must be 
found.  
As numerous factors influence the uptake and the intracellular delivery of particles, 
like the size and the surface charge of the particles [75], the particle design requires 
a profound understanding of the cellular mechanisms. Additionally, there are many 
ways leading inside a cell but the pathway chosen for delivery itself can already 
determine the fate of the colloid inside the cell [76]. After clathrin dependent uptake, 
for instance, particles are trapped in endosomes and can further be degraded in 
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lysosomes or be exocytosed [7]. Hence, for a better understanding of these 
processes, in the following section the most widely used cellular uptake-mechanisms 
for delivery of nanoparticles will be described. After this general section, concrete 
approaches of non-specific and specific cell targeting with QDs will be presented. 
6.1 Gateways for cellular uptake and QD delivery 
For intracellular delivery of nanoparticles, it is helpful to take a closer look at the 
uptake-mechanisms of the cells which are subsumed under the global term 
endocytosis. By this process, macromolecules and small particles are transported 
across the plasma membrane. Cells use these pathways for the supply with 
nutrients, for intercellular communication and for immune response as well as for 
other essential functions, but these highly-developed routes can also be exploited to 
deliver other kinds of freights, like drug-loaded nanoparticles or QDs. According to 
the mechanism of endocytosis, this process can be subdivided into two major 
categories: phagocytosis, which is the uptake of large particles, and pinocytosis, 
which is the uptake of fluid and solutes (figure 3; for review, see [76]). While the first 
mechanism is only typical for specialized mammalian cells, like macrophages, 
monocytes and neutrophils, pinocytosis can be found at every cell. Pinocytosis can 
be further classified into at least four mechanisms: macropinocytosis, clathrin-
mediated endocytosis, caveolae-mediated endocytosis and clathrin- and caveolae-
independent endocytosis (figure 3). Macropinocytosis represents an efficient route for 
non-selective endocytosis of solute macromolecules. The formation of 
macropinosomes (diameter up to 5 µm) is started by actin-driven ruffling of the cell 
membrane which is induced by growth factors or other signals. The membrane 
protrusions engulf large volumes of extracellular fluid [78]. Micropinocytosis is 
preferred for the uptake of smaller particles. The different uptake-mechanisms result 
in differently sized vesicles and can be classified into clathrin- (~120 nm), caveolin- 
(~60 nm) or clathrin- and caveolin-independent endocytosis (~90 nm). Clathrin-
mediated endocytosis (specified later) is the most important mechanism for receptor-
mediated uptake, occurs in all mammalian cells and plays an important physiological 
role, for example in mediating the uptake of low-density lipoprotein (LDL).  Caveolae, 
small flask-shaped invaginations in the plasma membrane, can most notably be 
found in endothelial cells, smooth muscle cells and adipocytes. Their physiological 
role is still being discussed (e.g. cholesterol uptake, solute transport and tumor 
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suppression) [79]. Pathogens, e.g. the SV40 virus [80], are also able to enter cells via 
caveolae which do not fuse with lysosomes after endocytosis, which enables their 
entry into the cell without impairing their activity in the acidic environment of 
lysosomes. This fact makes endocytosis via caveolae interesting for nanoparticle 
delivery, since compared to other mechanisms, the particles are neither entrapped in 
endosomes nor degraded in lysosomes and therefore can directly head for their 
intracellular targets. However, it is more complicated as caveolae uptake can also 
result in delivery to the Golgi complex and to the endoplasmic reticulum as well as in 
discharge of the particles by transcytosis [81].  
Clathrin- and caveolin-independent endocytosis is only described for a few examples, 
e.g. for the recovery of membrane proteins in neurons or the internalization of the 
interleukin-2 (IL-2) receptor on lymphocytes [76]. It is still unclear how this not clearly 
defined way of endocytosis can be selectively addressed by nanoparticles. QD-
based colloids could help to investigate these ways of uptake due to their small size, 
narrow size distribution and easy detectability. 
Phagocytosis Pinocytosis
Macropinocytosis
Clathrin-
mediated
endocytosis 
(CME)
Caveolin-
mediated
endocytosis
Clathrin- and 
caveolin-
independent 
endocytosis
 
Figure 3: Survey of different endocytic pathways. The pathways can be classified 
by the mechanism of vesicle formation, the nature and the size of the cargo (for 
details, please see text). Adopted from [75]. 
6.2 Receptor-mediated endocytosis 
One pathway for active and selective transport of nanoparticulate systems into the 
cell is exploited in many applications – the receptor mediated endocytosis [82-84]. 
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This is due to the fact that a number of ligands specific for certain receptors is known 
and that this pathway allows for a 1000-fold increase of the intracellular concentration 
of macromolecules, rendering this form of uptake very effective. The most frequent 
form of receptor-mediated endocytosis is the clathrin-mediated endocytosis (CME) 
[77] (figure 4). This process begins with the binding of a ligand to a specific cell 
surface receptor, followed by the clustering of the ligand-receptor complexes in 
coated pits, which are formed by the assembly of cytosolic coat proteins, mainly 
clathrin. The coated pits then invaginate and pinch off of the plasma membrane, 
aided by dynamin, to form intracellular clathrin coated vesicles (CCVs). After 
depolymerisation of clathrin, the endosomes are acidified due to proton influx which 
leads to late endosomes. In this state, the ligands dissociate from the receptors and 
are subsequently either released from the endosome or degraded after the fusion of 
the late endosomes with lysosomes [7,76,85]. A crucial prerogative for intracellular 
particle delivery is the endosomal release of the particles, otherwise the particles will 
be degraded. A possible solution to this problem can be the use of pH-sensitive 
polymeric building blocks for the nanoparticle design [86-89].  
QDs which were delivered into cells by CME are for example connected to 
transferrin, growth factors or folic acid. Details of these approaches will be described 
later. 
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Figure 4: Clathrin-mediated endocytosis. (1) Ligand binds to a specific cell surface 
receptor. (2) Invagination of cell membrane, clustering of the ligand-receptor 
complexes and (3) formation of clathrin-coated pit. After pinching off of the cell 
membrane the ligand-receptor complexes are sequestered in clathrin-coated vesicles 
(4). Clathrin depolymerizes and proton influx acidifies the early endosomes (pH ~6) 
(5). Several early endosomes can fuse to build late endosomes (pH ~5) (6) from 
which the receptors can be recycled after release of the ligand (7) or fuse with 
lysosomes (8) leading to degradation. Adopted from [7]. 
6.3 Protein transduction domains 
Another pathway into cells which is clathrin-independent and which attracted growing 
attention during the last decade is mediated by protein transduction domains (PTDs). 
This cell delivery system enables the transport of certain peptides and proteins [90], 
liposomes [91,92] and nanoparticles [93,94] across the cell membrane. QDs have 
also been successfully delivered via PTD, examples of which will be given later.  
In literature, also the term cell penetrating peptides (CPPs) is used for both peptides 
and proteins of this class. For every cell type PTDs can be found which can deliver 
proteins into these cells. Additionally, PTDs are able to cross the blood brain barrier 
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and can even enter intracellular sites and the nucleus though the exact mechanism 
for the cellular uptake has not been completely resolved, yet [95,96].  
An important sample is the TAT PTD [97], derived from the TAT protein from the 
human immunodeficiency virus (HIV-1), which is able to deliver proteins into cells. 
Other PTDs, like the third α-helix of Antennapedia homeodomain and VP22 protein 
from herpes simplex virus, can also serve as vector for protein delivery in vivo [95].  
Morris et al. enhanced the possibilities of peptide transfection by engineering the 
peptide carrier Pep-1. This 21-residue peptide consists of two domains which are 
separated by a spacer. A tryptophan-rich domain allows for efficient cell membrane 
translocation and the hydrophilic lysine-rich domain, derived from the simian virus 40 
(SV-40) T large antigen nuclear localization sequence (NLS), facilitates solubility and 
intracellular delivery [98]. 
Contemporary research deals with the question, if delivery mediated by PTDs does 
not end in endosomes, unlike CME [95]. This would enable more effective 
intracellular delivery. However, this form of uptake is non-specific which may also be 
desirable if a collective of cells has to be addressed effectively, especially in vitro. But 
the lack of selectivity can also be a limiting factor for drug targeting in vivo.  
7. Non-specific particle uptake 
Non-specific uptake of QDs, which is not mediated by certain targeting moieties, can 
be desirable for simply labeling a collective of cells, for example for in vivo 
applications in which cells are needed to be identified within an application. The 
following approaches demonstrate, how the unique properties of QDs can be used 
for effective whole-cell labeling. 
Phagocytosis, a form of non-specific uptake, was exploited for the investigation of 
cell motility and migration of small epithelial cancer cells (phagokinetic tracks). After 
the deposition of small, non-PEGylated and silica-capped QDs on collagen coated 
substrates and seeding of cells, QDs were internalized by phagocytosis [99]. The 
change in fluorescence intensity and thus the migration of the cells was observed by 
confocal microscopy. By the use of QDs problems of other previous approaches 
could be overcome. Conventional fluorophores suffered from photobleaching, while 
large, submicrometer gold particles would probably show interactions with cell 
motility when more particles are ingested. The phagokinetic tracks are a powerful tool 
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for the classification of cancer cells [65]. In another approach, phagocytosis of 
albumin-coated QDs by peritoneal mouse macrophages was used for immune cell 
tracing. The QDs were rapidly incorporated by the macrophages and then applied to 
the peritoneum of mice. After hapten injection, accumulation of the QDs on the 
inflammation site could be observed after tissue resection, detected by a handheld 
UV-lamp [100]. QDs emitting light in the NIR were able to label sentinel lymph nodes 
for imaging during resection. After intradermal injection, non-specific uptake by the 
RES was exploited for mapping and subsequent resection of sentinel lymph nodes 
guided by in vivo imaging [32].  
The process of non-specific uptake was further investigated by Osaki et al., who 
proved that endocytosis is also an extremely size-dependent process. They 
investigated endocytosis by means of amphiphilic sugar-coated QDs (15 nm, 
determined by dynamic light scattering - DLS). Based upon fluorescence microscopy 
they suggest an optimum of particle incorporation at ~50 nm (shown for an artificial 
‘glycovirus’ consisting of plasmid DNA and the amphiphilic sugar), while the smaller 
sugar-coated QDs and larger aggregates of the glycovirus (> 100 nm) were taken up 
at a smaller degree [8]. However, this influence of the size effects on endocytosis has 
to be further investigated for more detailed information. Non-specific uptake of QDs 
can also be triggered by translocation peptides [12,101-104], cationic liposomes 
[51,68] and dendrimers [12], or enhanced physically by electroporation [13]. These 
methods, together with microinjection [47], are often used for intracellular delivery 
and subsequent organelle tracking (this will be addressed later). 
8. Reduction of non-specific binding and uptake 
However, in applications where specific cell-particle interactions have to be 
investigated, non-specific interactions have to be reduced. Otherwise, targeting of 
specific cells cannot be achieved, as every cell, even the non-targeted ones, would 
be addressed. A solution can be to mask the surfaces of the QDs with PEG (stealth 
effect) [3,4] which significantly reduces non-specific particle uptake, e.g. by the RES 
[3]. 
To this end, Chang et al. showed at a human breast cancer cell line (SK-BR-3) that 
surface modification with PEG remarkably reduced non-specific QD uptake [105]. To 
this end, carboxylate-terminated QDs were used without modification or coupled to 
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PEGs of different molecular weights (750 to 6000 Da). Photoluminescence 
measurements after incubation with the differently modified QDs and after washing of 
the cells revealed significantly reduced non-specific uptake of PEG-coated particles 
as compared to the QDs without PEG (approximately by the factor of 10 after two 
hours of incubation). Quite interestingly, an increase of the molecular weight of the 
PEG only slightly reduced the uptake. Non-specific uptake was also shown to 
increase at prolonged incubation times and higher concentrations, despite the PEG-
coating of the QDs. 
Similar effects were observed in another study for non-specific binding of QDs to 
cells [106] when QDs of different degrees of PEGylation were used. Here, non-
specific binding studies using different cell lines revealed that this effect is also 
strongly depending upon the cell type. Non-specific binding to HEK cells was the 
highest while 3T3 cells only slightly interacted with QDs. In addition, effective 
reduction of non-specific binding can also be achieved by a partial coating of the 
QDs. Here, reduction of PEG bound to the carboxyl-modified QDs to one third still 
sufficiently reduced non-specific binding. This partial PEGylation provides additional 
binding sites for biomolecules on the surface of the QDs. Ballou et al. demonstrated 
that the circulating half-lifes of QDs in mice can be considerably improved by 
PEGylation which increase with longer molecular weights from 5 to 71 minutes [17]. 
However, phagocytosis and subsequent particle removal by the RES still remains a 
problem [107,108].  
Gao et al. investigated passive targeting of tumor tissue by PEGylated polymer 
coated QDs in vivo exploiting the enhanced permeability and retention (EPR) of 
tumors [67]. Since the leaky tumor vasculature is permeable for macromolecules and 
tumors lack an effective lymphatic drainage system macromolecule or nanoparticle 
accumulation in these tissues is enforced [109]. The QDs were injected into mice in 
which prostate cancer cells were implanted. After this, the distribution of the QDs was 
observed by in vivo fluorescence imaging. Passive targeting was observed 6h after 
injection of 6.0 nmol of the QDs. However, when compared to active tumor targeting, 
which was also achieved in this study after the QDs were additionally linked to an 
antibody against PSMA (a prostate cancer marker) and applied in a dose of 0.4 nmol, 
passive targeting showed a lower accumulation in the tumor. Additionally, the 
accumulation, mediated by the antibody, was significantly faster (2h). These findings 
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show that active targeting of specific cells and tissues, here using an antibody, leads 
to more effective particle delivery to the target. 
9. Specific cell-particle interactions 
9.1  Cell surface antigens  
In first approaches QDs were applied as fluorescent label of specific cells for 
analytical purposes. Many of them made use of antibodies [20,24,55,67,110], favored 
by the fact that antibodies against numerous cell-surface proteins are commercially 
available. In this technique, usually, a primary antibody specific for a cell-specific 
protein is applied. Subsequently, this antibody is addressed by a secondary antibody 
which can be connected to the QDs. The advantage of this method is that it is quite 
flexible, since the unit consisting of QDs and secondary antibodies can be used to 
bind to several primary antibodies. 
However, it is obvious that large complexes consisting of primary and secondary 
antibodies and QDs can be excluded from such uptake pathways which discriminate 
larger particles. Therefore, antibodies are more suitable in diagnostics and in labeling 
than with regard to nanoparticle delivery into cells. 
Wu et al. used QDs conjugated to antibodies to label cell surface cancer markers, the 
epidermal growth factor receptor Her2, on SK-BR-3 cells. The biotinylated secondary 
antibodies were conjugated to streptavidin-tagged polyacrylic acid-coated QDs. It 
was also possible to label intracellular structures, actin and microtubules, but this 
required fixation of the cells since the QD-antibody conjugates are not taken up into 
living cells [111].  
An alternative to antibodies is presented by Howarth et al. They genetically attached 
an acceptor peptide to AMPA receptors (glutamate activated ion channels) of 
neurons [112]. Furthermore, E. coli biotin ligase was added to perform biotinylation of 
the acceptor peptide on the receptor. In a last step, streptavidin-coated QDs were 
addressed to the modified receptor in order to label it. This allowed following the 
trafficking of the QD-tagged receptors in the neurons by fluorescence microscopy. 
The advantage of this labeling strategy is that customized chemistry for each ligand 
and antibody are not required.  
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9.2 The transferrin receptor 
Serum-transferrin, a 80 kDa glycoprotein, plays a crucial role in the maintenance of 
iron in the organism since it carries Fe3+-ions from the sites of intake, the mucosa 
cells, into the systemic circulation to the cells and tissues. The transferrin receptor 
(TfR), a homodimeric membrane receptor of 90 kDa per subunit, is internalized after 
Tf binding, followed by endosomal release of iron and recycling of the Tf-TfR 
complex. As the TfR is highly expressed in rapidly dividing cells, like tumor cells, it 
provides a target for specific particle delivery [82].  
Several approaches with transferrin-conjugated QDs were made to prove specific 
uptake [10,113-115]. In an early report, Chan and Nie demonstrated the use of QDs 
for bioimaging by coupling mercaptoacetic acid-coated QDs to Tf using EDC [10]. 
Fluorescence microscopy indicated specific uptake of Tf-QDs by HeLa cells, 
compared to non-conjugated QDs. The colloid was further improved by cross-linking 
the mercapto-acid-coating with lysine yielding higher stability in a large pH-range 
(regarding the quantum yields) and high salt concentrations (regarding the 
monodispersity of particle size distribution). To prove the monodispersity, blinking 
was investigated by epi-fluorescence microscopy as this phenomenon can only be 
observed for single QDs. Bioconjugation to Tf and subsequent uptake was achieved 
in a similar manner than before [113]. Two other approaches further confirmed Tf-
mediated endocytosis of QDs by atomic force microscopy (AFM) and two-photon 
excitation CLSM [114,115]. 
9.3 Tyrosine kinases  
In the family of transmembrane receptor tyrosine kinases (TRKs), growth factor 
receptors, especially the epidermal growth factor receptors (EGFRs), are of special 
interest concerning cancer targeting, since they are implicated in the development 
and progression of many human solid tumors [116]. There are numerous approaches 
investigating interactions of QDs with EGFRs [11,115,117,118]. Lidke et al. applied 
streptavidin-coated QDs for cellular uptake studies at the erbB1 receptor, one of four 
homologous receptor subtypes [11]. The receptor was expressed in CHO cells 
together with green fluorescent protein (GFP) as fusion protein. After binding of 
biotinylated EGF to the receptor, the streptavidin-QDs were added and accumulated 
at the cell membrane due to the strong streptavidin-biotin binding and could be 
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observed by confocal microscopy. The ligand-receptor complex quickly internalized 
at 37° C while at 4° C endocytosis could be blocked (figure 5). After endocytosis 
which was furthermore demonstrated to be clathrin-dependent by colocalization of 
transferrin-Alexa 633, fusion of the QD containing vesicles could be observed. 
Furthermore, the erbB1 was shown to be active after binding of EGF-linked QDs by 
staining with Cy5-anti-activated erbB1. These results indicate that the small QDs do 
not impair the biological function of the attached growth factor and the receptor 
trafficking. Incubation of the EGF-QDs with A431 cells which express the erbB1 
constitutively unveiled a rapid movement of the ligand-receptor complexes along 
filopodia, thin extensions of the cell body, by a retrograde transport to the cell body. 
Similarly, the nerve growth factor receptor TrkA was targeted by QDs conjugated to 
anti-TrkA as well as by QDs attached to nerve growth factor (NGF), the naturally 
occurring ligand [119]. After binding of the QD-bioconjugates to the receptor on PC12 
nerve cells, rapid internalization was observed by confocal microscopy. The shuttling 
of the endosomal QD-receptor complexes inside the cells was shown to be 
associated with microtubules. After addition of nocodazole, a microtubule inhibitor, 
the transport was inhibited.  
 
Figure 5: Binding of EGF-QDs to EGFRs and endocytosis at erB1-eGFP 
expressing CHO cells. The EGFRs are marked by GFP, QDs show red 
fluorescence. Upper panels: After addition of biotin-EGF to the cells, QDs bind to the 
EGFRs and show colocalization with the receptor on the plasma membrane. 
Endocytosis is inhibited at 4° C. Lower panels: At 37° C endocytosis takes place. The 
ligand-receptor complexes are visible inside the cell in endocytic vesicles. Scale 
bars: 20 µm (reprinted from [11]). 
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9.4 Integrins 
Integrins are a family of α,β-heterodimeric receptors that mediate dynamic linkages 
between extracellular adhesion molecules and the intracellular actin cytoskeleton 
[120]. Several integrins play an important role in angiogenesis and metastasis and 
are therefore upregulated in numerous tumor cell types. Integrins bind to the 
arginine-glycine-aspartic acid (RGD) peptide sequence present in many extracellular 
matrix proteins. This sequence binds for example to ανβ3 and ανβ5 integrins [121], 
which are overexpressed at the vasculature of tumors [122]. Therefore, these 
integrins are selective targets for cancer targeting. QDs attached to antibodies 
specific for the αν  subunit as well as QDs bound to RGD were able to bind to the 
nerve cell line SK-N-SH [110]. NIR-emitting, PEG-coated QDs connected to cyclic 
RGD were targeted to integrin-positive cells in vivo [108]. At increasing receptor 
expression levels, depending on the respective tumor cell lines, staining of the cells 
became more visible, while the effect could be blocked by excess free RGD and did 
not occur when the blank QDs were applied. In the same study, these RGD-
decorated QDs were also able to stain frozen tumor tissue in vitro, in contrast to QDs 
without RGD. Application to tumor bearing mice resulted in staining of the tumor 
vasculature, visualized by in vivo imaging (figure 6), but also in non-selective 
accumulation in the RES, mainly in liver, lymph nodes and bone-marrow, though the 
particles were PEG-coated. This approach shows that in vivo targeting with QDs on 
principle is feasible but for more selectivity of targeting the colloids still have to be 
improved. 
Another approach proved specific uptake of QDs coated with paramagnetic 
phospholipids containing the MRI-traceable element Gadolinium [36]. Therefore, the 
colloid is in addition to the fluorescence of the QDs also detectable by MRI. Thiolated 
RGD was connected to the colloid via maleimide-linkage. The maleimide function 
was introduced by partial incorporation of maleimide-derivatized PEG-phospholipids 
into the coating. After incubation, HUVEC cells (ανβ3 positive) showed increased 
uptake of the QDs compared to control (bare QDs without RGD), visualized by 
fluorescence microscopy. However, non-specific uptake of the bare QDs was also 
observed. 
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Figure 6: In vivo imaging of tumor bearing mice (left shoulder, arrows) after 
injection of RGD-QD (left sides) and QDs without RGD (right sides). After 6h location 
of RGD-QDs in the tumor is visible. Strong fluorescence in live, bone marrow and 
lymph nodes indicates uptake by the RES (reprinted from [107]).  
9.5 The folate receptor 
The folate receptor (FR) represents an adequate target for intracellular nanoparticle 
delivery since it is overexpressed in many cancer cell-lines [123] due to the increased 
need of cancer cells for folic acid as this coenzyme is essential for the synthesis of 
amino acids as well as nucleic acids. Since folic acid can be easily connected to 
functionalized nanoparticles by carbodiimide/NHS chemistry and because of its 
cheap availability, several approaches have been made to exploit FRs for drug 
targeting [124,125]. After preliminary results presented by Chan et al. [126], Bharali 
et al. showed uptake of QDs by KB cells, a FR positive epithelial cancer cell line, 
when mercaptoacetic acid-coated InP-ZnS QDs decorated by folic acid were applied. 
The QD uptake was proven by confocal microscopy. However their control-
experiments showed non-specific particle-uptake by FR-negative cells (A549 cells) 
which reduces the selectivity of the uptake of the QDs by FRs [69]. This problem of 
non-specific particle-uptake is already known and can be reduced by introducing 
PEG into the coating of the QDs, as mentioned before [105,106]. Hence, further 
experiments are necessary to ensure specific uptake after optimization of the QD 
surface. 
9.6 Phage displayed peptides 
Screening of phage displayed peptide libraries yielded a number of peptides which 
are selective for specific tumor tissues and have great potential for the development 
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of novel cancer-targeted drugs and could replace bulky antibodies in the future 
[127,128]. With this technique, phages are genetically engineered to display 
polypeptides on their surfaces which are encoded by their DNA which can be 
manipulated by insertion of randomized oligonucleotide fragments. The resulting 
phage displayed peptide libraries are subsequently screened for the binding affinity 
of the peptides to certain receptors (biopanning).  
Akerman et al. applied three pre-scanned peptides from phage display, each 
connected to QDs [53]. These isolated peptides already have been proven to bind to 
specific sites in mice in vivo and were homing to membrane dipeptidase on 
endothelial cells in lung blood vessels, tumor blood vessels or lymphatic vessels and 
tumor cells, respectively [127]. After modification with iminothiolane to introduce a 
thiol group into the peptides, the compounds were subsequently bound to 
mercaptoacetic acid coated QDs via thiol exchange. Thiolated PEG was also 
attached for passivation of the QDs. Following injection into mice, the QDs were 
found in the respective tissues using fluorescent microscopy depending on the 
peptide attached. Tissue samples of liver and spleen revealed reduced uptake of 
PEGylated QDs by the RES compared to non-PEGylated ones.  
In another approach, peptide from phage display was used to target QDs, which 
were attached via streptavidin, to a lung carcinoma cell line. The colloid was 
internalized by the cells, whereas QDs attached to a tetrameric control peptide 
remained extracellular [129]. However, future studies have to prove the selectivity of 
the peptide for tumor cells only. Similar results were obtained by Kim et al. for 
another peptide [130]. They showed QD uptake and also transport of the QD-
peptide-receptor complex into the endoplasmatic reticulum which was fluorescently 
labeled with Glibenclamide. 
9.7 Other targets 
The largest cell surface receptor family is represented by the G-protein coupled 
receptors (GPCRs) [131]. These receptors modulate various kinds of physiological 
processes and are involved in a number of diseases. Therefore, GPCRs represent 
the largest class of therapeutic targets [132]. As the localization of many of these 
receptors has been investigated intensively and as numerous ligands for these 
receptors are known, they might also be interesting for drug targeting. After binding 
of a ligand which can be a biogenic amine or a peptide, the ligand-receptor 
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complexes are usually internalized, mediated by clathrin. Therefore, this mechanism 
should also provide a gateway for selective uptake of particles tagged to ligands 
selective for certain GPCRs.  
An early approach using ligand-conjugated QDs was presented by Rosenthal et al. 
[133]. In this publication, serotonin molecules were covalently bound to TOPO-coated 
CdSe QDs, referred to as serotonin-labeled CdSe nanocrystals (SNACs). The 
biogenic amine serotonin is recognized by serotonin transporter proteins (SERTs) 
which are responsible for the termination of neurotransmitter signal by clearing these 
molecules from extracellular spaces after release. The SNACs were able to label cell 
surface SERTs in transfected HEK cells but with reduced binding affinity, compared 
to free serotonin. However, electrophysiological experiments at Xenopus oocytes 
expressing the human serotonin receptor 5HT3 suggest that the steric hindrance of 
the relatively large QDs can impair the biological activity of the small 
neurotransmitter. This point is subject to further improvements for specific 
substances binding to serotonin and dopamine transporters [134,135]. 
In a later approach by Mason et al. it was possible to label cell surface GPCRs, in 
this case for a peptidic ligand [136] offering a more favorable size ratio between the 
QDs and the ligand. Mercaptoacetic acid-coated QDs were covalently EDC-coupled 
with PEG and angiotensin II (ANG II), an octapeptide binding to angiotensin 
receptors (AT). These QD bioconjugates can bind to AT 1 receptors expressed in 
transfected CHO cells. Binding did not take place either when excess ANG II was 
applied or when AT 1-negative CHO cells were incubated. Similar results were 
presented by Young and Rozengurt for streptavidin-functionalized QDs conjugated to 
biotinylated ANG II. Agonist-induced internalization was observed with fluorescence 
microscopy which could be inhibited at 4° C, indicating uptake via endocytosis [137]. 
10.  Intracellular delivery  
As mentioned above, many targets of therapeutical relevance are located inside the 
cell, like the nucleus or the mitochondria, which requires intracellular delivery of 
nanoparticles [138]. Recent studies meet this requirement by the investigation of QD-
based intracellular targeting strategies.  
The nucleus, for example, plays a dominant role in gene therapy, since here most of 
the genetic information of a cell is located. In principle, nanoparticles are able to 
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enter the nucleus by diffusion through the nuclear pores. Since these pores are in 
most cases too small for most of the particles (up to 26_nm) [139], active transport 
via nuclear localization sequences (NLS) seems more promising for targeting this 
organelle. Similarly, mitochondria can be addressed with mitochondrial localization 
sequences (MLS). These organelles play a role in a number of pathophysiological 
dysfunctions, like neurodegenerative and cardiovascular diseases and cancer 
[140,141]. This fact renders mitochondria interesting targets for drug therapy. 
Before QDs are able to find intracellular targets, the particles first have to enter the 
cell. Therefore, the complex problem of intracellular delivery has been divided into 
two parts. The first one, as described above, deals with the cellular uptake of 
colloids. CME is promising, due to its selective uptake of colloids, but also poses the 
problem that the particles remain sequestered in endosomal vesicles preventing 
intracellular tracking. Therefore, to study the intracellular targeting processes other 
delivery methods are used, usually non-specific ones, for direct delivery of the 
particles into the cytosol. A next step would be to combine specific uptake with 
intracellular delivery when both of these processes are better understood and when 
the colloids are further developed. The following approaches embark on this strategy 
in which first the QDs are delivered into the cytosol. Subsequently the QDs are able 
to addresses the respective organelles.  
In order to facilitate further studies of intracellular targeting of organelles with QDs, 
Derfus et al. investigated several methods to find an appropriate method to deliver 
PEG-coated QDs into the cytosol of cells [12]. Quantification of cellular uptake using 
HeLa cells, determined by flow cytometry, revealed that cationic liposomes 
(Lipofectamine™) yielded the highest delivery efficiency, followed by dendrimers 
(Superfect™) and translocation peptides (Chariot™). To prove whether green-light-
emitting QDs remain trapped in vesicles, which would disturb later organelle tracking, 
a second fraction of red-light-emitting QDs which were coupled to EGF was 
simultaneously incubated and analyzed by fluorescence microscopy. Since EGF-
QDs were shown to enter cells via CME, they were used as an endosome marker. 
The approach showed only few colocalization of the both QD-fractions in vesicles 
after Lipofectamine-delivery, indicating that QDs can escape the endosomes (figure 
7A). However, in this delivery method particles formed aggregates of several 
hundred nanometres. Electroporation showed similar effects (figure 7B), only 
microinjection prevented aggregation (figure 7C). Aggregation of the particles in the 
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cytosol has to be avoided since larger aggregates would prevent trafficking to the 
nucleus or mitochondria, e.g. when pores have to be passed. Additionally, nuclear 
localization sequences (NLS) -the SV40 T antigen- and mitochondrial localization 
sequences (MLS), consisting of the targeting presequence from human cytochrome 
oxidase subunit VIII (COX8), were adsorbed on the QD surface. These sequences 
are small peptides specific for transporter proteins at the respective organelle and 
should prove the possibility to address these organelles. After microinjection of the 
NLS- and MLS-conjugated QDs into the cytosol, the particles were delivered into the 
nuclei and the mitochonria, respectively. However, control experiments with random 
peptides would be needed to accredit this intracellular delivery to the activity of the 
localization sequences only. 
 
Figure 7: Depiction of several delivery methods.  Transfection via cationic 
liposomes (A) and electroporation (B). Both methods allow for parallel delivery in the 
cells simultaneously but result in aggregation of the QDs (green spots). 
Microinjection into single cells (C) yields in an aggregate-free dispersion of the QDs 
inside the cell (reprinted from [12]). 
 
Similar results were obtained by Chen et al. for silica-coated QDs connected to SV40 
T antigen via streptavidin-biotin linkage [13]. Here, QDs were delivered into the 
cytosol of HeLa cells via electroporation. Subsequently, QDs were delivered into the 
nucleus, mediated by the NLS. Controls with random peptides were not localized 
inside the nucleus which indicates the uptake was dependent upon the NLS. Silica 
QDs were chosen as they are fairly non-cytotoxic and small enough (10-15 nm) for 
passing the nuclear pores. A colonigenic assay revealed no significant change of the 
surviving cell colony numbers after transfection compared to control. After 5 days and 
cell division, QDs were visible in the nuclei of the newly divided cells by fluorescence 
microscopy. 
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The peptide carrier Pep-1 was successfully connected to QDs in several studies and 
proved its potential for cellular delivery of QDs. Rozenhak et al. delivered streptavidin 
coated QDs non-covalently linked to Pep-1 into mammalian cells [104]. The QD-Pep-
1 complexes were visible in the cytoplasm as aggregates. Besides nuclear targeting 
which was achieved via additional attachment of biotinylated SV-40 T-antigen, also 
mitochondrial targeting was possible. For this purpose, the GH3 domain of the Grim 
protein, an inducer of mitochondrial apoptosis, was coupled to the QDs before to 
Pep-1 was attached. After incubation of the cells, apoptosis was observed, as 
membrane blebbing and nuclear condensation in cells started to take place, an 
indirect sign of mitochondrial targeting.  
In another study, an oligoarginine CPP, based on the HIV-1 Tat-protein, containing a 
terminal polyhistidine tag, was applied. By this sequence the peptide could be 
attached to QDs capped with dihydrolipoic acid (DHLA) via metal-affinity interactions 
between the polyhistidine and the Zn atoms on the QD surface [142]. The colloid was 
able to be internalized into HEK293T/17 and COS-1 cells in a significantly higher 
manner than a control group without CPP. After uptake, colocalization with Alexa-
labeled transferrin, an endocytic marker, showed localization of the QD-peptide 
conjugates in endosomes. Since uptake could be inhibited at 4° C, the group 
suggests endocytic uptake though the exact mechanism was not further 
characterized.  
The Tat-protein coupled to QDs, coated with tiopronin (N-2-
mercaptopropionylglycine) by EDC, mediated uptake into fibroblast and even nuclear 
targeting though in this approach no quantitative statement can be made [143]. Tat 
could also mediate brain targeting of QDs after injection into living mice [144]. The 
QDs were visible in the brain after its resection by the use of a handheld UV-lamp.  
11.  Conclusion and outlook 
Nanoparticles as colloidal drug carriers seem to be promising tools for targeting 
specific cells, tissues or organs. These drug carriers have not only to head for 
specific cell-types but should also address distinct cellular uptake processes to 
deliver their payload into cells. In order to investigate the pathways for nanoparticles 
into specific cells, model colloids of defined size and shape, which in addition have to 
be easy to detect, are a powerful tool. 
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As presented above, the use of QDs for the investigation of cellular uptake and 
intracellular delivery of nanoparticles offers new possibilities in order to study sub-
cellular processes, due to the small, uniform size and due to the unique optical 
properties of the QDs. The approaches demonstrated that the pathway into the cell 
should be considered carefully since it also determines the intracellular fate of the 
colloid. CME was shown effective for targeting and uptake into cells but the 
endosomal release of the colloid after uptake can be a limiting factor for intracellular 
targeting.   
Other promising pathways are the caveolae-mediated uptake [145] and uptake 
mediated by CPPs which circumvent the clathrin pathway. However, there is still 
need for more information on the distinct mechanisms for this uptake, as the 
examples of the SV40 virus (caveolae-dependent [80] and caveolae-independent 
[146]) and the Tat peptide (macropinocytosis [147] and caveolae [148]) show. A 
better understanding of such processes would obviously help to design colloids 
targeted nanoparticles for numerous applications.  
Finally, new concepts can exploit specific pathophysiological situations, e.g. when an 
enzyme is upregulated, and activate particle delivery at the affected site on demand. 
A first promising approach was presented by Zhang et al. In this study, non-specific, 
transduction peptide-driven uptake of QDs was rendered cell-selective by linking a 
negatively charged, transduction-inhibiting peptide which was additionally substrate 
for matrix metalloproteases (MMPs). After cleavage of the negatively charged 
peptide by MMPs, the colloid could enter the target cells [149]. Since MMPs are 
upregulated in many tumors and in arthritic tissues this approach should be selective 
for these targets. This example shows that for the design of effective, cell-targeting 
colloids probably several targeting strategies have to be combined in one particle. 
Exploiting differently expressed enzymes or other forms of regulation specific for 
certain (patho)physiological events inside cells to ‘switch on’ colloids on the 
intracellular level could be an issue for the future development of advanced colloids.  
In the field of nanomedicine [150], QDs can make a worthy contribution to the 
development new diagnostic and delivery systems as they offer unique optical 
properties for highly sensitive detection, as well as they are well-defined in size and 
shape and as they can be modified with various targeting principles. 
Chapter 1 Introduction 
 
- 36 - 
References 
 [1] V.P. Torchilin, Drug targeting, European Journal of Pharmaceutical Sciences 
11 (2000) S81-S91 
 [2] D.A. Groneberg, M. Giersig, T. Welte, U. Pison, Nanoparticle-based diagnosis 
and therapy, Current Drug Targets 7 (2006) 643-648 
 [3] D.E. Owens, N.A. Peppas, Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles, Int. J. Pharm. 307 (2006) 93-102 
 [4] H. Otsuka, Y. Nagasaki, K. Kataoka, PEGylated nanoparticles for biological 
and pharmaceutical applications, Adv. Drug Deliv. Rev. 55 (2003) 403-419 
 [5] J. Vasir, M. Reddy, V. Labhasetwar, Nanosystems in Drug Targeting: 
Opportunities and Challenges, Current Nanoscience 1 (2005) 47-64 
 [6] I.A. Khalil, K. Kogure, H. Akita, H. Harashima, Uptake Pathways and 
Subsequent Intracellular Trafficking in Nonviral Gene Delivery, Pharmacol. 
Rev. 58 (2006) 32-45 
 [7] B. Rabinow, M.V. Chaubal, Injectable nanoparticles for efficient drug delivery, 
Drugs and the Pharmaceutical Sciences 159 (2006) 199-229 
 [8] F. Osaki, T. Kanamori, S. Sando, T. Sera, Y. Aoyama, A Quantum Dot 
Conjugated Sugar Ball and Its Cellular Uptake. On the Size Effects of 
Endocytosis in the Subviral Region, J. Am. Chem. Soc. 126 (2004) 6520-6521 
 [9] E. Chang, W.W. Yu, V.L. Colvin, R. Drezek, Quantifying the influence of 
surface coatings on quantum dot uptake in cells, J. Biomed. Nanotechnol. 1 
(2005) 397-401 
 [10] W.C.W. Chan, S. Nie, Quantum dot bioconjugates for ultrasensitive 
nonisotopic detection, Science 281 (1998) 2016-2018 
 [11] D.S. Lidke, P. Nagy, R. Heintzmann, D.J. Arndt-Jovin, J.N. Post, H.E. Grecco, 
E.A. Jares-Erijman, T.M. Jovin, Quantum dot ligands provide new insights into 
erbB/HER receptor-mediated signal transduction, Nat. Biotechnol. 22 (2004) 
198-203 
 [12] A.M. Derfus, W.C.W. Chan, S.N. Bhatia, Intracellular delivery of quantum dots 
for live cell labeling and organelle tracking, Adv. Mater. 16 (2004) 961-966 
 [13] F. Chen, D. Gerion, Fluorescent CdSe/ZnS Nanocrystal-Peptide Conjugates 
for Long-term, Nontoxic Imaging and Nuclear Targeting in Living Cells, Nano 
Lett. 4 (2004) 1827-1832 
 Introduction Chapter 1 
 
- 37 - 
 [14] P. Sharma, S. Brown, G. Walter, S. Santra, B. Moudgil, Nanoparticles for 
bioimaging, Adv. Colloid Interface Sci. 123-126 (2006) 471-485 
 [15] L.J. Thorek Daniel, A.K. Chen, J. Czupryna, A. Tsourkas, Superparamagnetic 
iron oxide nanoparticle probes for molecular imaging, Ann. Biomed. Eng. 34 
23-38 
 [16] B. Bonnemain, Superparamagnetic agents in magnetic resonance imaging: 
physicochemical characteristics and clinical applications. A review, J. Drug 
Target. 6 (2004) 167-174 
 [17] B. Ballou, B.C. Lagerholm, L.A. Ernst, M.P. Bruchez, A.S. Waggoner, 
Noninvasive imaging of quantum dots in mice, Bioconjug. Chem. 15 (2004) 
79-86 
 [18] B.D. Chithrani, A.A. Ghazani, W.C.W. Chan, Determining the Size and Shape 
Dependence of Gold Nanoparticle Uptake into Mammalian Cells, Nano Letters 
6 (2006) 662-668 
 [19] S. Gross, D. Piwnica-Worms, Molecular imaging strategies for drug discovery 
and development, Curr. Opin. Chem. Biol. 10 (2006) 334-342 
 [20] M. Dahan, S. Levi, C. Luccardini, P. Rostaing, B. Riveau, A. Triller, Diffusion 
dynamics of glycine receptors revealed by single-quantum dot tracking, 
Science 302 (2003) 442-445 
 [21] Z.A. Peng, X. Peng, Formation of high-quality CdTe, CdSe, and CdS 
nanocrystals using CdO as precursor, J. Am. Chem. Soc. 123 (2001) 183-184 
 [22] A.M. Smith, S. Nie, Chemical analysis and cellular imaging with quantum dots, 
Analyst 129 (2004) 672-677 
 [23] M. Bruchez, Jr., M. Moronne, P. Gin, S. Weiss, A.P. Alivisatos, Semiconductor 
nanocrystals as fluorescent biological labels, Science 281 (1998) 2013-2016 
 [24] J.K. Jaiswal, H. Mattoussi, J.M. Mauro, S.M. Simon, Long-term multiple color 
imaging of live cells using quantum dot bioconjugates, Nat. Biotechnol. 21 
(2003) 47-51 
 [25] X. Gao, L. Yang, J.A. Petros, F.F. Marshall, J.W. Simons, S. Nie, In vivo 
molecular and cellular imaging with quantum dots, Curr. Opin. Biotechnol. 16 
(2005) 63-72 
 [26] M. Dahan, T. Laurence, F. Pinaud, D.S. Chemla, A.P. Alivisatos, M. Sauer, S. 
Weiss, Time-gated biological imaging by use of colloidal quantum dots, Opt. 
Lett. 26 (2001) 825-827 
Chapter 1 Introduction 
 
- 38 - 
 [27] J.M. Costa-Fernandez, R. Pereiro, A. Sanz-Medel, The use of luminescent 
quantum dots for optical sensing, Trends in Analytical Chemistry 25 (2006) 
207-218 
 [28] C.B. Murray, D.J. Norris, M.G. Bawendi, Synthesis and characterization of 
nearly monodisperse CdE (E = sulfur, selenium, tellurium) semiconductor 
nanocrystallites, J. Am. Chem. Soc. 115 (1993) 8706-8715 
 [29] M.A. Hines, P. Guyot-Sionnest, Synthesis and Characterization of Strongly 
Luminescing ZnS-Capped CdSe Nanocrystals, J. Phys. Chem. 100 (1996) 
468-471 
 [30] B.O. Dabbousi, J. Rodriguez-Viejo, F.V. Mikulec, J.R. Heine, H. Mattoussi, R. 
Ober, K.F. Jensen, M.G. Bawendi, (CdSe)ZnS Core-Shell Quantum Dots: 
Synthesis and Optical and Structural Characterization of a Size Series of 
Highly Luminescent Materials, J. Phys. Chem. B 101 (1997) 9463-9475 
 [31] X. Michalet, F. Pinaud, T.D. Lacoste, M. Dahan, M.P. Bruchez, A.P. Alivisatos, 
S. Weiss, Properties of fluorescent semiconductor nanocrystals and their 
application to biological labeling, Single Mol. 2 (2001) 261-276 
 [32] S. Kim, Y.T. Lim, E.G. Soltesz, A.M. De Grand, J. Lee, A. Nakayama, J.A. 
Parker, T. Mihaljevic, R.G. Laurence, D.M. Dor, L.H. Cohn, M.G. Bawendi, 
J.V. Frangioni, Near-infrared fluorescent type II quantum dots for sentinel 
lymph node mapping, Nat. Biotechnol. 22 (2004) 93-97 
 [33] J. Frangioni, V, In vivo near-infrared fluorescence imaging, Curr Opin Chem 
Biol 7 (2003) 626-634 
 [34] B. Ballou, Quantum dot surfaces for use in vivo and in vitro, Curr Top Dev Biol 
70 (2005) 103-120 
 
 [35] Y. Sahoo, P. Poddar, H. Srikanth, D.W. Lucey, P.N. Prasad, Chemically 
Fabricated Magnetic Quantum Dots of InP:Mn, J. Phys. Chem. B 109 (2005) 
15221-15225 
 [36] W.J.M. Mulder, R. Koole, R.J. Brandwijk, G. Storm, P.T.K. Chin, G.J. Strijkers, 
C. de Donega, K. Nicolay, A.W. Griffioen, Quantum Dots with a Paramagnetic 
Coating as a Bimodal Molecular Imaging Probe, Nano Lett. 6 (2006) 1-6 
 [37] L. Prinzen, R.J. Miserus, A. Dirksen, T.M. Hackeng, N. Deckers, N.J. Bitsch, 
R.T.A. Megens, K. Douma, J.W. Heemskerk, M.E. Kooi, P.M. Frederik, D.W. 
Slaaf, M.A.M.J. van Zandvoort, C.P.M. Reutelingsperger, Optical and 
 Introduction Chapter 1 
 
- 39 - 
Magnetic Resonance Imaging of Cell Death and Platelet Activation Using 
Annexin A5-Functionalized Quantum Dots, Nano Lett. 7 (2007) 93-100 
 [38] M.K. So, C. Xu, A.M. Loening, S.S. Gambhir, J. Rao, Self-illuminating 
quantum dot conjugates for in vivo imaging, Nat. Biotechnol. 24 (2006) 339-
343 
 [39] H. Mattoussi, J.M. Mauro, E.R. Goldman, G.P. Anderson, V.C. Sundar, F.V. 
Mikulec, M.G. Bawendi, Self-Assembly of CdSe-ZnS Quantum Dot 
Bioconjugates Using an Engineered Recombinant Protein, J. Am. Chem. Soc. 
122 (2000) 12142-12150 
 [40] S. Kim, M.G. Bawendi, Oligomeric Ligands for Luminescent and Stable 
Nanocrystal Quantum Dots, J. Am. Chem. Soc. 125 (2003) 14652-14653 
 [41] W. Guo, J.J. Li, Y.A. Wang, X. Peng, Conjugation Chemistry and 
Bioapplications of Semiconductor Box Nanocrystals Prepared via Dendrimer 
Bridging, Chem. Mater. 15 (2003) 3125-3133 
 [42] F. Pinaud, D. King, H.P. Moore, S. Weiss, Bioactivation and Cell Targeting of 
Semiconductor CdSe/ZnS Nanocrystals with Phytochelatin-Related Peptides, 
J. Am. Chem. Soc. 126 (2004) 6115-6123 
 [43] H. Mattoussi, J.M. Mauro, E.R. Goldman, G.P. Anderson, V.C. Sundar, F.V. 
Mikulec, M.G. Bawendi, Self-Assembly of CdSe-ZnS Quantum Dot 
Bioconjugates Using an Engineered Recombinant Protein, J. Am. Chem. Soc. 
122 (2000) 12142-12150 
 [44] D. Gerion, F. Pinaud, S.C. Williams, W.J. Parak, D. Zanchet, S. Weiss, A.P. 
Alivisatos, Synthesis and Properties of Biocompatible Water-Soluble Silica-
Coated CdSe/ZnS Semiconductor Quantum Dots, J. Phys. Chem. B 105 
(2001) 8861-8871 
 [45] T. Pellegrino, L. Manna, S. Kudera, T. Liedl, D. Koktysh, A.L. Rogach, S. 
Keller, J. Raedler, G. Natile, W.J. Parak, Hydrophobic Nanocrystals Coated 
with an Amphiphilic Polymer Shell: A General Route to Water Soluble 
Nanocrystals, Nano Lett. 4 (2004) 703-707 
 [46] X. Gao, Y. Cui, R.M. Levenson, L.W.K. Chung, S. Nie, In vivo cancer targeting 
and imaging with semiconductor quantum dots, Nat. Biotechnol. 22 (2004) 
969-976 
Chapter 1 Introduction 
 
- 40 - 
 [47] B. Dubertret, P. Skourides, D.J. Norris, V. Noireaux, A.H. Brivanlou, A. 
Libchaber, In vivo imaging of quantum dots encapsulated in phospholipid 
micelles, Science 298 (2002) 1759-1762 
 [48] A. Hezinger, J. Tessmar, A. Goepferich, Polymer coating of Quantum Dots - A 
powerful Tool toward Diagnostics and Sensorics, Eur. J. Pharm. Biopharm. in 
press (2007)  
 [49] X. Wu, H. Liu, J. Liu, K.N. Haley, J.A. Treadway, J.P. Larson, N. Ge, F. Peale, 
M.P. Bruchez, Immunofluorescent labeling of cancer marker Her2 and other 
cellular targets with semiconductor quantum dots, Nat. Biotechnol. 21 (2003) 
41-46 
 [50] C. Zhang, H. Ma, Y. Ding, L. Jin, D. Chen, S. Nie, Quantum dot-labeled 
trichosanthin, Analyst 125 (2000) 1029-1031 
 [51] C. Srinivasan, J. Lee, F. Papadimitrakopoulos, L.K. Silbart, M. Zhao, D.J. 
Burgess, Labeling and Intracellular Tracking of Functionally Active Plasmid 
DNA with Semiconductor Quantum Dots, Mol. Ther. 14 (2006) 192-201 
 [52] W.J. Parak, D. Gerion, D. Zanchet, A.S. Woerz, T. Pellegrino, C. Micheel, S.C. 
Williams, M. Seitz, R.E. Bruehl, Z. Bryant, C. Bustamante, C.R. Bertozzi, A.P. 
Alivisatos, Conjugation of DNA to silanized colloidal semiconductor 
nanocrystalline quantum dots, Chem. Mater. 14 (2002) 2113-2119 
 [53] M.E. Akerman, W.C.W. Chan, P. Laakkonen, S.N. Bhatia, E. Ruoslahti, 
Nanocrystal targeting in vivo, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12617-
12621 
 [54] K.I. Hanaki, A. Momo, T. Oku, A. Komoto, S. Maenosono, Y. Yamaguchi, K. 
Yamamoto, Semiconductor quantum dot/albumin complex is a long-life and 
highly photostable endosome marker, Biochem. Biophys. Res. Commun. 302 
(2003) 496-501 
 [55] E.R. Goldman, G.P. Anderson, P.T. Tran, H. Mattoussi, P.T. Charles, J.M. 
Mauro, Conjugation of Luminescent Quantum Dots with Antibodies Using an 
Engineered Adaptor Protein To Provide New Reagents for 
Fluoroimmunoassays, Anal. Chem. 74 (2002) 841-847 
 [56] W.J. Parak, T. Pellegrino, C. Plank, Labelling of cells with quantum dots, 
Nanotechnology 16 (2005) R9-R25 
 Introduction Chapter 1 
 
- 41 - 
 [57] X. Michalet, F.F. Pinaud, L.A. Bentolila, J.M. Tsay, S. Doose, J.J. Li, G. 
Sundaresan, A.M. Wu, S.S. Gambhir, S. Weiss, Quantum Dots for Live Cells, 
in Vivo Imaging, and Diagnostics, Science 307 (2005) 538-544 
 [58] R. Shukla, V. Bansal, M. Chaudhary, A. Basu, R.R. Bhonde, M. Sastry, 
Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the 
Cellular Compartment: A Microscopic Overview, Langmuir 21 (2005) 10644-
10654 
 [59] A.K. Gupta, M. Gupta, Synthesis and surface engineering of iron oxide 
nanoparticles for biomedical applications, Biomaterials 26 (2005) 3995-4021 
 [60] A.M. Derfus, W.C.W. Chan, S.N. Bhatia, Probing the Cytotoxicity of 
Semiconductor Quantum Dots, Nano Lett. 4 (2004) 11-18 
 [61] N. Pradhan, D. Goorskey, J. Thessing, X. Peng, An Alternative of CdSe 
Nanocrystal Emitters: Pure and Tunable Impurity Emissions in ZnSe 
Nanocrystals, J. Am. Chem. Soc. 127 (2005) 17586-17587 
 [62] C. Kirchner, T. Liedl, S. Kudera, T. Pellegrino, A.M. Javier, H.E. Gaub, S. 
Stoelzle, N. Fertig, W.J. Parak, Cytotoxicity of Colloidal CdSe and CdSe/ZnS 
Nanoparticles, Nano Lett. 5 (2005) 331-338 
 [63] A. Hoshino, K. Fujioka, T. Oku, M. Suga, Y.F. Sasaki, T. Ohta, M. Yasuhara, 
K. Suzuki, K. Yamamoto, Physicochemical Properties and Cellular Toxicity of 
Nanocrystal Quantum Dots Depend on Their Surface Modification, Nano Lett. 
4 (2004) 2163-2169 
 [64] J. Aldana, Y.A. Wang, X. Peng, Photochemical Instability of CdSe 
Nanocrystals Coated by Hydrophilic Thiols, J. Am. Chem. Soc. 123 (2001) 
8844-8850 
 [65] W.J. Parak, R. Boudreau, M. Le Gros, D. Gerion, D. Zanchet, C.M. Micheel, 
S.C. Williams, A.P. Alivisatos, C. Larabell, Cell motility and metastatic potential 
studies based on quantum dot imaging of phagokinetic tracks, Adv. Mater. 14 
(2002) 882-885 
 [66] A. Hoshino, K.I. Hanaki, K. Suzuki, K. Yamamoto, Applications of T-lymphoma 
labeled with fluorescent quantum dots to cell tracing markers in mouse body, 
Biochem. Biophys. Res. Commun. 314 (2004) 46-53 
 [67] X. Gao, Y. Cui, R.M. Levenson, L.W.K. Chung, S. Nie, In vivo cancer targeting 
and imaging with semiconductor quantum dots, Nat. Biotechnol. 22 (2004) 
969-976 
Chapter 1 Introduction 
 
- 42 - 
 [68] E.B. Voura, J.K. Jaiswal, H. Mattoussi, S.M. Simon, Tracking metastatic tumor 
cell extravasation with quantum dot nanocrystals and fluorescence emission-
scanning microscopy, Nat. Med. 10 (2004) 993-998 
 [69] D.J. Bharali, D.W. Lucey, H. Jayakumar, H.E. Pudavar, P.N. Prasad, Folate-
Receptor-Mediated Delivery of InP Quantum Dots for Bioimaging Using 
Confocal and Two-Photon Microscopy, J. Am. Chem. Soc. 127 (2005) 11364-
11371 
 [70] J. Lovric, S.J. Cho, F.M. Winnik, D. Maysinger, Unmodified Cadmium Telluride 
Quantum Dots Induce Reactive Oxygen Species Formation Leading to 
Multiple Organelle Damage and Cell Death, Chem. Biol. 12 (2005) 1227-1234 
 [71] B.I. Ipe, M. Lehnig, C.M. Niemeyer, On the generation of free radical species 
from quantum dots, Small 1 (2005) 706-709 
 [72] W.-H. Chan, N.-H. Shiao, P.-Z. Lu, CdSe quantum dots induce apoptosis in 
human neuroblastoma cells via mitochondrial-dependent pathways and 
inhibition of survival signals, Toxicology Letters In Press, Corrected Proof 
(2006)  
 [73] M. Green, E. Howman, Semiconductor quantum dots and free radical induced 
DNA nicking, Chemical communications (Cambridge, England) (2004) 121-
123 
 [74] T. Zhang, J.L. Stilwell, D. Gerion, L. Ding, O. Elboudwarej, P.A. Cooke, J.W. 
Gray, A.P. Alivisatos, F.F. Chen, Cellular Effect of High Doses of Silica-Coated 
Quantum Dot Profiled with High Throughput Gene Expression Analysis and 
High Content Cellomics Measurements, Nano Lett. 6 (2006) 800-808 
 [75] S.-W. Pang, H.-Y. Park, Y.-S. Jang, W. Kim, J.-H. Kim, Effects of charge 
density and particle size of poly(styrene/(dimethylamino)ethyl methacrylate) 
nanoparticle for gene delivery in 293 cells, Colloids and surfaces. B, 
Biointerfaces 26 (2002) 213-222 
 [76] S.D. Conner, S.L. Schmid, Regulated portals of entry into the cell, Nature 422 
(2003) 37-44 
 [77] M. Marsh, H.T. McMahon, The Structural Era of Endocytosis, Science 285 
(1999) 215-220 
 [78] J.A. Swanson, C. Watts, Macropinocytosis, Trends Cell Biol. 5 (1995) 424-428 
 [79] J.S. Shin, S.N. Abraham, CELL BIOLOGY: Caveolae--Not Just Craters in the 
Cellular Landscape, Science 293 (2001) 1447-1448 
 Introduction Chapter 1 
 
- 43 - 
 [80] R.G. Anderson, The caveolae membrane system, Annu. Rev. Biochem. 67 
(1998) 199-225 
 [81] L. Pelkmans, A. Helenius, Endocytosis via caveolae, Traffic 3 (2002) 311-320 
 [82] Z.M. Qian, H. Li, H. Sun, K. Ho, Targeted Drug Delivery via the Transferrin 
Receptor-Mediated Endocytosis Pathway, Pharmacol. Rev. 54 (2002) 561-587 
 [83] C. Sun, R. Sze, M. Zhang, Folic acid-PEG conjugated superparamagnetic 
nanoparticles for targeted cellular uptake and detection by MRI, J. Biomed. 
Mater. Res. A 78A (2006) 550-557 
 [84] R. Sinha, G. Kim, S. Nie, D. Shin, Nanotechnology in cancer therapeutics: 
bioconjugated nanoparticles for drug delivery, Mol. Cancer Ther. 5 (2006) 
1909-1917 
 [85] M. Higgins, H. McMahon, Snap-shots of clathrin-mediated endocytosis, 
Trends Biochem. Sci. 27 (2002) 257-263 
 [86] Y. Chan, V. Bulmus, M.H. Zareie, F.L. Byrne, L. Barner, M. Kavallaris, Acid-
cleavable polymeric core-shell particles for delivery of hydrophobic drugs, J. 
Control. Release 115 (2006) 197-207 
 [87] A. Potineni, D.M. Lynn, R. Langer, M.M. Amiji, Poly(ethylene oxide)-modified 
poly(b-amino ester) nanoparticles as a pH-sensitive biodegradable system for 
paclitaxel delivery, J. Control. Release 86 (2003) 223-234 
 [88] Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, K. Kataoka, 
Preparation and Biological Characterization of Polymeric Micelle Drug Carriers 
with Intracellular pH-Triggered Drug Release Property: Tumor Permeability, 
Controlled Subcellular Drug Distribution, and Enhanced in Vivo Antitumor 
Efficacy, Bioconjug. Chem. 16 (2005) 122-130 
 [89] J. Panyam, W.-Z. Zhou, S. Prabha, S.K. Sahoo, V. Labhasetwar, Rapid endo-
lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications 
for drug and gene delivery, FASEB J. 16 (2002) 1217-1226 
 [90] M. Lindgren, M. Hallbrink, A. Prochiantz, U. Langel, Cell-penetrating peptides, 
Trends Pharmacol. Sci. 21 (2000) 99-103 
 [91] Y.L. Tseng, J.J. Liu, R.L. Hong, Translocation of liposomes into cancer cells 
by cell-penetrating peptides penetratin and Tat: a kinetic and efficacy study, 
Mol. Pharmacol. 62 (2002) 864-872 
Chapter 1 Introduction 
 
- 44 - 
 [92] T.S. Levchenko, R. Rammohan, N. Volodina, V.P. Torchilin, Tat peptide-
mediated intracellular delivery of liposomes, Methods in Enzymology 372 
(2003) 339-349 
 [93] M. Lewin, N. Carlesso, C.H. Tung, X.W. Tang, D. Cory, D.T. Scadden, R. 
Weissleder, Tat peptide-derivatized magnetic nanoparticles allow in vivo 
tracking and recovery of progenitor cells, Nat. Biotechnol. 18 410-414 
 [94] J.S. Suk, J. Suh, K. Choy, S.K. Lai, J. Fu, J. Hanes, Gene delivery to 
differentiated neurotypic cells with RGD and HIV Tat peptide functionalized 
polymeric nanoparticles, Biomaterials 27 (2006) 5143-5150 
 [95] M.A. Bogoyevitch, T.S. Kendrick, D.C.H. Ng, R.K. Barr, Taking the cell by 
stealth or storm? Protein transduction domains (PTDs) as versatile vectors for 
delivery, DNA Cell Biol. 21 (2002) 879-894 
 [96] M. Zorko, U. Langel, Cell-penetrating peptides: mechanism and kinetics of 
cargo delivery, Adv. Drug Deliv. Rev. 57 (2005) 529-545 
 [97] H. Brooks, B. Lebleu, E. Vives, Tat peptide-mediated cellular delivery: back to 
basics, Adv. Drug Deliv. Rev. 57 (2005) 559-577 
 [98] M.C. Morris, J. Depollier, J. Mery, F. Heitz, G. Divita, A peptide carrier for the 
delivery of biologically active proteins into mammalian cells, Nat. Biotechnol. 
19 (2001) 1173-1176 
 [99] T. Pellegrino, W.J. Parak, R. Boudreau, M.A. Le Gros, D. Gerion, A.P. 
Alivisatos, C.A. Larabell, Quantum dot-based cell motility assay, Differentiation 
71 (2003) 542-548 
 [100] A. Hoshino, K. Fujioka, Y.I. Kawamura, N. Toyama-Sorimachi, M. Yasuhara, 
T. Dohi, K. Yamamoto, Immune cells tracing using quantum dots, Proc. of 
SPIE 6096 (2006) 609613/1-609613/8 
 [101] J. Silver, W. Ou, Photoactivation of quantum dot fluorescence following 
endocytosis, Nano Lett. 5 (2005) 1445-1449 
 [102] B.C. Lagerholm, M. Wang, L.A. Ernst, D.H. Ly, H. Liu, M.P. Bruchez, A.S. 
Waggoner, Multicolor Coding of Cells with Cationic Peptide Coated Quantum 
Dots, Nano Lett. 4 (2004) 2019-2022 
 [103] L.C. Mattheakis, J.M. Dias, Y.J. Choi, J. Gong, M.P. Bruchez, J. Liu, E. Wang, 
Optical coding of mammalian cells using semiconductor quantum dots, Anal. 
Biochem. 327 (2004) 200-208 
 Introduction Chapter 1 
 
- 45 - 
 [104] S.M. Rozenzhak, M.P. Kadakia, T.M. Caserta, T.R. Westbrook, M.O. Stone, 
R.R. Naik, Cellular internalization and targeting of semiconductor quantum 
dots, Chem. Commun. (2005) 2217-2219 
 [105] E. Chang, W.W. Yu, V.L. Colvin, R. Drezek, Quantifying the influence of 
surface coatings on quantum dot uptake in cells, J. Biomed. Nanotechnol. 1 
(2005) 397-401 
 [106] E.L. Bentzen, I.D. Tomlinson, J. Mason, P. Gresch, M.R. Warnement, D. 
Wright, E. Sanders-Bush, R. Blakely, S.J. Rosenthal, Surface Modification To 
Reduce Nonspecific Binding of Quantum Dots in Live Cell Assays, Bioconjug. 
Chem. 16 (2005) 1488-1494 
 [107] B. Ballou, B.C. Lagerholm, L.A. Ernst, M.P. Bruchez, A.S. Waggoner, 
Noninvasive imaging of quantum dots in mice, Bioconjug. Chem. 15 (2004) 
79-86 
 [108] W. Cai, D. Shin, K. Chen, O. Gheysens, Q. Cao, S. Wang, X, S.S. Gambhir, X. 
Chen, Peptide-labeled near-infrared quantum dots for imaging tumor 
vasculature in living subjects, Nano Lett. 6 (2006) 669-676 
 [109] R.K. Jain, Transport of molecules across tumor vasculature, Cancer 
Metastasis Rev. 6 (1987) 559-593 
 [110] J.O. Winter, T.Y. Liu, B.A. Korgel, C.E. Schmidt, Recognition molecule 
directed interfacing between semiconductor quantum dots and nerve cells, 
Adv. Mater. 13 (2001) 1673-1677 
 [111] X. Wu, H. Liu, J. Liu, K.N. Haley, J.A. Treadway, J.P. Larson, N. Ge, F. Peale, 
M.P. Bruchez, Immunofluorescent labeling of cancer marker Her2 and other 
cellular targets with semiconductor quantum dots, Nature Biotechnology 21 
(2002) 41-46 
 [112] M. Howarth, K. Takao, Y. Hayashi, A.Y. Ting, Targeting quantum dots to 
surface proteins in living cells with biotin ligase, Proc. Natl. Acad. Sci. U. S. A. 
102 (2005) 7583-7588 
 [113] W. Jiang, S. Mardyani, H. Fischer, W.C.W. Chan, Design and Characterization 
of Lysine Cross-Linked Mercapto-Acid Biocompatible Quantum Dots, Chem. 
Mater. 18 (2006) 872-878 
 [114] Y. Pan, J. Cai, L. Qin, H. Wang, Atomic force microscopy-based cell 
nanostructure for ligand-conjugated quantum dot endocytosis, Acta biochimica 
et biophysica Sinica 38 (2006) 646-652 
Chapter 1 Introduction 
 
- 46 - 
 [115] H.E. Grecco, K.A. Lidke, R. Heintzmann, D.S. Lidke, C. Spagnuolo, O.E. 
Martinez, E.A. Jares-Erijman, T.M. Jovin, Ensemble and single particle 
photophysical properties (two-photon excitation, anisotropy, FRET, lifetime, 
spectral conversion) of commercial quantum dots in solution and in live cells, 
Microsc. Res. Tech. 65 (2004) 169-179 
 [116] J. Mendelsohn, J. Baselga, The EGF receptor family as targets for cancer 
therapy, Oncogene 19 (2000) 6550-6565 
 [117] A. Kriete, E. Papazoglou, B. Edrissi, H. Pais, K. Pourrezaei, Automated 
quantification of quantum-dot-labelled epidermal growth factor receptor 
internalization via multiscale image segmentation, Journal of microscopy 222 
(2005) 22-27 
 [118] J. Wang, P.T. Vernier, Y. Sun, M.A. Gundersen, L. Marcu, A fluorescence 
microscopy study of quantum dots as fluorescent probes for brain tumor 
diagnosis, Proc. of SPIE 5703 (2005) 127-134 
 [119] S.S. Rajan, T.Q. Vu, Quantum Dots Monitor TrkA Receptor Dynamics in the 
Interior of Neural PC12 Cells, Nano Lett. 6 (2006) 2049-2059 
 [120] M.J. Humphries, Integrin structure, Biochem. Soc. Trans. 28 (2000) 311-340 
 [121] E. Koivunen, B. Wang, E. Ruoslahti, Phage libraries displaying cyclic peptides 
with different ring sizes: ligand specificities of the RGD-directed integrins, 
Biotechnology 13 (1995) 265-270 
 [122] R. Pasqualini, E. Koivunen, E. Ruoslahti, av Integrins as receptors for tumor 
targeting by circulating ligands, Nat. Biotechnol. 15 (1997) 542-546 
 [123] C.P. Leamon, P.S. Low, Folate-mediated targeting: from diagnostics to drug 
and gene delivery, Drug Discov. Today 6 (2001) 44-51 
 [124] J. Reddy, D. Dean, M. Kennedy, P. Low, Optimization of folate-conjugated 
liposomal vectors for folate receptor-mediated gene therapy, J. Pharm. Sci. 88 
(2000) 1112-1118 
 [125] A.R. Hilgenbrink, P.S. Low, Folate receptor-mediated drug targeting: From 
therapeutics to diagnostics, J. Pharm. Sci. 94 (2005) 2135-2146 
 [126] W.C.W. Chan, D.J. Maxwell, X. Gao, R.E. Bailey, M. Han, S. Nie, Luminescent 
quantum dots for multiplexed biological detection and imaging, Curr. Opin. 
Biotechnol. 13 (2002) 40-46 
 [127] E. Ruoslahti, Targeting tumor vasculature with homing peptides from phage 
display, Semin. Cancer Biol. 10 (2000) 435-442 
 Introduction Chapter 1 
 
- 47 - 
 [128] L.R.H. Krumpe, T. Mori, The use of phage-displayed peptide libraries to 
develop tumor-targeting drugs, International Journal of Peptide Research and 
Therapeutics 12 (2006) 79-91 
 [129] T. Oyama, I.T. Rombel, K.N. Samli, X. Zhou, K.C. Brown, Isolation of multiple 
cell-binding ligands from different phage displayed-peptide libraries, 
Biosensors & Bioelectronics 21 (2006) 1867-1875 
 [130] Y. Kim, A.M. Lillo, S.C.J. Steiniger, Y. Liu, C. Ballatore, A. Anichini, R. 
Mortarini, G.F. Kaufmann, B. Zhou, B. Felding-Habermann, K.D. Janda, 
Targeting Heat Shock Proteins on Cancer Cells: Selection, Characterization, 
and Cell-Penetrating Properties of a Peptidic GRP78 Ligand, Biochemistry 45 
(2006) 9434-9444 
 [131] S. Takeda, S. Kadowaki, T. Haga, H. Takaesu, S. Mitaku, Identification of G 
protein-coupled receptor genes from the human genome sequence, FEBS 
Lett. 520 (2002) 97-101 
 [132] B.L. Cushing, V.L. Kolesnichenko, C.J. O'Connor, Recent Advances in the 
Liquid-Phase Syntheses of Inorganic Nanoparticles, Chem. Rev. 104 (2004) 
3893-3946 
 [133] S.J. Rosenthal, I. Tomlinson, E.M. Adkins, S. Schroeter, S. Adams, L. 
Swafford, J. McBride, Y. Wang, L.J. DeFelice, R.D. Blakely, Targeting Cell 
Surface Receptors with Ligand-Conjugated Nanocrystals, J. Am. Chem. Soc. 
124 (2002) 4586-4594 
 [134] I.D. Tomlinson, J.N. Mason, R.D. Blakely, S.J. Rosenthal, Inhibitors of the 
serotonin transporter protein (SERT): The design and synthesis of biotinylated 
derivatives of 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles. High-affinity 
serotonergic ligands for conjugation with quantum dots, Bioorg. Med. Chem. 
Lett. 15 (2005) 5307-5310 
 [135] I.D. Tomlinson, J.N. Mason, R.D. Blakely, S.J. Rosenthal, High affinity 
inhibitors of the dopamine transporter (DAT): Novel biotinylated ligands for 
conjugation to quantum dots, Bioorg. Med. Chem. Lett. 16 (2006) 4664-4667 
 [136] J.N. Mason, H. Farmer, I.D. Tomlinson, J.W. Schwartz, V. Savchenko, L.J. 
DeFelice, S.J. Rosenthal, R.D. Blakely, Novel fluorescence-based approaches 
for the study of biogenic amine transporter localization, activity, and regulation, 
J. Neurosci. Methods 143 (2005) 3-25 
Chapter 1 Introduction 
 
- 48 - 
 [137] S.H. Young, E. Rozengurt, Qdot nanocrystal conjugates conjugated to 
bombesin or ANG II label the cognate G protein-coupled receptor in living 
cells, Am. J. Physiol. 290 (2006) C728-C732 
 [138] J. Panyam, V. Labhasetwar, Targeting Intracellular Targets, Current Drug 
Delivery 1 (2004) 235-247 
 [139] B. Fahrenkrog, U. Aebi, The nuclear pore complex: Nucleocytoplasmic 
transport and beyond, Nat. Rev. Mol. Cell Biol. 4 (2003) 757-766 
 [140] A. Szewczyk, L. Wojtczak, Mitochondria as a pharmacological target, 
Pharmacol. Rev. 54 (2002) 101-127 
 [141] N. Dias, C. Bailly, Drugs targeting mitochondrial functions to control tumor cell 
growth, Biochem. Pharmacol. 70 (2005) 1-12 
 [142] J.B. Delehanty, I.L. Medintz, T. Pons, F.M. Brunel, P.E. Dawson, H. Mattoussi, 
Self-Assembled Quantum Dot-Peptide Bioconjugates for Selective Intracellular 
Delivery, Bioconjug. Chem. 17 (2006) 920-927 
 [143] J.M. de la Fuente, M. Fandel, C.C. Berry, M. Riehle, L. Cronin, G. Aitchison, 
A.S.G. Curtis, Quantum dots protected with tiopronin: A new fluorescence 
system for cell-biology studies, ChemBioChem 6 (2005) 989-991 
 [144] S. Santra, H. Yang, J.T. Stanley, P.H. Holloway, B.M. Moudgil, G. Walter, R.A. 
Mericle, Rapid and effective labeling of brain tissue using TAT-conjugated 
CdS[ratio]Mn/ZnS quantum dots, Chem. Commun. (2005) 3144-3146 
 [145] M. Gumbleton, A.J. Hollins, Y. Omidi, L. Campbell, G. Taylor, Targeting 
caveolae for vesicular drug transport, J. Control. Release 87 (2003) 139-151 
 [146] E.M. Damm, L. Pelkmans, J. Kartenbeck, A. Mezzacasa, T. Kurzchalia, A. 
Helenius, Clathrin- and caveolin-1-independent endocytosis: Entry of simian 
virus 40 into cells devoid of caveolae, J. Cell Biol. 168 (2005) 477-488 
 [147] I.M. Kaplan, J.S. Wadia, S.F. Dowdy, Cationic TAT peptide transduction 
domain enters cells by macropinocytosis, J. Control. Release 102 (2005) 247-
253 
 [148] A. Ferrari, V. Pellegrini, C. Arcangeli, A. Fittipaldi, M. Giacca, F. Beltram, 
Caveolae-Mediated internalization of extracellular HIV-1 tat fusion proteins 
visualized in real time, Mol. Ther. 8 (2003) 284-294 
 [149] Y. Zhang, M.K. So, J. Rao, Protease-Modulated Cellular Uptake of Quantum 
Dots, Nano Lett. 6 (2006) 1988-1992 
 Introduction Chapter 1 
 
- 49 - 
 [150] S.D. Caruthers, S.A. Wickline, G.M. Lanza, Nanotechnological applications in 
medicine, Curr. Opin. Biotechnol.18 (2007) 26-30 
 
 
Chapter 1 Introduction 
 
- 50 - 
 
Cellular Nanoparticle Delivery by G-Protein Coupled Receptors 
 
 
 
 
Chapter 2 
 
 
Goals of the Thesis 
 
Chapter 2 Goals of the Thesis 
 
- 52 - 
Considering the significant benefits that site-specific drug therapy offers, the goal of 
this thesis was to investigate the potential of G-protein-coupled receptors (GPCRs) 
as candidates for a new class of targets in the field of drug targeting. In order to 
evaluate this potential at the cellular level, nanoparticles were conjugated with 
specific ligands for the human neuropeptide Y (hNPY) Y1 receptor and characterized 
according to their affinity to cells expressing this receptor. A second objective was to 
explore whether GPCRs provide a portal for nanoparticle delivery into cells, since 
GPCRs are known to internalize after agonist binding. 
GPCRs represent the largest class of receptors in the human genome and have, 
therefore, been a key area of focus in drug research for several decades. 
Consequently, we know a number of specifically binding ligands as well as the organ 
distribution of many GPCRs. This makes GPCRs extremely interesting candidates for 
nanoparticle drug targeting. The human Y1 receptor was chosen as model receptor to 
prove the principle of this new form of targeting. The peptidic ligands of this receptor 
were supposed to show more affinity towards their receptor after immobilization on a 
nanoparticle compared to small native ligands. Instead of using drug-loaded 
polymeric nanoparticles, a model colloid was chosen to provide optimal conditions for 
the investigation of the particle-cell-interactions. Quantum dots (QDs), semiconductor 
nanocrystals, offer a number of advantages over conventional nanoparticles, such as 
their increased detectability and their small and uniform size (chapter 1). While their 
small size is a prerequisite for entering distinct cellular uptake pathways, their strong 
fluorescence enables sensitive and highly resolved detection by fluorescence 
microscopy. 
For the design of the QD-based model colloid, an initial aim was to synthesize QDs 
via traditional methods in organic solvents using safe, non-organometallic precursors. 
For this purpose, the conditions for the growth of the particles were optimized and the 
synthesis processes in coordinating as well as in non-coordinating solvents were 
compared (chapter 3). 
Since these organic soluble nanoparticles are to be used in aqueous systems for the 
cellular investigations, different methods of modifying the nanoparticles were 
examined in order to render the particles water-soluble. Moreover, it was a goal to 
attach poly(ethylene glycol) (PEG) to the particles, since this modification is known to 
enhance the stability of the colloid and to reduce non-specific binding to cells – an 
important prerequisite for further studies of specific uptake (chapter 4). 
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Following this, the aqueous QDs were characterized according to their dispersity 
using different methods, such as transmission electron microscopy (TEM), dynamic 
light scattering (DLS) and asymmetric flow field-flow fractionation (AF4), since 
dispersity should strongly influence the cellular uptake pathway of nanoparticles. 
Furthermore, the cell-compatibility was evaluated (chapter 5). 
Having optimized the preparation and the characterization of PEGylated QDs, their 
potential for use in cellular studies had to be evaluated. Therefore, their stability 
under cell-culture conditions and their detectability in fluorescence microscopy was 
investigated. Cytotoxicity, a major concern when dealing with QDs, was also 
analyzed. (chapter 6). 
In establishing the conditions for the conjugation of the QDs with the peptidic ligands 
for the Y1 receptor, easily preparable micelles of PEGylated phospholipids, which 
were also used for the coating of the QDs, served as the surrogate for the PEGylated 
QDs. In addition to the ease of preparation, the absence of the QDs in this similar 
colloid facilitated the analytics of the bioconjugates by mass spectrometry and 
spectrometric methods. The micelles were additionally tested for their ligand-
mediated delivery to Y1-receptor positive MCF-7 cells (chapter 7). 
The subsequent investigations focused on the biological activity of QDs conjugated 
with specific ligands of the Y1 receptor. Therefore, several peptidic analogs of the 
hNPY were bound to QDs and their binding and internalization at different human 
cancer cell lines (MCF-7, SK-N-MC) were investigated. Through confocal laser 
scanning microscopy, the specificity of binding and uptake was monitored and 
matched with different control groups and cells lacking the Y1 receptor (MDA). In 
order to evaluate whether a small non-peptidic Y1 receptor antagonist can be used 
for drug targeting as well, bioconjugates of QDs with an analog of BIBP3226 were 
examined using the same cell lines. The binding affinity of the agonistic and 
antagonistic QDs is a crucial parameter in estimating the potential of GPCR-targeted 
nanoparticles. Therefore, flow-cytometric binding and displacement studies were 
conducted to see whether the affinity and specificity towards the Y1-receptor is 
acceptably high for such particles (chapter 8).  
Finally, the way in which the particles are internalized into the target cells was 
explored. To compare the uptake of the QDs to non-specific uptake, QDs were 
coated with poly(ethylene imine) (PEI) and compared to NPY-QDs by confocal 
microscopy. An endosome marker and free NPY, labeled with a small fluorophore 
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were used to evaluate differences in uptake caused by the conjugation of the ligand 
to the QDs (chapter 9). 
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Abstract 
Over the last decade, quantum dots (QDs) have attracted considerable attention in 
biomedical research, since these semiconductor nanocrystals are both extremely 
small and also exhibit unique optical properties, such as their bright and stable 
fluorescence in particular. These characteristics render QDs promising tools for 
discovering biological processes. 
Up to now, a number of synthesis methods have been described to produce QDs for 
such purposes. However, the huge number of processes makes it hard to determine 
the most convenient method. In order to find a pragmatic method for the synthesis of 
CdSe/ZnS nanocrystals of favorable optical properties and narrow size distributions, 
protocols for the synthesis in organic solvents were established by comparing two 
common classes of synthesis routes. In this study, the preparation of quantum dots in 
non-coordinating solvent (octadecene) with those synthesized in non-coordinating 
solvents (trioctylphosphine oxide and hexadecylamine) was compared. Having 
optimized the synthesis routes, the preparation in coordinating solvents turned out to 
be more favorable. Narrower emission peaks and higher quantum yields of up to 
80% were obtained. 
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Introduction 
Quantum dots (QDs), semiconductor nanocrystals in the size-range of approx. 1-10 
nm, have become very important in various applications covering physical and 
chemical as well as biomedical sciences [1-4]. The major benefit of these 
nanocrystals lies in their small and very uniform size as well as in their remarkable 
optical properties, namely their bright photoluminescence obtained after excitation 
[5]. In contrast to organic fluorescent dyes, the emission peak of QDs is very sharp 
while their excitation spectra are very broad. Consequently, these characteristics 
provide large practical Stokes-shifts, the difference between the wavelengths of 
absorbed and emitted light. Moreover, QDs are very stable with regard to 
photobleaching, a phenomenon that has been a drawback for conventional dyes in 
long-term fluorescence imaging of cells and tissues [6,7]. Nanocrystals composed of 
cadmium selenide (CdSe) are advantageous for the application in cellular imaging, 
since this material exhibits photoluminescence in the visible range of the spectrum 
which can be detected by standard equipment of fluorescence microscopes and the 
detectors of flow cytometers [8]. To improve the optical properties of CdSe 
nanocrystals, layers of a semiconductor of higher bandgap are usually grown onto 
the particles [9] to provide an insulating effect for the exciton, the electron-hole-pair 
responsible for the fluorescence. Zinc sulfide (ZnS) [10] proved to be helpful, since 
this material on the one hand provides the mentioned prerequisite, and on the other 
hand shows only moderate lattice-mismatch with the CdSe crystals [11] when 
forming close coatings on the core particles. 
Synthesis routes towards CdSe nanocrystals can be divided into methods using 
aqueous precursors yielding water-dispersable QDs [12,13], and into the vast 
majority of routes making use of organic solvents. The QDs synthesized using 
aqueous routes have the advantage that there is no additional surface-modification 
on the nanocrystals for solubilisation necessary. However, these nanocrystals cannot 
compete with the narrow size-distributions and high quantum yields of the ones 
obtained by using organic solvents. QDs synthesized in organic solvents usually 
exhibit narrower sizes and higher quantum yields [14]. Therefore, routes for QD 
synthesis in non-aqueous solvents at high temperatures are currently strongly 
preferred. Organic-soluble QDs were first produced by thermal decomposition of 
organo-metallic precursors, such as dimethylcadmium, which for the first time lead to 
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high-quality nanocrystals [15-17]. However in order to establish a QD synthesis 
route, safer reagents prove to be more favorable [18] by exchanging 
dimethylcadmium against cadmium oxide. Organic synthesis processes can be 
classified into ones making use of coordinating solvents, i.e. solvents forming 
complexes with metal ions, like trioctylphosphine oxide (TOPO) and hexadecylamine 
(HDA) [19], and ones based on non-coordinating ones, like octadecene (ODE) [20] or 
paraffin [21].    
The objective of this study was to compare the synthesis of CdSe/ZnS nanocrystals 
in the coordinating solvents HDA/TOPO to the ones obtained in the non-coordinating 
solvent ODE. Therefore, both synthesis routes were optimized with respect to the 
main influence factors, such as temperature and precursor concentration. Methods 
for the purification of the particles were developed as well. After appropriate surface-
modification, the particles obtained are intended for use in biological studies. 
 
Materials and methods 
Cadmium oxide (CdO, 99.5%), hexadecylamine (HDA, tech. grade 90%), lauric acid 
(LA 98%), methanol (anhydr. 99.8%), octadecene (ODE, tech. grade 90%), oleic acid 
(OA, reagent grade 99%), sulfur (99.5%), toluene (anhydr. 99.8%), trioctylphosphine 
(TOP, tech. grade 90%), trioctylphosphine oxide (TOPO, tech. grade 90%) and zinc 
stearate (tech. grade) were obtained from Sigma-Aldrich (St. Louis, MO). 
 
Synthesis of CdSe/ZnS nanocrystals 
All reactions were carried-out under water-free conditions and under N2 inert gas 
atmosphere. All reagents, unless obtained in water-free quality, were dried in vacuum 
at elevated temperatures. 
 
Synthesis using non-coordinating solvents (ODE) 
CdSe nanocrystals were synthesized with some modifications according to 
previously published methods [20,22]. In order to improve the reaction conditions, 
various parameters were changed. In the following, the synthesis is described by 
making use of the optimized conditions. The respective amount of CdO (0.4 mmol) 
was dissolved in OA (4.8 ml) at 200 °C. Afterwards, ODE (40 ml) was added and the 
solution was heated to 280 °C. At this temperature, the Se-precursor, which was kept 
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at room temperature, was injected quickly using a syringe. The Se-precursor was 
prepared by dissolving Se (0.2 mmol) in TOP (0.2 ml) and ODE (3.2 ml) under slight 
heating (60 °C). After injection, the nanocrystals were grown in the heating bath. 
Samples were taken at the respective time-points by a syringe. At the desired 
nanocrystal size, the reaction was stopped by injecting ODE (10 ml) at room 
temperature. For the set of different OA amounts, the following conditions were used: 
CdO: 0.1 mmol; OA: 0.3-2.0 ml (3-20%); T = 250 °C; Se: 0.07 mmol. For the set of 
different total precursor concentrations: CdO: 0.05/0.1/0.2/0.3/0.4 mmol; OA: 
0.06/1.2/2.4/3.6/4.8 ml; ODE: 10 ml; T = 250 °C; Se: 0.0125/0.025/0.05/0.1/0.2 mmol. 
For the set of different reaction temperatures: T = 220/235/250/265/280 °C. 
After preparation, the nanocrystals were precipitated by adding acetone of the same 
volume. After centrifugation at 20.000 g, the precipitated QDs were redispersed in 
500 µl of toluene. For coating with ZnS, the CdSe nanocrystals in toluene were 
added to 20 ml of ODE and heated to the respective coating temperature 
(100/150/200 °C). For ZnS-coating, the exact amounts of zinc stearate and S were 
calculated in correlation to the amount and diameter of the CdSe cores which were 
determined by UV-absorption using estimations for the extinction coefficients and 
nanocrystal diameter [23]. By calculating the volume for a ZnS-shell of 4 monolayers, 
the theoretical amount of Z and S for all particles was determined (density of ZnS 
4.1x10-21 g/nm3, thickness of ZnS monolayer 0.31 nm). Zinc stearate and S were 
dissolved in 6 ml of TOP under heating to 100 °C. After cooling to room temperature, 
the precursor was added dropwise to the CdSe cores over 30 or 60 minutes each at 
100/150/200 °C. The CdSe/ZnS nanocrystals were precipitated and redispersed as 
described above.  
 
Synthesis using coordinating solvents (TOPO/HDA) 
The cadmium precursor was prepared by dissolving CdO (0.2 mmol) in lauric acid 
(1.6 mmol) at 200 °C. TOPO (10 mmol, 3.88 mg) and HDA (16 mmol, 3.88 mg) were 
added and the mixture was heated to 285 °C. At this temperature, the heating bath 
was removed and Se (2 mmol) dissolved in 3.5 ml of TOP (room temperature) was 
injected. At the desired nanocrystal size, the reaction was stopped by adding 20 ml of 
toluene. The CdSe cores were precipitated with an equal volume of methanol and 
centrifuged and redispersed as described above. ZnS-coating was conducted after 
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dispersing the CdSe cores in the same amount of TOPO and HDA as for the core 
synthesis at the respective temperature (100/150/200 °C) over 30 or 60 min. The 
amounts for the ZnS precursor were calculated as described above. After shell-
growth, the nanocrystals were purified by precipitation as described above.  
 
Spectrophotometric measurements 
UV absorbance spectra were recorded using an Uvikon 941 (Kontron Instruments, 
UK) and 10 cm quartz cuvettes. Fluorescence was determined in 10 cm quartz 
cuvettes using a RF-1501 spectrometer (Shimadzu Deutschland GmbH, Duisburg, 
Germany) in order to follow the growth of the CdSe QDs in ODE. For all other 
fluorescence measurements (including all determinations of quantum yields), an LS 
55 fluorescence spectrometer from PerkinElmer (Waltham, MA) was used. 
Fluorescence quantum yields were determined in correlation to a fluorescein 
standard in 0.1 N NaOH (quantum yield 90%). Samples were excited at 450 nm. 
 
Size determination 
The size (solvodynamic diameter) of the QDs was determined by dynamic light 
scattering (DLS) using a ZetaSizer 3000 HSA (Malvern, Worcestershire, UK) at 20 °C 
and an angle of 90° in toluene. Data was processed using the NNLS algorithm. 
  
Results and discussion 
Synthesis of CdSe nanocrystals 
Two chemically different routes towards CdSe/ZnS quantum dots have been 
established in order to compare them with each other concerning the reproducibility 
and the optical properties of the resulting nanocrystals. Both processes are based 
upon the thermal decomposition of the respective precursors for CdSe and ZnS (see 
fig. 1A). For both reactions the cadmium precursor was based on CdO to avoid 
hazardous and dangerous organometallic precursors. In both cases, 
trioctylphosphine selenide (TOPSe) was used as the selenium precursor. The 
approaches varied with the solvents used: non-coordinating (ODE) or coordinating 
(TOPO), both exhibiting commonly-used systems. As shown in the reaction scheme 
(fig. 1A), CdSe nanocrystals are formed by reacting the cadmium precursors 
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(cadmium oleate or cadmium laurate) with TOPSe in either a non-coordinating (ODE) 
or a coordinating solvent (TOPO/HDA). The setup for the reactions comprising 
standard Schlenk methods is depicted in fig. 1B.  
 
N2
precursor
solution
A B
1.   Cd(R-COO-)2  +  TOPSe CdSe
2.   CdSe  +  Zn(R'-COO-) +  TOPS CdSe/ZnS
TOPO/HDA
or
ODE
TOPO/HDA
or
ODE
R:     -CH3(CH2)10    
         -CH3(CH2)7CH=CH(CH2)7
R':     -CH3(CH2)16
 
Figure 1: Preparation of CdSe/ZnS nanocrystals. (A) Synthesis scheme, starting 
from two different Cd-salts (laurate or oleate). CdSe nanocrystals were either formed 
in the coordinating solvent mixture TOPO/HDA or ODE by reaction with the selenium 
precursor (TOPSe) (1). The coating with ZnS was subsequently achieved by using 
zinc stearate and the sulfur precursor (TOPS) under the same solvent conditions (2). 
(B) Setup of the reaction. The reactions were carried out under inert gas atmosphere. 
For CdSe-formation, the Se-precursor was injected quickly. For the coating, the ZnS-
precursor was added dropwise via a syringe. 
 
CdSe-growth in non-coordinating solvents 
In order to optimize this reaction in the non-coordinating solvent ODE towards high 
emission wavelengths and narrow emission peaks, beneficial features for probes in 
biological investigations, the optimal reaction conditions concerning the amount of 
oleic acid were determined. Oleic acid serves as a complexing stabilizer for the Cd-
precursor and depending on the concentration it influences, the reaction kinetics of 
the crystal growth. In the growth curve (fig. 2A), the fluorescence emission maxima 
are plotted against the growth time. Since the emission maxima grow with increasing 
particle size, the curves are representative of the corresponding particle sizes. Each 
curve follows typical growth characteristics. After a short nucleation phase, during 
which small CdSe nanocrystals are generated, the crystals grow and as a result 
rapidly increasing emission maxima were observed. Nucleation decreases due to the 
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loss of temperature resulting from the injection of the cold Se-precursor and due to 
the decrease of the monomer concentration. During the growth phase, small crystals 
are dissolved in favor of larger ones (focusing of the size distribution) [24]. This 
phase continues until the curves finally level off, when equilibrium between growth 
and decomposition is reached. Finally, decomposition begins to dominate and hence 
reactions are then stopped before this point by rapidly reducing the temperature. This 
behavior can also be seen when regarding the full width at half maximum (FWHM) 
values of the corresponding emission peaks of the growth curves (fig. 1B). These 
values are correlated with the particle size-distribution: the broader the size 
distribution, the higher the FWHM values. After initial higher values, the FWHM 
decreases during the growth phase until the point of the maximum size is reached 
and decomposition processes start. The optimum OA concentration was found to be 
12%, relative to the total volume. Here, the growth is controllable over about 400 
seconds. High emission maxima can be reached while lower OA concentrations 
yielded lower maxima and shorter time spans of controllable growth. The FWHM 
values are the lowest and, therefore, the best when applying the 12% OA 
concentration. Thus, OA was kept at this concentration for further studies.  
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Figure 2: Influence of OA concentration on growth and size distribution 
(FWHM). Higher OA concentrations yield more controllable growth to higher emission 
wavelengths and therefore higher nanocrystal sizes (A). The FWHM values and, 
therefore, the size-distributions of the nanocrystals decrease during the reaction. The 
lowest and thus the best values were obtained at 12% of OA (B). (OA concentration: 
 3%;  6%;  9%;  12 %;  20%). 
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In order to produce larger amounts of nanocrystals, it was investigated whether an 
increase in the total amounts of the precursors exerts an influence on the nanocrystal 
growth. Therefore, the total volume of the reaction solution was kept constant while 
an x-fold amount of all precursors was used. Fig. 3A shows the effect of the total 
concentration of the precursors by maintaining the ratio Cd : Se : OA. For the sake of 
clarity, only the concentration of Cd is depicted. An increase in the total concentration 
of all precursors causes a decrease in emission maxima. Under the chosen 
conditions, the FWHM decrease for higher precursor concentrations (fig. 3B). This 
proves that the growth reaction is related to the amount of precursors, even when 
their ratio is unchanged. A possible reason for this behavior might be the hindered 
diffusion from the precursor solution to the nanocrystals.  For the Cd-concentrations 
of 7.5 and 10 mM, the reaction is well controllable and yields higher amounts than for 
lower concentrations. Therefore, these concentrations are considered favorable.  
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Figure 3: Influence of the total precursor concentration on growth and size 
distribution (FWHM). Keeping the ratio of the precursors constant the influence of 
the total precursor concentration showed an optimum for the threefold batch-size. 
Here, relatively high amounts of QDs can be produced and growth continues up to 
high emission maxima (A). The FWHM values are optimal for this batch size (B). 
(Values calculated in correlation to Cd concentration:  1.25 mM;  2.5 mM;  5.0 
mM;  7.5 mM;  10 mM). 
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The largest influence on the growth characteristics of the CdSe nanocrystals is 
related to the process temperature. In a series from 220 to 280 °C, the final particle 
increases in correlation with the emission maxima (fig. 4A). Therefore, for the 
optimization of the reaction conditions later on, the temperature was set to 280 °C. 
This provided the highest flexibility for the preparation of a broad spectrum of 
differently emitting QDs. Moreover, at this growth temperature, the size distribution 
and, therefore, the FWHM value of the resulting CdSe QDs is the lowest which 
emphasizes that the optimum growth temperature is at 280 °C (fig. 4B). 
As shown in fig. 5, the nanocrystal growth under the optimized conditions is well-
controllable, since deviations in the growth curve as well as in the FWHM values are 
on an acceptably low level. The data show that during the growth reaction, the 
FWHM values are narrow and therefore the size-distributions are focussing.  
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Figure 4: Influence of the growth temperature on growth and size distribution 
(FWHM). Increasing the growth temperature of the nanocrystals leads to longer 
growth times and higher emission maxima, with an optimum at 280 °C (A). For this 
temperature, the FWHM values corresponding to the broadness of the size 
distribution are lowest (B). (Growth temperatures:  220 °C;  235 °C;  250 °C;  
265 °C;  280 °C). 
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An overview of the optical properties of the CdSe nanocrystals prepared under the 
optimized conditions in the non-coordinating solvent ODE is given in fig. 6. Here, five 
collectives of CdSe QDs of distinguishable fluorescence spectra are depicted 
together with the absorbance spectrum of the QDs exhibiting an emission maximum 
of 606 nm. Typical fluorescence quantum yields obtained under these conditions are 
around 5%.  
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Figure 5: Growth kinetics of CdSe nanocrystals in the non-coordinating solvent ODE 
(   ), represented by the emission maxima plotted against the growth time. After 
rapid nucleation, growth goes on for about 200 s and finally levels off. Together with 
growth, a focussing of the crystal size-distribution takes place, represented by the 
time course of the FWHM values (  ).  
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Figure 6: Emission spectra (colored lines) of different-sized CdSe nanocrystals 
grown in the non-coordinating solvent ODE. The crystal samples were taken at 
different time-points during growth and exhibit five distinguishable colors. The 
corresponding absorbance spectrum of the sample exhibiting an emission maximum 
of 606 nm is represented by the circle-marked curve. 
 
CdSe-growth in coordinating solvents 
In order to compare the results obtained by the synthesis of CdSe QDs in non-
coordinating solvents with the ones obtained in coordinating solvents, and then 
identify the most convenient synthesis method, the nanocrystal growth was 
conducted in a 1:1 mixture of TOPO and HDA. 
In these experiments, the reaction conditions published in literature were converted 
[25,26], since the TOPO/HDA system is quite common. The resulting overview of the 
growth reaction is given in fig. 7. Under the chosen conditions, QDs emitting light in 
the green to orange range of the spectrum were obtained. These QDs are optimal for 
modification with PEG phospholipids (see chapter 4). Like the synthesis in ODE, here 
the growth which was initiated at 280 °C and maintained at approx. 250 °C quickly 
takes place after the nucleation. Further growth was stopped by quickly reducing the 
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temperature by injecting toluene. Moreover, addition of solvent prevented the 
TOPO/HDA mixture from solidification.  
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Figure 7: Overview of the growth kinetics of the QDs obtained by synthesis in 
the coordinating solvents TOPO/HDA. Growth was stopped after 60 seconds. 
Again, the size distributions are focusing during the reaction, yielding low FHWM 
values around 30nm. 
 
Likewise, during crystal growth, the size distribution of the particle fractions, 
correlating with the FWHM, narrows. However, the final FWHM values were 
significantly lower than compared to the QDs obtained in OA, about 26 nm. The 
range of the fluorescent quantum yields was around 10-30 %.Their reproducibility 
was comparable to the synthesis in the non-coordinating solvent. 
An overview of the emission and absorbance properties of the CdSe nanocrystals 
obtained in the coordinating solvent mixture is given in fig. 8. Here, the emission 
peaks exhibit a favorable, very sharp form. 
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Figure 8: Overview of the emission and absorbance properties of the CdSe 
nanocrystals obtained in the coordinating solvent mixture. The emission peaks 
which show maxima between 517 and 553nm exhibit a sharp appearance. The 
absorbance spectrum of the highest emitting QDs is represented by the optical circle-
marked curve. 
 
To sum up the synthesis of CdSe nanocrystals in non-coordinating and coordinating 
solvents, the latter exhibits several advantages. The size distribution of the particles 
is significantly lower and the reaction produces nanocrystals of higher quantum 
yields. In addition to this, the purification of the particles obtained in the non-
coordinating solvent mixture was easier, since solvent residues could be easily 
removed by centrifugation as they are solids at room temperature. 
 
Coating of CdSe nanocrystals with ZnS 
Both species of CdSe nanocrystals were further coated with a ZnS shell in order to 
increase the quantum yields. Fig. 1A shows the scheme of the coating reaction after 
the synthesis of the CdSe QDs. Similar solvent mixtures to the growth of the CdSe 
cores were used while the ZnS precursors consisted of zinc stearate and 
trioctylphosphine sulfide (TOPS). 
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In an ideal case, a significant increase in the quantum yields as well as a red-shift of 
the emission maximum of the CdSe nanocrystals indicates a successful coating 
process [11]. Changes in the CdSe cores, like broadening of the size distribution, are 
undesired and have to be avoided, e.g. by adjusting the temperature. The growth 
temperature should allow for the growth of ZnS onto CdSe, but should avoid the 
formation of ZnS nanocrystals as well as changes in the core nanocrystals. 
Therefore, the optimum temperature as well as the growth reaction time for both 
kinds of solvents was investigated.  
 
ZnS shell-growth in non-coordinating solvent 
In fig. 9, the conditions investigated for the ZnS growth in the non-coordinating 
solvent ODE are compared. Temperatures from 100 to 200 °C over 30 and 60 
minutes of reaction time were compared. For all conditions, no increase in the 
emission maximum was observed. Moreover, the FWHM values increased after the 
coating process, indicating that the CdSe cores were not stable under these 
conditions. Both facts suggest insufficient ZnS coating of the particles. However, for 
all coating reaction conditions, an increase of the quantum yields was registered.   
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Figure 9: Coating of CdSe nanocrystals with ZnS in the non-coordinating 
solvent ODE. (A) Comparison of emission maxima and FWHM values before and 
after coating with ZnS for 30 and 60 minutes reaction time at temperatures between 
100 and 200 °C. (B)  The corresponding quantum yields obtained for CdSe/ZnS 
nanocrystals under these conditions show an increase compared to the CdSe 
nanocrystals. 
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Figure 10: Coating of CdSe nanocrystals with ZnS in the coordinating solvent 
mixture TOPO/HDA. (A) A significant increase in the emission maxima of the 
nanocrystals was obtained for the reaction conducted at 200 °C while lower 
temperatures did not yield a red-shift of the emission maxima. (B) Under these 
conditions the FWHM values remain constant. For all reactions an increase in the 
quantum yields was observed. 
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ZnS shell-growth in coordinating solvent 
In contrast, the ZnS coating under similar conditions using the coordinating solvent 
mixture was successful (fig. 10A). However, for the modification, only a reaction 
temperature of 200 °C yielded a significant red-shift of the emission maxima, 
indicating successful shell growth. Despite the high temperatures, the FWHM before 
and after coating remained nearly constant which shows the CdSe cores were not 
affected. The quantum yields increased after modification with ZnS under these 
conditions (fig. 10B). Since only in the coordinating solvent mixture a successful ZnS 
coating could be achieved, further investigations were carried out only using this 
solvent. To find out whether thicker ZnS shells can additionally improve optical 
properties, increasing amounts of ZnS precursors were reacted with the CdSe cores. 
In order to do this, the amount of ZnS was calculated based on the theoretical 
amount which is needed for one or more monolayers. As shown in fig. 11, the 
increasing amounts of ZnS yielded an increase in the absorbance and emission 
maxima as well as in an increase in the fluorescence quantum yields. The FWHM 
values were constant under these conditions. The results clearly show that shell 
growth needs more precursors and thus becomes more complete. 
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Figure 11: Influence of the amount of ZnS-precursors on optical properties of 
CdSe nanocrystals. The properties were investigated for unmodified CdSe and an 
increasing amount of ZnS, calculated for 1-4 theoretical monolayers. 
Phololuminescence (PL) and absorbance maxima increase as well as the quantum 
yields. 
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Figure 10: Size distribution of the CdSe/ZnS nanocrystals optimized for growth 
in the coordinating solvent TOPO. The small size (3.6nm) and narrow size-
distribution (PI = 0.076) render the crystals suitable for surface modifications such as 
embedding in polymeric micelles. 
 
Finally, DLS measurements were conducted in order to determine the size of the 
obtained CdSe/ZnS QDs. Fig. 11 shows the size distribution of the CdSe/ZnS 
nanocrystals after repeated precipitation and redispersion in toluene. The particles 
exhibit a size of 3.6 nm and very low polydispersity (polydispersity index 0.076). This 
shows that even after the coating with ZnS, the crystal diameter remains low which is 
desirable for its incorporation in phospholipid micelles (see chapter 4). The low 
polydisperity shows that after precipitation, particulate impurities are effectively 
removed.  
 
Summary and conclusion 
In order to establish a facile and reproducible method for the synthesis of CdSe/ZnS 
QDs, two commonly used synthesis routes were optimized and compared, one in the 
non-coordinating solvent ODE, and the other in the coordinating solvent mixture 
TOPO/HDA. Both methods led to CdSe nanocrystals emitting over a wide range of 
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the spectrum. However, for the preparation of high-quality CdSe/ZnS nanocrystals, 
the route using the coordinating solvent mixture proved to be more favorable. In this 
route, the particles exhibited narrower size-distributions and higher fluorescence 
quantum yields. The coating with ZnS also yielded significantly brighter QDs. By 
increasing the amount of ZnS, this effect could even be amplified. In summary, a 
convenient method for the preparation of CdSe/ZnS nanocrystals was established 
using the TOPO/HDA route and the CdO precursor.  
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Abstract 
With the introduction of quantum dots (QDs) in modern bioanalytics and 
biosensorics, a quantum leap with regard to sensitivity and traceability was taken. 
Meanwhile, the protocols for the synthesis of such nanocrystals have become highly 
developed. The vast majority of these protocols have their organic synthesis medium 
in common. Consequently, the as-prepared QDs are extremely hydrophobic. 
Therefore, powerful methods for the solubilization of QDs in aqueous media are 
needed. With respect to the various applications, an appropriate surface coating 
must keep the particles as small as possible, and must also prevent aggregation and 
provide defined sites for chemical modifications, such as the attachment of 
biomolecules. In this study, different strategies for the surface modification of QDs 
were compared. Exchange of the surface bound hydrophobic stabilizing ligands by 
mercaptoundecanoic acid was compared with a more complex approach using 
phosphine oxide-modified poly(ethylene glycol) (PEG). Finally, the coating of QDs by 
PEGylated phospholipids was investigated in detail, concentrating on the fabrication, 
low polydispersity and functionalization with reactive groups. Taking into account all 
the investigated methods, the last one is the most favorable concerning the optical as 
well as the colloidal properties of the solubilized QDs.  
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Introduction 
Quantum dots (QDs), small semiconductor nanocrystals (2-10 nm), exhibit 
outstanding optical properties which have rendered them extremely attractive labels 
in biological applications [1-4]. In contrast to conventional organic fluorescent dyes, 
QDs do not suffer from photobleaching [5] and exhibit a very sharp emission range, 
which can be tuned precisely by adjusting the particle size during synthesis. 
Moreover, QDs have been used in numerous studies as templates for small 
nanoparticles and could be traced easily. Therefore, over the past decade, routes for 
the synthesis of high-quality QDs with optimized optical properties have been 
elaborated and further enhanced. Thus, QDs have been prepared in organic 
solvents, like trialkylphosphine oxide and aliphatic amines [6] or alkylphosphonic 
acids [7]. These solvents not only provide a reaction medium for the growth of the 
nanocrystals, but they also coordinate with the metal atoms on the surface of the 
QDs to prevent excessive growth of the nanocrystals which would yield larger 
crystals -bulk semiconductors- lacking the optical properties of QDs. As a 
consequence, the QD surfaces are capped with hydrophobic ligands after synthesis 
and the particles cannot be dispersed in aqueous media. However, biological studies, 
such as cell culture experiments [8,9] or in vivo investigations [10,11], are usually 
conducted in aqueous environments. Therefore, the surfaces of the QDs have to be 
modified in order to render them hydrophilic and to be able to make use of the 
particles and their unique optical properties in biological studies. Several studies 
show that the properties of the nanoparticle surface significantly influence the 
reaction of the biological system towards the particles, such as non-specific binding 
[12] and cell-uptake [13]. 
In order to gain control over these processes, a first step is to modify the particle 
surface with coatings that reduce adsorption to proteins and cells. One solution is the 
introduction of poly(ethylene glycol) (PEG) on the particle surface. This surface 
modification proved to be a powerful tool for stabilization and could even prolong the 
circulation half-life of QDs in mice [14]. The interactions of the particles with the 
target cells or the organism can then be influenced by attaching bioactive substances 
to the QDs, like peptides [15], proteins [1] or antibodies [16]. To enable this 
bioconjugation, the surface coating of the QDs has to carry functional groups. From 
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all reactive groups, amine groups are preferable in most of the studies since they are 
versatile and stable by forming covalent amide bonds with carboxylic acids.  
In this study, three different methods for the surface modification of QDs were 
investigated. The first two approaches are based on a ligand-exchange strategy 
where the hydrophobic surface-bound stabilizing ligands were exchanged with more 
hydrophilic ones. In this scenario, the exchange with mercaptoundecanoic acid 
(MUA) was compared to ligand-exchange with a custom-synthesized phosphine 
oxide-modified PEG. In a second approach, the hydrophobic QDs were surface-
coated with amphiphilic PEGylated phospholipids. The last method was explored in 
depth in order to check whether it fulfils the above requirements regarding a coating 
of QDs that can be used in biological studies.   
 
Materials and methods 
1,2-bis(dichlorophosphino)ethane, cadmium oxide (CdO, 99.5%), N,N′-
dicyclohexylcarbodiimide (DCC, 99%), DL-lysine (98%), hexadecylamine (HDA, tech. 
grade 90%), lauric acid (98%), methanol (anhydr. 99.8%), sulfur (99.5%), 
poly(ethylene glycol) (PEG, MW 600 Da), toluene (anhydr. 99.8%), trioctylphosphine 
(TOP, tech. grade 90%), trioctylphosphine oxide (TOPO, tech. grade 90%) and zinc 
stearate (tech. grade) were obtained from Sigma-Aldrich (St. Louis, MO). 1,2-
distearoyl-sn-glycero-3-phosphatidylethanolamine covalently linked to methoxy-PEG 
(PEG-PE) and linked to amino-PEG (amino-PEG-PE), both PEGs having an average 
molecular weight of 2000 Da, were obtained from Lipoid (Ludwigshafen, Germany) 
and from Avanti Polar Lipids (Alabaster, AL), respectively. 
 
Synthesis of CdSe/ZnS nanocrystals 
CdSe/ZnS QDs were synthesized by thermal decomposition of the corresponding 
precursors as described in chapter 3. In brief, CdO (0.2 mmol) was dissolved in lauric 
acid (1.6 mmol) at 200 °C. TOPO (10 mmol, 3.88 mg) and HDA (16 mmol, 3.88 mg) 
were added and the mixture was heated to 285 °C. After removing the heating bath, 
Se (2 mmol) dissolved in 3.5 ml of TOP was injected. At the desired nanocrystal size 
(5-30 sec of crystal growth), the growth was stopped by injection of 20 ml of toluene. 
The CdSe cores were precipitated with an equal volume of methanol and centrifuged 
at 6000 x g for 5 min and redispersed as described above. ZnS-coating was 
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conducted after dispersing the CdSe cores in the same amount of TOPO and HDA 
as for the core synthesis at 200 °C over 60 min. The amounts for the ZnS precursor 
were calculated for four theoretical monolayers per QD. After shell-growth, the 
nanocrystals were purified by precipitation as described above and redissolved in 
toluene.  
 
Synthesis of phosphine oxide modified PEG (PO-PEG) 
Phosphine oxide modified poly(ethylene glycol) (PO-PEG) was synthesized 
according to the method published by Kim et al. [17]. Therefore, PEG of an average 
molecular weight of 600 Da (12.9 mmol) was dried under heat and vacuum, rinsed 
with Ar and transferred into a glovebox. The polymer was dissolved in 20 ml of DMF. 
To this solution, 1,2-Bis(dichlorophosphino)ethane (4.3 mmol) was added dropwise 
over 1 h. After stirring over a period of 1 d, the solution was neutralized with approx. 
3 g of K2CO3 and stirred for 2 d. After this, the salts were removed by filtration and 
the polymer was precipitated in cold ether and finally redissolved in dichloromethane. 
The precipitation was repeated twice. The polymer was analyzed in CDCl3 by 1H-
NMR using an Avance 300 NMR spectrometer (Bruker BioSpin, Rheinstetten, 
Germany). 
 
Hydrophilization of QDs with mercaptoundecanoic acid 
Ligand-exchange by mercaptoundecanoic acid (MUA) and subsequent cross-linking 
by lysine was conducted as described by Jiang et al. [18]. In brief, 1 g of MUA was 
molten at 65 °C under Ar-atmosphere and 0.33 µmol of QDs dissolved in chloroform 
were added. After 2h of stirring at 80 °C, 25 ml of DMSO was added and the solution 
was stirred for another 2h. The QDs were precipitated by addition of 80 ml of 
chloroform, isolated by centrifugation at 600 x g for 5 min and redissolved in DMSO 
(MUA-QDs). For cross-linking, lysine (9.6 mmol) was dissolved in 10 ml of 10 mM 
PBS and DCC (48 mmol) was dissolved in 25 ml of DMSO. Both solutions were 
added to the MUA-QDs and the mixture was stirred for 2h. The precipitated LM-QDs 
were then isolated by centrifugation, washed with THF and redissolved in water. The 
LM-QDs were subsequently purified by dialysis using a 5000 MWCO membrane. 
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Hydrophilization of QDs with PO-PEG 
600 mg of the PO-PEG and 0.04 µmol of CdSe/ZnS QDs were dissolved in 2 ml of 
chloroform and stirred overnight under reflux. After removing the solvent under 
reduced pressure, the particles were dissolved in 2 ml of water and ultrasonicated for 
5 min. After this, the colloid was centrifuged and the supernatant was filtered using a 
0.22 mm pore-size syringe filter. 
 
Hydrophilization of QDs with PEG-PE 
0.1 µmol of QDs in toluene were precipitated with the same amount of methanol and 
isolated by centrifugation at 6000 x g for 5 min. The pellet was dissolved in 500 µl of 
DCM and transferred into a 10 ml flask. 2.5 µmol of PEG-PE was dissolved in 500 µl 
dichloromethane and added to the QD-solution. The solvent was removed under 
reduced pressure to form a QD-PEG-PE film. After removing solvent residues under 
vacuum overnight, the film was heated to 80 °C in a water bath and water of the 
same temperature was added. The samples were vortexed for 30 sec and cooled to 
room temperature. Thereafter, non-coated QDs were removed by centrifugation at 
16000 x g and the pellet was removed. To remove excess PEG-PE, the samples 
were purified by ultracentrifugation at 47000 x g for 2 h. The supernatant was 
discarded, the QDs were redissolved in water and the purification was repeated 
twice. Samples were stored at 4 °C. 
 
Spectrophotometric measurements 
UV absorbance spectra were recorded using an Uvikon 941 (Kontron Instruments, 
UK) and 10 cm quartz cuvettes. Fluorescence was determined in 10 cm quartz 
cuvettes using a RF-1501 spectrometer (Shimadzu Deutschland GmbH, Duisburg, 
Germany) for the spectra of the MUA-QDs and the PO-PEG-QDs. For all other 
fluorescence measurements (including all determinations of quantum yields), an LS 
55 fluorescence spectrometer from PerkinElmer (Waltham, MA) was used. 
Fluorescence quantum yields were determined in correlation to a fluorescein 
standard in 0.1 N NaOH (quantum yield 90%). Samples were excited at 450 nm. 
Fluorescence decay was determined using a Fluorolog F112A fluorimeter (Horiba 
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Jobin Yvon, Bensheim, Germany), with excitation at 375 nm and emission at 540 nm 
at 25° C. 
 
Dynamic light scattering 
The hydrodynamic diameter of the PEG-PE-QDs was determined by dynamic light 
scattering (DLS) using a ZetaSizer 3000 HSA (Malvern, Worcestershire, UK) at 20 °C 
and an angle of 90° in toluene or water. Therefore, samples were purified by 
centrifugation at 16000 x g for 15 min and subsequently syringe-filtered (0.22 µm 
pore diameter).  Data was processed using the CONTIN algorithm [19]. 
 
Cryo-transmission electron microscopy (cryo-TEM) 
For imaging of the QDs using cryo-TEM, a few microlitres of the dilute aqueous 
samples were transferred onto a 600 mesh copper grid (Plano, Wetzlar, Germany) 
and spare sample was removed by suction. Thereafter, the samples were 
immediately frozen by submerging them in liquid ethane in a cryo-box. After 
mounting the sample on a cryo-transfer holder (CT 3500, Gatan, Munich), images 
were obtained by a Zeiss EM 922 EFTEM (ZeissNTS, Oberkochen, Germany) at 
200 kV and a temperature of 90 K.  
 
Determination of amines 
Before the determination of the amines per QD, different ratios of amino-PEG-PE to 
unreactive PEG-PE were used for the hydrophilization of the QDs 
(0%/25%/50%/100%). After hydrophilization and purification as described above, the 
concentration of the QDs was determined using a plate reader (Shimadzu, Duisburg, 
Germany) and the absorbance maximum at 518 nm and the common approximation 
for the absorbance coefficient [20]. The same batch of QDs was used for all 
experiments. To determine the number of amines per QD, 5 µl of the PEG-PE QDs 
were transferred into a 96 well-plate, 135 µl of borate buffer (50 mM, pH 8.5) and 60 
µl of a 1 mM solution of fluorescamine in acetone were added. Immediately after the 
addition of fluorescamine, fluorescence was measured by a LS 55 fluorescence 
spectrometer from PerkinElmer (Waltham, MA) equipped with a plate reader unit 
(excitation at 390 nm, emission at 475 nm). Amino-PEG-PE was the calibration 
standard. In order to reduce the inner-filter effect of the QDs towards the 
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fluorescence of the amine-activated fluorescamine, QDs were kept at low optical 
densities below 0.1, according to literature [21]. 
 
Determination of hydrohilization capacity 
Different-sized QD-samples were hydrophilized with PEG-PE and purified as 
described above using the same amounts of PEG-PE and QDs for each batch. After 
preparation, non-coated QDs were removed by centrifugation at 16000 x g for 10 
min. The diameter of the QDs before coating with PEG-PE was determined using the 
correlation between the highest maximum of the absorbance spectrum and the size 
of the nanocrystals as published by Yu et al. [20]. The concentration after the 
hydrophilization procedure was calculated using the common approximation of the 
absorbance coefficient and the optical density of the sample [20]. 
 
 
Results and discussion 
In this investigation, three different strategies for the surface modification of QDs 
were compared to each other in order to find out the most appropriate one to be used 
for subsequent biological investigations. While the first method represents a simple 
exchange of the surface-bound stabilizing ligands of the organic-soluble QDs by 
MUA, in a second approach, PEG is used to replace these ligands and to bind to the 
QDs (fig. 1). 
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Figure 1: Hydrophilization of organic-soluble QDs by ligand exchange. The 
organic-soluble QDs are coated with a hydrophobic monolayer of stabilizing ligands 
(here shown for TOPO). For hydrophilization, the ligands are removed either by MUA 
or by PO-PEG. 
 
The exchange of the surface bound stabilizing ligands by the small molecule MUA 
was easy to conduct (fig. 1A). The particles obtained were dispersible in water and 
showed hardly any change in their absorbance behavior (fig. 2). 
As shown in fig. 3, the QDs exhibit small hydrodynamic radii (approx. 4 nm) after 
coating with MUA. However, due to photooxidation of the thiols and aggregation [22], 
the size distribution broadened. Therefore, the coating was stabilized by cross-linking 
with lysine. The obtained particles (CL-MUA-QDs) are slightly larger due to an 
increasing coating layer. However, a lack of colloidal stability is visible as the DLS 
measurements show an increase in the mean diameter even after the cross-linking 
procedure and purification by dialysis, together with an increasing polydispersity 
index (fig. 3). This aggregation can also be attributed to the lack of a PEG-layer on 
the particle surfaces which efficiently serves as a steric stabilizer. A second 
drawback is the drastic loss of quantum efficiency after changing the surface 
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environment of the particles by the ligand exchange. The quantum yields for the 
obtained particles were far below 1%.  
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Figure 2: Absorbance spectra before and after coating with MUA. Both curves 
show similar characteristics in organic and in aqueous media which proves the 
successful transfer from the organic to aqueous phase. 
 
In order to overcome the lack of stability, a strategy for introducing PEG on the 
particle surface had to be developed. Since the processes on the particle surface 
always represent equilibria between association and dissociation of surface-bound 
stabilizing ligands, multidentate PEG-ligands were developed to increase the affinity 
of the ligands to the particle surface [17,23]. 
It was investigated whether multidentate phosphine oxide modified PEGs could 
sufficiently maintain the optical properties of the QDs and moreover prevent 
aggregation. Since the phosphine oxide groups of this polymer are similar to those of 
TOPO, a stabilizing ligand for the synthesis of the QDs, it was expected to be able to 
replace these ligands and thus introduce PEG on the surface of the QDs (fig. 1B).                     
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Figure 3: Size analysis of MUA-QDs and MUA-QDs crosslinked with lysine. After 
surface-modification, the MUA-QDs exhibit small sizes (bars) of approx. 4 nm and 
increased polydispersity (  ). Crosslinked with lysine (CL-MUA-QD), the diameter 
increases up to 14 nm (after 1 day of dialysis).  
 
As described by Kim et al., the reaction between PEG and the chlorides of the 
phosphinic acid derivatives yields covalent networks (fig. 4). PEG (B) is reacted with 
1,2-bis(dichlorophosphino)ethane (A) under water-free conditions to form random 
networks of esters of PEG and the phosphonous acid derivative (C) which are 
subsequently oxidized to the phosphonic acid derivative resulting in PO-PEG (D). 
The success of the reaction was examined using 1H NMR (fig. 5). The spectrum is 
characterized by the signal of the protons of the PEG methylene groups at -3.6 ppm 
and the multiplet of the terminal methylene groups at -4.2 ppm which couple with the 
phosphine oxide groups. 
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Figure 4: Synthesis scheme for the modification of PEG with phosphine oxide 
groups. PEG (B) is esterified with 1,2-bis(dichlorophosphino)ethane (A) forming 
covalent random-networks (C) which are subsequently oxidized to PO-PEG (D). 
 
(ppm)
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Figure 5: 1H NMR of PO-PEG. The methylene groups at -3.6 ppm refer to the PEG. 
The multiplet at -4.2 ppm represents the outer methylene groups which are 
chemically shifted into the deep field due to its proximity to the phosphine oxide 
groups. 
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The polymer is able to bind to the QDs and to render the initially organic soluble 
nanocrystals water soluble. Thus, the quality of the optical properties of the QDs 
remains unchanged. As depicted in fig. 6, the appearance of both the absorbance 
and the emission spectra of the unmodified QDs in chloroform as well as after 
modification with PO-PEG in aqueous the medium, is very similar. The successful 
transfer into aqueous medium as well as the retention of the optical properties shows 
the effective coupling of the modified PEG to the QDs. Due to PEG, the polymer 
modified QDs reveal good colloidal stability in the aqueous medium. 
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Figure 6: Absorbance and emission spectrum of QDs before and after 
solubilization with PO-PEG. The absorbance spectra (marked with circles) before 
(red) and after (blue) transfer of the QDs into the aqueous medium using the PO-
PEG are nearly unchanged. The position of the emission peak in the aqueous 
medium also shows almost no difference compared to the organic soluble QDs. 
 
Fig. 7 shows the size distribution of the PO-PEG-QDs determined by DLS. Whereas 
the free modified PEG forms loose networks of high sizes and broad size-
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distributions, the system becomes more ordered when bound to the QDs. As a 
consequence, the hydrodynamic diameter of the PEGylated particles as well as the 
polydispersity index decreases after modification with the QDs, an effect which is 
also described in literature [17]. The colloid is well-stabilized by the polymer; no sign 
of aggregation was visible for the aqueous colloid after two years of storage at room 
temperature. 
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Figure 7: Size analysis and distribution of PO-PEG-modified water soluble QDs 
and of the pure polymer obtained by DLS. (A) The loose and disordered polymer 
network (PO-PEG) shows higher sizes and higher polydispersity than when bound to 
the QDs (PO-PEG-QDs) (left panel). The PEGylated particles exhibit a size of 
approx. 60 nm and a polydispersity index below 0.2. (B) Size distribution of both 
species.  
 
Though the modification of the QDs with PEG using the PO-PEG polymer yields 
quite stable and water soluble particles, there were still some drawbacks. Firstly, the 
optical properties again were too low for the use of the QDs in biological applications 
(below 1%). Moreover, the phosphine oxide modified PEG increases the 
hydrodynamic diameter of the particles drastically (over 50 nm) which might be a 
disadvantage when investigating size-dependent uptake processes in cells [24]. 
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Finally, the PEG-networks created exhibit no defined site for the chemical attachment 
of biologically active compounds, like peptides, proteins or antibodies. 
To meet these requirements, an approach was chosen that was not based on 
exchanging the stabilizing surface ligands. By leveraging van-der-Waals interactions, 
it is possible to build a coating of amphiphilic molecules around the QDs that show 
aliphatic chains on their surface. In this context, PEGylated 
phosphatidylethanolamines (PEG-PE) prove to be favorable [10]. The coating of QDs 
with PEG-PE was achieved in two simple steps (fig. 8). After forming a film consisting 
of QDs and PEG-PE, it was then hydrated by warm water. During this procedure, the 
polymer arranges itself spontaneously around the QDs. Since excess PEG-PE is 
used, PEG-PE micelles form as well. To remove empty PEG-PE micelles, the PEG-
PE-QDs were purified by ultracentrifugation. 
 
 
Figure 8: Coating of organic soluble QDs with PEG-PE. After dissolving a film of 
PEG-PE and QDs (left side) with water, the polymer spontaneously arranges itself 
around the nanocrystals (PEG-PE-QD). PEG-PE forms micelles which were 
separated by centrifugation. 
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Figure 9: Optical properties of PEG-PE-QDs. (A) Absorbance (marked with circles) 
and emission spectrum of PEG-PE-QDs. The particles maintain their optical 
properties when coated with the polymer. Quantum yields typically range between 3 
and 10%. (B) Photographs of PEG-PE-QDs under visible light (left) and under UV 
light (right) showing the bright fluorescence. (C) Fluorescence decay curve exhibiting 
a fluorescence half-life of approx. 20 ns. 
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The resulting PEG-PE-QDs have favorable optical properties similar to those of 
organic soluble QDs. The absorbance and emission spectra have a similar 
appearance to the ones obtained for unmodified QDs (fig. 9A). The PEG-PE-QDs 
exhibited quantum yields of 3-10% which were the highest values of all the 
investigated methods for solubilization. The photograph in fig. 9B depicts the PEG-
PE-QDs under ambient light as well as upon excitation by UV light showing the bright 
fluorescence of the QDs in aqueous medium. A fluorescence decay-curve is given in 
fig. 9C. The fluorescence half-life is approx. 20 ns. Though not extremely high, this 
decay characteristic allows for signal separation from fast-decaying biological 
samples and increases the signal-to-background ratio after termination of 
autofluorescence. In comparison to a lysate of murine kidney cells, the QDs showed 
prolonged fluorescence and could be detected after the disappearance of the cell 
fluorescence (data published elsewhere).    
Size analysis of the PEG-PE-QDs revealed a uniform size (PI approx. 0.2) and an 
acceptable low hydrodynamic diameter, around 20-25 nm, determined by DLS (fig. 
10A). Compared to the unmodified PEG-PE micelles, the PEG-PE-QDs exhibit larger 
sizes due to the encapsulation of one or several QDs. Fig. 10B shows the 
corresponding size distributions of both the PEG-PE micelles and the PEG-PE-QDs. 
The graph shows that after encapsulating the QDs inside the PEG-PE, the initial 
uniformity of the PEG-PE micelles is widely maintained.  
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Figure 10: Size analysis and distribution of PEG-PE-QDs in comparison to 
micelles of PEG-PE. (A) Size analysis by DLS. Compared to the PEG-PE micelles, 
the PEG-PE-QDs exhibit an increased hydrodynamic radius (below 25 nm) due to 
the loading of PEG-PE with QDs. For both species polydispersity is low. (B) The size 
distribution of both species is narrow. The shift in sizes is caused by the loading of 
the PEG-PE with the QDs.  
 
In order to examine which size of QDs fits optimally inside the PEG-PE micelles, a 
series of QD batches with increasing diameters were encapsulated in PEG-PE. 
Thereafter, the concentration of the solubilized QDs was determined by UV 
spectroscopy. During preparation, aggregates were removed and therefore only the 
encapsulated QDs were measured. As shown in fig. 11, the amount of QDs 
solubilized by the same amount of PEG-PE is decreases by the diameter of the QDs. 
The higher the size of the QDs, the more difficult it is for the nanoparticles to fit into 
PEG-PE micelles. In this study, QDs of a diameter of 3.8 nm could successfully be 
encapsulated whereas larger QDs of up to 7 nm in diameter showed significantly 
lower concentrations in the aqueous medium. The reason for this behavior is due to 
the properties of the PEG-PE micelles. Since the PEG-PE molecules have a fixed 
size and geometry, they consequently always arrange themselves around micelles of 
a fixed size. This proves that there has to be an optimum for the size of a particle to 
be encapsulated inside such a micelle. As a consequence of this size-dependence, 
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QDs emitting around the green range (around 500-550 nm) of the spectrum can be 
encapsulated favorably, since the photoluminescence maximum and the particle 
diameter are strongly correlated [20].  
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Figure 11: Size-dependence of the solubilization behavior of QDs in PEG-PE-
micelles. Small QDs (3.8 nm) are encapsulated more efficiently than larger particles 
(up to 7 nm) since the absorbance of the QDs after solubilization drastically 
decreases by size. 
 
These findings were confirmed by cryo-TEM. QDs of 3.8 nm in diameter were quite 
homogeneously distributed (fig. 12A, left panel). Only a few aggregates of several 
QDs can be found. The majority of the nanocrystals was separated inside the PEG-
PE, resulting in quite uniform PEG-PE coated particles (right panel). In all pictures, 
the QDs are represented by the small dark spots which result from the high contrast 
of the semiconductor nanocrystals. In contrast, when solubilizing particles of 7.0 nm 
in diameter, the particles tend to aggregate and form large clusters (fig. 12B). The 
reason for this behavior is the already mentioned unfavorable size of this species of 
QDs that does not fit properly inside the micelles. 
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Figure 12: Cryo-TEM micrographs of PEG-PE-QDs. (A) QDs of 3.8 nm 
encapsulated in PEG-PE micelles. The nanocrystals are evenly distributed 
throughout the sample (left panel). The majority of the nanocrystals are separated 
and only a few aggregates can be found (right panel). (B) QDs of 7.0 nm solubilized 
by PEG-PE. The particles tend to form aggregates and are located in large clusters 
(left and right panel). The dark spots in the pictures represent the semiconductor 
nanocrystals that exhibit high contrast under TEM. The light grey spherical structures 
are caused by PEG-PE. 
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Having optimized the conditions to obtain PEGylated QDs of narrow size-distribution 
and small size, it is crucial to ensure that the particles exhibit a sufficient number of 
reactive sites on the colloid surface in order to connect the particles to biologically 
active substances. For the attachment of a number of biomolecules, amines proved 
to be useful [15]. Through direct coupling to the biomolecules or by using crosslinkers 
[25], amine groups form stable covalent conjugates via amide bonds. Since PEG-PE 
is available with a number of functional groups, it is easy to introduce such functional 
groups, like amines, into the colloid. 
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Figure 13: Determination of the content of primary amines per QD when using 
different amounts of amino-PEG-PE. Increasing amounts of amino-PEG-PE for the 
coating of the hydrophobic QDs yields PEG-PE-QDs of increasing amine content. 
The maximum number of amines per QD was approx. 12.     
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It was investigated how many amine groups per PEG-PE-QD are available when 
coating the QDs with different amounts of amino-PEG-PE. The fluorescamine 
reaction with primary amines yields a fluorescent product with fluorescence intensity 
proportional to the concentration of free amines. As expected, when using increasing 
amounts of amino-PEG-PE for the coating of the QDs, the resulting PEG-PE-QDs 
carry increasing amounts of amines on the colloid surface as well (fig. 13). The 
maximum number of amines per PEG-PE-QD was hereby found to be around 12 
when using 100% of amino-PEG-PE for the coating. Therefore, a maximum of 12 
biomolecules per particle can be conjugated to the PEG-PE-QDs which should be 
sufficient for most of the applications. It was also possible to tune the number of 
amines per QD to lower amounts by adjusting the ratio between non-functionalized 
PEG-PE and amino-PEG-PE. The results show that coating with PEG-PE, besides 
providing a powerful method for the solubilization of QDs, represents a versatile 
strategy for the functionalization of QD surfaces. 
 
Summary and conclusion 
Several different strategies for the hydrophilization of QD-surfaces were explored. 
The exchange of the surface-bound organic ligands allows for the creation of both 
small, but not highly stable, hydrophilic QDs when using thiol-containing carboxylic 
acids, as well as more stable PEGylated QDs. However, the latter are characterized 
by a large hydrodynamic diameter. For both routes the quantum yields in aqueous 
medium were low. The coating of QDs with PEG-PE overcomes the restrictions of 
the above mentioned strategies. The resulting PEG-PE-QDs are stable in aqueous 
media, exhibit small sizes around of 20 nm and good quantum yields. When 
encapsulating QDs of diameters of up to 4 nm, the PEG-PE-QDs are characterized 
by low polydispersity. Additionally, when applying functionalized PEG-PEs, like 
amino-PEG-PE, the QDs can be capped with a customized number of functional 
groups, which enable the attachment of various molecules, such as peptides, 
proteins or antibodies.  
Therefore, PEG-PE-QDs are versatile candidates for bioprobes after chemical 
modification with biologically active substances.   
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Abstract 
Quantum dots (QDs) emerged as a powerful tool in biomedical investigations due to 
their well-characterized optical properties, emitting strong and stable fluorescence. 
QDs are usually covered by hydrophilic coatings, preferably consisting of 
poly(ethylene glycol) (PEG) to minimize  non-specific interactions, such as adsorption 
and aggregation, and to render them accessible for use in biological systems. 
Together with the rising demand for high-quality QDs of defined size and narrow 
size-distribution, the need for powerful analytics increased as well. Unfortunately, 
standard methods, like dynamic light scattering (DLS) and transmission electron 
microscopy (TEM), have various drawbacks. Dynamic light scattering suffers from 
missing separation of nanoparticles of different sizes and transmission electron 
microscopy requires extremely high experimental effort. Asymmetrical flow field-flow 
fractionation (AF4), in contrast, seems to be a promising alternative due to its high-
resolving separation. Coupling to multiple angle light scattering (MALS) detection 
allows for obtaining even molecular masses of single fractions. In this study, the 
feasibility of using AF4 for the analysis of PEGylated QDs was investigated and a 
method for the reliable separation and analysis of QDs by AF4 coupled with MALS 
detection was developed. The method was then used for the analysis of QDs of 
different dispersity and the comparison with commercially available QDs.   
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Introduction 
Quantum dots, semiconductor nanocrystals, have emerged as ideal model colloids 
for biomedical investigations, since they exhibit unique optical properties, such as 
bright fluorescence that is resistant to photobleaching, sharp and tuneable emissions 
as well as a large Stokes shift [1-4]. QDs have been used for approaches in labeling 
cancerous tissues [5], unveiling transport mechanisms into cells [6] and as labels of 
cellular structures in the discovery of distinct mechanisms, like receptor trafficking [7-
9]. 
Along with the tremendous progress that has been made since the introduction of 
their first colloidal syntheses [10] and the development of powerful surface coatings 
to render QDs more biocompatible [11], the need for powerful analytics of the 
dispersity of QDs has grown. Recent approaches emphasize the enormous influence 
of particle size on interactions with biological systems, such as cellular uptake and 
other cellular responses [12] and even toxicity [13]. In order to obtain highly 
monodisperse collectives of QDs with hydrophilic surface coatings, like PEGylated 
surfaces [14], a powerful separation technique is needed for highly specific biological 
investigations. Up to now, the standard analytics for the determination of the size of 
hydrophilic QDs comprise mainly of microscopic methods or dynamic light scattering 
(DLS). These microscopic methods consist of transmission electron microscopy 
(TEM) and atomic force microscopy (AFM) in particular. Even though both 
techniques provide an unmatched resolution, they are highly-demanding in terms of 
the equipment used and the time needed for obtaining a statistically relevant number 
of pictures for their analysis. Therefore, these methods cannot serve for standard 
analytics for the quality assurance of QDs. In contrast, DLS represents a valuable 
method for characterizing batches in a short period of time. However, the results are 
only based on averaged values of the sample dispersity. Moreover, there is no 
possibility to characterize polydispers samples or even to fractionate them for all the 
above mentioned methods. 
Asymmetrical flow field-flow fractionation would be a method to overcome these 
drawbacks by offering a powerful method for the separation of samples of various 
compositions according to the particle size. When coupled with a multiple angle light 
scattering detector (MALS), it is also possible to obtain detailed information on the 
size as well as the molar mass of the single fractions [15-17]. 
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Figure 1: Schematic depiction of the functionality of AF4. The sample is 
introduced into the flow channel and focused. Then, separation takes place along the 
channel due to the influence of a flow perpendicular to the laminar channel flow 
(cross flow). Because of this cross flow and the size-dependent diffusion of the 
particles, the particles are localized in regions of higher (small particles) or lower 
(larger particles) flow speed. Smaller particles are eluted before larger ones. 
 
Fig. 1 shows the principle of the separation obtained by AF4. After injection and 
focussing at the beginning of the flow channel, the sample is carried by a controllable 
laminar flow along the flow channel. Separation is caused by a cross flow 
perpendicular to the channel flow which passes through a membrane of defined 
molecular weight cut-off (MWCO) on the bottom of the flow chamber. After this, the 
analyte leaves the regions of faster flow and moves towards the bottom region of the 
flow cell which exhibits slower flow. According to the sample size and thus the 
diffusion coefficient, smaller particles diffuse back into regions of higher flow speed 
faster than larger particles. Therefore, smaller particles are eluted before larger 
particles. Subsequently, molar masses can be obtained by analysis using MALS 
detection [18]. 
In this approach, this advanced technique was introduced for the analysis of 
PEGylated QDs concerning the dispersity as well as approximations of their molar 
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mass. The objective of this study was to prove the feasibility of using AF4 for the 
characterization of QDs, since at the time of the investigations only one report was 
available [19]. 
 
Materials and methods 
Cadmium oxide (CdO, 99.5%), hexadecylamine (HDA, tech. grade 90%), lauric acid 
(LA 98%), methanol (anhydr. 99.8%), sulfur (99.5%), toluene (anhydr. 99.8%), 
trioctylphosphine (TOP, tech. grade 90%), trioctylphosphine oxide (TOPO, tech. 
grade 90%) and zinc stearate (tech. grade) were obtained from Sigma-Aldrich (St. 
Louis, MO). 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine covalently linked 
to methoxy-PEG (PEG-PE) of an average molecular weight of 2000 Da was obtained 
from Lipoid (Ludwigshafen, Germany). EviTags were obtained from Evident 
Technologies (Troy, NY).   
 
Synthesis of CdSe/ZnS nanocrystals and PEG-PE coating 
CdSe/ZnS QDs were synthesized by thermal decomposition of the corresponding 
precursors as described in chapter 3. In brief, CdO (0.2 mmol) was dissolved in lauric 
acid (1.6 mmol) at 200 °C. TOPO (10 mmol, 3.88 mg) and HDA (16 mmol, 3.88 mg) 
were added and the mixture was heated to 285 °C. After removing the heating bath, 
Se (2 mmol) dissolved in 3.5 ml of TOP was injected. At the desired nanocrystal size 
(5-30 sec of crystal growth), the growth was stopped by injection of 20 ml of toluene. 
The CdSe cores were precipitated with an equal volume of methanol and centrifuged 
at 6000 x g for 5 min and redispersed as described above. ZnS-coating was 
conducted after dispersing the CdSe cores in the same amount of TOPO and HDA 
as for the core synthesis at 200 °C over 60 min. The amounts for the ZnS precursor 
were calculated for four theoretical monolayers per QD. After shell-growth, the 
nanocrystals were purified by precipitation as described above and redissolved in 
toluene. For the coating with PEG-PE, the nanocrystals were precipitated with 
methanol and redispersed in dichloromethane together with the phospholipids as 
described in chapter 3. Thereafter, dichloromethane was evaporated and the 
obtained film was hydrated at 80 °C. The solution was vortexed and centrifuged to 
remove aggregates. Then, the PEG-PE-QDs were collected as pellet after 
ultracentrifugation (for details, see chapter 4). Three samples were prepared. Sample 
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A represents a rather monodisperse sample (compare to fig 12A and 10, chapter 4, 
core size 3.8 nm) while sample C was a sample rich in aggregates (compare to fig 
12B, chapter 4, core size 7.0 nm). Sample B was an intermediate between both (core 
size 5.4 nm). For all measurements sample A was used, unless stated differently. 
 
Asymmetric flow field-flow fractionation and molar mass determination 
For the particle separation, an Eclipse2 separation system (Wyatt Technology, 
Dernbach, Germany) was used. The separation channel was equipped with a 5000 
Da MWCO membrane consisting of regenerated cellulose. The system was coupled 
to a Dawn EOS multiple angle light scattering (MALS) detector (Wyatt Technologies) 
and a multiple wavelength detector (Agilent, Santa Clara, CA) operating at 280 nm. 
As eluent 10 mM sodium phosphate buffer pH 6.8 was used. The following flow 
profile was used: channel flow: 1.5 ml/min; focus flow: 3.0 ml/min (0-8 min); cross 
flow: 2.0 ml/min (8-23 min), 2.0-0.15 ml/min (23-28 min), 0.15-0.00 ml/min (28-29 
min), 0 ml/min (29-49 min). An overview of the flow profile is depicted in fig. 2. For 
the determination of the molecular mass, the absolute absorption coefficient of the 
PEG-PE-QD samples was determined by freeze-drying a sample of known molar 
concentration inside a microcentrifuge cup (Eppendorff, Hamburg, Germany). The 
molar concentration of the sample was determined by UV-measurement before 
drying, using an Uvikon 941 (Kontron Instruments, UK) and 10 cm quartz cuvettes. 
The concentrations were calculated using commonly used approximations of the 
absorbance coefficient for QDs [20] and Lambert-Beer’s law. After this, the weight of 
the dried QDs was determined. For the PEG-PE-QDs the absolute absorbance 
coefficient obtained at 280 nm was 2.089 ml/mg*cm. Because the Evitags used 
exhibit a similar absorbance maximum to a lipid-based, PEG 2000-containing 
coating, and since high amounts of QDs are needed for an accurate determination, 
the absorbance coefficient obtained was used for the EviTags as well. 
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Figure 2: Flow profile for AF4 separation. The channel flow was kept constant at 
1.5 ml/min. 
 
Results and discussion 
The described flow profile was applied to separate QDs which were coated with 
PEGylated phospholipids (PEG-PE). In order to obtain a reproducible method for the 
analysis of water-soluble QDs, several cross flow profiles were tested (data not 
shown) and the one yielding the best separation was chosen. In order to identify the 
QD-fraction, UV detection was applied at two wavelengths. While at 280 nm most of 
the sample content could be detected, at 530 nm only the QDs could be detected. As 
shown in fig. 3A, for both channels, the chromatogram exhibits a main peak at 
approx. 15 min, which corresponds to the colloid. At 280 nm, a signal from the QD-
cores as well as from other material, such as the coating, can be obtained. In 
contrast, at 530 nm, only the absorbance of the QDs can be detected. This ensures 
that the main peak indeed is due to the presence of the QDs and it also ensures that 
the sample is free from excess coating material, as far as possible, since other peaks 
in the chromatogram are weak. The UV spectrum of the PEG-PE-QDs is presented 
in fig. 3B and shows that the QDs are able to absorb over a wide range, enabling 
detection at various wavelengths. 
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Figure 3: AF4 measurement of PEG-PE-QDs at different UV/VIS wavelengths. 
(A) The chromatogram shows a main peak at approx. 15 min representing the PEG-
PE-QDs.  While the signal obtained by UV 280 (before normalization) is more 
intense, the signal at 530 nm is weaker and only correlated to the absorbance of the 
QD-cores. (B) Absorbance spectrum of PEG-PE-QDs. 
 
In order to investigate whether the approach is sound and yields reproducible results, 
different amounts of QDs were injected repeatedly. By doing this, it was ensured that 
the recovery of the main peak was constant when reproducing the measurements 
and using different amounts of PEG-PD-QDs. Only when reproducibility is granted, 
reliable results covering the whole sample can be obtained. As depicted in fig. 4, the 
injection of increasing amounts of PEG-PE-QDs does not result in changes in the 
appearance and retention time of the main peak. Only the peak area is enlarged due 
to the increasing amounts of PEG-PE-QDs injected. The results are summarized in 
tab. 1 and prove that the ratio of the mass of the PEG-PE-QD main peak to the total 
mass remains under the chosen conditions for increasing injected amounts constant 
and is reproducible for the same injected amounts. Therefore, adsorption of the 
sample to the membrane through which the cross flow leaves the flow channel can 
be excluded, as well as washing-out of the sample through the pores of the 
membrane.  
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Figure 4: Reproducibility of the AF4 method for the determination of PEG-PE-
QDs. Increasing amounts of PEG-PE-QDs were applied and no change in the peak 
position and shape of the PEG-PE-QD fraction was detected. For quantitative 
evaluation, see tab. 1.  
 
74.620µg (2)
77.320µg (1)
73.710µg (2)
75.410µg (1)
71.75µg (2)
69.05µg (1)
mass 1st
peak [%]
injected mass
[mg]
 
Table 1: Quantitative analysis of the peak area of the samples (and repetition) 
in fig. 4. The three different PEG-PE-QD amounts were measured repeatedly and 
the peak area of the main fraction was correlated with the injected amount. Values 
for the ratio of the first peak to the whole sample are stable and remain quite 
constant proving reproducibility of the method. 
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In the next step, the established method was used to characterize different batches 
of PEG-PE-QDs. For this purpose, three samples (A-C) of different composition and 
dispersity were analyzed. As shown in fig. 5A, the three batches exhibit significant 
differences in their chromatograms regarding the UV-signal which was used for 
determining the concentration. While the first peak (15 min) for all three of the 
batches is decreasing, corresponding to the intact and dispersed PEG-PE-QDs, a 
peak also forms at 17 min as well as at the fraction of large aggregates (around 30 
min). This leads to the conclusion that sample A is rather monodisperse, while in 
sample B the first signs of aggregation are emerging. Sample C, finally, has a high 
amount of large aggregates. These findings are supported when analyzing the molar 
masses of the samples and their fractions. While the first fraction exhibits a mass of 
more than 100 kDa, the mass of the second fraction is higher, about twice the 
amount, indicating small aggregates. The third fraction, however, contains 
aggregates beyond 1 MDa. This shows that the composition of hydrophilic QDs can 
be characterized precisely using AF4 coupled to UV- and MALS-detection. The 
extent of these fractions was determined by calculating the area under the curve for 
all fractions. An overview is depicted in fig 5B. While sample A is dominated by the 
first fraction, the second fraction and the aggregates grow larger for fraction B and C. 
The method therefore represents a valuable technique for the quality control 
monitoring of the preparation of hydrophilic QDs. While under PCS sample B and C 
will appear polydisperse, the separation using AF4 allows for analysis of the product 
and consequently for optimizations of the colloid preparation. 
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Figure 5: AF4-analysis of three different batches of PEG-PE-QDs. 
(A) Chromatogram of three different batches of PEG-PE-QDs. All batches are 
characterized by three typical fractions: 15 min (QDs of low dispersity), 17 min (small 
aggregates of QDs), 30 min (large aggregates). The lines represent the signal 
obtained from UV-detection; the spots represent the MALS-signal. The first and 
second fractions exhibit molar masses of 300 kDa and higher; the third fraction 
exhibits aggregates over 1 MDa. (B) Quantitative classification of the three different 
fractions of each batch. 
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Finally, the PEG-PE-QDs were compared to commercially available PEGylated QDs 
(EviTags). According to the information from the manufacturer, the QDs were coated 
by polar lipids which were conjugated to PEG of a molecular weight of 2000 Da, like 
the PEG-PE. Therefore, the PEG-PE-QDs exhibit similar properties to the EviTags 
concerning their AF4 chromatogram. The hypothesis is supported by the results 
presented in figure 6. Both species exhibit a main peak around 15 min in the UV-
signal in the AF4 chromatogram. The molar masses obtained by the MALS detector 
are resident in the same range of around 300 kDa. For both kinds of hydrophilic QDs, 
the aggregate fraction is low, almost on the background level obtained by a blank run 
(not shown). This is a valuable indication that the developed PEG-PE-QDs are 
comparable to the quality of commercially available QDs concerning their dispersity. 
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Figure 6: Comparison between PEG-PE-QDs and commercially available 
PEGylated QDs (EviTag). Both species exhibit a main peak at approx. 15 min 
(obtained by UV) and masses of around 300 kDa (obtained by MALS).  
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Summary and conclusion 
An AF4 method for the separation of a collective of hydrophilic QDs containing 
different-sized fractions has been established. Besides the use of this fractionation 
for the preparation of hydrophilic QDs of lower dispersity, the method also allows for 
the quantification of the fractions. Using the MALS detector, molar masses of QDs 
were calculated. Taking into account the powerful separation obtained by AF4, this 
method has great potential for the quality assurance of QDs and as a tool for the 
optimization of preparation techniques. 
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Abstract 
Quantum dots (QDs), semiconductor nanocrystals, offer outstanding fluorescence 
properties which render them ideal tools for studying interactions of nanoparticles 
with cells, such as specific binding or endocytosis. As the QDs have to be surface-
modified in order to render them water-soluble and thus accessible for biological 
studies, a number of strategies for their hydrophilization have been developed. A 
promising solution for the hydrophilic coating of QDs is represented by poly(ethylene 
glycol)-modified phospholipids (PEG-PE). After reliable coating steps, this material 
forms dense layers of PEG on the QDs and offers a multitude of different functional 
groups that can be introduced on the surface of the QDs by choice. These groups 
enable versatile attachment of different biomolecules, like nanoparticle targeting to 
specific cells. To ensure that PEG-PE-QDs can be used for such purposes, we 
investigated their behavior under cell-culture conditions. Besides the colloidal 
stability, non-specific binding to cells as well as cytotoxicity was explored. While 
PEG-PE-QDs are stable during the investigations, toxicity remains a concern. 
However, PEG-PE-QDs can be used within a comfortable range of concentration 
without impairing cells (up to 500 nM). The results confirmed that PEG-PE-QDs are 
promising candidates for cellular investigations.  
 
 
 
 Cell-culture Characterization of Quantum Dots Chapter 6 
 - 123 - 
Introduction 
Quantum dots (QDs), semiconductor nanocrystals, have contributed essentially over 
the past several years in that we have been able to follow cellular processes with 
high resolution and high sensitivity over much longer periods of observation than 
when using conventional organic fluorophores [1-4]. This is possible through the 
paramount optical properties these nanocrystals exhibit. QDs provide us with strong 
fluorescence which is not extinguished by photobleaching over long spans of time [5], 
a disadvantage that organic fluorescent dyes suffer from. Moreover, QDs exhibit 
rather small sizes and thus are favorable to enter small pathways in cellular and 
intracellular targeting as well as organelle tracking [6-8]. 
Besides the favorable narrow size distributions and adequate optical properties in 
vitro, there are several requirements a QD-based colloid has to fulfil in order to be 
successfully used in biological investigations as a biomarker or model nanoparticle. 
Therefore, it is a logical prerequisite that the QDs are not only detectable in vitro but 
also in biological environments. The colloid has to exhibit sufficient stability under the 
conditions necessary for such investigations, i.e. in the presence of a cell culture 
medium containing high salt concentrations and proteins. In a huge number of 
experiments where QDs are used as a model particle of high detectability, cellular 
processes mediated by biomolecules are investigated. Such investigations include 
specific labeling and targeting of cell-surface structures with QDs decorated with 
peptides and proteins [9-11] or antibodies [12,13]. Of course, in these cases, non-
specific interactions of the QDs with the target cells have to be excluded. Otherwise, 
the non-specific binding will dominate the specific one and thus undermine the initial 
idea of specific targeting. The introduction of poly(ethylene glycol) (PEG) onto the 
surface of QDs has been shown to be an effective tool for the reduction of such non-
specific interactions [3,14,15]. Therefore, the QDs tested in this study have been 
coated with PEGylated phosphatidylehtanolamines (PEG-PE). A final, but very 
important aspect is the biocompatibility of QDs [16-19]. Since these materials are 
usually composed of heavy metals, consideration must be given to whether these 
nanoparticles influence the viability of the cells to be investigated. Therefore, a range 
of concentration was determined, inside which QDs can be applied to cells safely. By 
measuring the differences in metabolic activity of CHO and MCF-7 cells after 
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exposition to PEG-PE-modified QDs using a MTT-assay, the concentration-
dependent cytotoxicity of QDs was determined.  
 
Materials and methods 
Cadmium oxide (CdO, 99.5% purity), hexadecylamine (HDA, tech. grade 90%), lauric 
acid (LA 98%), methanol (anhydr. 99.8%), sulfur (99.5%), toluene (anhydr. 99.8%), 
trioctylphosphine (TOP, tech. grade 90%), trioctylphosphine oxide (TOPO, tech. 
grade 90%) and zinc stearate (tech. grade) were obtained from Sigma-Aldrich (St. 
Louis, MO). 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[methoxy-
(polyethylene glycol)-2000] (PEG-PE) of an average molecular weight of 2000 Da 
was obtained from Lipoid (Ludwigshafen, Germany). All cell-culture media and 
trypsin EDTA as well as fetal calf serum (FCS) were obtained from Sigma-Aldrich (St. 
Louis, MO). Phosphate buffered saline (PBS) was obtained by Invitrogen (Karlsruhe, 
Germany). 
 
Synthesis of CdSe/ZnS nanocrystals and PEG-PE coating 
CdSe/ZnS QDs were synthesized according to the methods described in chapter 3 of 
this thesis. Coating with PEG-PE was conducted as described in chapter 4. In brief, 
CdSe cores were grown in a mixture of TOPO and HDA (each 3.88 g) by quickly 
injecting the selenium precursor (2 mmol Se dissolved in 3.5 ml TOP) into the 
dissolved cadmium precursor consisting of 0.2 mmol CdO and 1.6 mmol lauric acid. 
After approx. 15 sec, the growth was stopped with toluene. The CdSe cores were 
isolated by precipitation with methanol and redissolved in the TOPO / HDA mixture. 
Shell growth was obtained by dropping a solution of 0.14 mmol  sulfur in 3 ml of TOP 
together with 0.16 mmol zinc stearate over 1 h. After this, QDs were isolated as 
described above and redissolved in dichloromethane. To this solution, an excess of 
PEG-PE in dichloromethane was added and a film was formed after removing the 
solvent at reduced pressure, as described in chapter 4. The film was subsequently 
dissolved in water at 80 °C leading to PEG-PE-QDs. The QDs were finally purified 
using ultracentrifugation. The PEG-PE-QDs exhibited a fluorescence maximum at 
533 nm which was ideal for the detection channels of the flow cytometer (see below). 
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Size analysis of PEG-PE-QDs 
The size of the QDs was analysed by dynamic light scattering (DLS) in cell culture 
medium (HAM F-15), supplemented with 5 % FCS. For the measurement, a 
ZetaSizer 3000 HSA (Malvern, Worcestershire, UK), operating at 20 °C and at an 
angle of 90°, was used. Data was processed using the CONTIN algorithm [20] 
regarding number distributions. 
 
Cell culture 
Cell lines were cultivated in 75 cm2 bottles at 37 °C, 5 % CO2 and saturated humidity. 
Chinese hamster ovary (CHO) cells were grown in HAM F-15 medium supplemented 
with 10 % of FCS. MCF-7 cells were maintained in Minimum Essential Medium 
containing Earl’s salts (EMEM).    
 
Observation of PEG-PE-QDs inside living cells 
PEG-PE-QDs in a concentration of 0.33 µM were injected into living CHO cells using 
a microcapillary and an injection unit consisting of InjectMan NI2 and FemtoJet 
(Eppendorf, Hamburg, Germany). The injection pressure was approx. 30-60 hPa and 
injection took up to 1 sec. 24 h after microinjection, cells were observed using a Zeiss 
Axiovert 200M inverted epifluorescence microscope coupled with a LSM 510 laser 
scanning device using the Axiovert software (Zeiss, Oberkochen, Germany). The 
PEG-PE-QDs were imaged upon excitation at 458 nm using a 505 nm longpass 
optical filter. Approx. 30 cells were treated while only few cells could be analyzed 
after the procedure.  
 
Flow-cytometric binding and uptake 
Cells were seeded into 24-well plates one day before the experiments and reached 
approx. 80 % confluence (approx. 80000 cells). Then, the medium was removed and 
cells were washed with PBS and the respective substances were added to the cells 
in the corresponding serum-free medium. The cells were incubated for 10 h, the 
substances were removed by suction and cells were washed with PBS. Then, the 
cells were detached using trypsin for 5 min. After this, the reaction was stopped with 
serum-containing medium and the cells were isolated by centrifugation for 5 min at 
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200 x g. After washing with PBS (4 °C) twice, the cells were resuspended in cold 
PBS (200 µl) and 0.5 µl of an aqueous solution of propidium iodide (1 mg/ml) was 
added. The cells were measured using a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA). The QD signal was obtained by excitation with an Ar 
laser at 488 nm and detection in channel FL1-H (530 / 30 nm). Propidium iodide was 
detected upon excitation at 635 nm in the channel FL3-H (670 nm longpass). The 
results were analyzed using WinMDI 2.8. For the diagrams describing the toxicity as 
well as the binding and uptake, the population containing the whole cells was gated 
and a threshold slightly above the background signal (obtained by recording cells 
without dye or QDs for each channel) was set. All cells above the threshold were 
counted and correlated to the total number of gated cells. 
 
Cytotoxicity assay 
For the determination of the cytotoxicity, two cell lines (CHO, MCF-7) were used. 
Cells were grown in 96-well plates to 80 % confluence. For the experiments, the 
medium was removed and the serum-free medium for the respective cell type 
containing the sample was added. After 4 h of incubation time under the conditions 
described above, a solution of MTT (0.5 mg/ml) was added. Cells were incubated for 
another 2 h. Then, the medium was removed carefully and the cells were lysed using 
a 10 % solution of sodium dodecyl sulfate (SDS) in 0.1 N HCl. After gentle shaking, 
the samples were measured by a plate reader (Shimadzu, Duisburg, Germany) at 
570 nm.  
 
Results and discussion 
To ensure that the PEG-PE-QDs exhibited sufficient colloidal stability under the 
conditions applied for cellular studies, the QDs were incubated for 24 h in cell culture 
medium rich in serum proteins. Under these conditions, poorly stabilized 
nanoparticles usually tended towards aggregation due to electrostatic and van-der-
Wals interactions. As shown in fig. 1, the particles maintained their size after 
incubation for 24 h in the serum-containing medium, as the size which was obtained 
before incubation and without serum (around 20 nm in hydrodynamic diameter), did 
not significantly change. The high stability of the QDs can be attributed to the steric 
stabilization caused by the PEG chains in the coating of the nanocrystals. Therefore, 
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the as prepared PEG-PE-QDs exhibited sufficient stability, at least for investigations 
over 24 h under cell culture conditions. 
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Figure 1: Stability of PEG-PE-QDs under cell-culture conditions. The QDs were 
investigated by DLS in cell culture medium before and after incubation for 24 h with 
5% of serum. After 24 h, the colloid size shows no significant change. QDs remain 
stable under these conditions. 
 
For many studies, QDs are used to follow the nanoparticle-uptake by cells. In the 
specific targeting of nanoparticles to distinct cell-types or even organs, the 
nanoparticles are connected with specific targeting molecules, such as peptides, 
proteins or antibodies [21]. In order to investigate the detectability of the nanocrystals 
inside living cells, the PEG-PE-QDs were microinjected into CHO cells. As depicted 
in fig. 2, the QDs are clearly visible inside the cytoplasm of the living CHO cells. 
Moreover, after 24 h of recovery time, which is necessary for the cells to overcome 
the harmful procedure of microinjection, the cells seem intact. 
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Figure 2: Fluorescence micrograph of CHO cells after microinjection with PEG-
PE-QDs. After microinjection and 24 h of recovery time, the QDs are clearly visible 
inside the cytosol of the cells. This shows that the prepared QDs are detectable 
inside living cells and do not lead to extensive cell damage after 24 h. (Scale bar = 20 
µm). 
 
To investigate the extent of non-specific binding and uptake of the PEG-PE-QDs by 
the cells as well as eventual toxic effects of the QDs on the cells, CHO cells were 
incubated with increasing concentrations of PEG-PE-QDs (up to 10 µm) and were 
subsequently analyzed by flow cytometry. In order to make the eventual toxic effects 
of the QDs visible, the cells were stained with propidium iodide. This dye is able to 
penetrate the membranes of damaged cells and starts fluorescing when intercalating 
with DNA. Therefore, each cell exhibiting an increased dye signal was regarded as 
dead. Fig 3A compares the histograms of the fluorescence of control cells and the 
fluorescence of cells incubated with 1 µM PEG-PE-QDs. Almost no shift in the 
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histogram is visible for the cells incubated with the QDs, indicating almost no non-
specific binding and uptake. Fig 3B confirms this result as the ratio of the cells 
exhibiting increased QD-fluorescence in relation to all cells is very low, almost on the 
level of the control cells. It can be seen that increasing amounts of QDs lead to 
increased cytotoxicity as the cell viability of the regarded cell population is decreasing 
for higher concentrations. However, compared to the entire collective of the regarded 
whole cells, the viability of the cells remains high.   
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Figure 3: Flow-cytometric analysis of non-specific binding and uptake of PEG-
PE-QDs. (A) Histogram of fluorescence intensity before (red) and after (green) 
incubation with 1 µM PEG-PE-QDs. (B) Gated living cell population investigated with 
regard to QD-fluorescence and cell viability by staining with propidium iodide. Even 
high concentrations (10 µM) show no significant non-specific binding or uptake as 
well as almost no loss of cell viability.  
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Figure 4: Investigation of metabolic activity of cells after incubation with PEG-
PE-QDs. (A) CHO cells show reduced metabolic activity for higher PEG-PE 
concentrations (2.5 and 1.0 µM) but no significant decrease for 0.5 µM. Interestingly, 
the control with 2.5 µM CdCl2 exhibits no significant stress on metabolic activity as 
well as excess of coating material (PEG-PE). (B) Similar results were obtained when 
using the MCF-7 cell line. 
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Besides the toxic effects which go along with the damage of cell membranes, the 
impairment of cells can also be recognized when looking at the metabolic activity. 
Measuring the metabolic activity is very sensitive in the determination of impairments 
of cells, as a decrease already occurs when the cells are morphologically not 
damaged and even when the cell membranes are still intact. When exploring 
nanoparticle targeting and controlled delivery into cells, it is important that the 
particles do not influence the physiology of the cells. To visualize the metabolic state 
of cells after the application of substances of eventual toxic properties, the MTT 
assay became state of the art [22,23]. In this assay, MTT is metabolized by the cells 
to a coloured formazan dependence of the metabolic activity of the cells. Fig. 4 
shows the metabolic activity of CHO (A) and MCF-7 cells (B) after the application of 
increasing amounts of PEG-PE-QDs. While lower concentrations (0.5 µM) do not 
impair the metabolic activity of both cell-types compared to control cells, higher 
concentrations lead to a reduction. This concentration-dependent effect is not due to 
the surface coating of the nanocrystals, which is the layer of the particles that the 
cells have contact with, since excess of PEG-PE does not reduce the metabolic 
activity of both cell-types. Since CdSe/ZnS QDs consist of toxic elements, it has been 
suggested that the toxicity of QDs is to a large extent caused by the heavy metal they 
may release [24,25]. To investigate this, a control group consisting of 2.5 mM 
cadmium chloride was tested. Intriguingly, here the metabolic activity of the cells was 
not impaired during the time of the investigations. This result shows that there might 
be a toxic effect of the QDs themselves and not only of the materials they consist of. 
However, for cellular investigations, QDs are usually applied in concentrations below 
100 nM [12,26,27]. Therefore, the range of concentration where PEG-PE-QDs can 
be used for such investigations is comfortable. 
 
Summary and conclusion 
The results show that PEG-PE-QDs are very well suited for cellular investigations in 
cellular environments as they fulfil the major requirements of nanoparticles for such 
purposes. The QDs exhibit high stability under cell culture conditions and are almost 
free of non-specific interactions with cells, which renders them interesting model 
nanoparticles for drug targeting. Moreover, PEG-PE-QDs exhibit tolerable toxic 
effects and can be used in a wide range (below 500 µM) that is sufficient for the vast 
Chapter 6  Cell-culture Characterization of Quantum Dots 
- 132 - 
majority of cellular assays. Together with the unique optical properties QDs offer, 
PEG-PE-QDs are a promising tool for the discovery of cellular uptake and targeting 
processes. 
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Abstract 
Targeted nanoparticle delivery to specific cells bears a high potential in diagnostics 
and drug therapy and has been in the focus of biomedical research for the past 
decade. However, for further progress in this field of research, establishing new 
targeting-strategies is necessary, since the number of relevant cell-surface targets 
that have proven useful so far is still highly limited. Up to now, G-protein coupled 
receptors (GPCRs), the largest class of receptors in humans, have hardly been 
investigated for nanoparticle targeting, though they do play a predominant role in 
modern drug therapy. For these receptors, numerous specific ligand-receptor 
combinations are known which could be exploited for cellular drug targeting.   
To gain access to this class of receptors, we investigated whether the human 
neuropeptide Y (NPY) Y1 receptor can serve as a model receptor for the active 
targeting of polymeric micelles to cells. Therefore, an analog of the porcine NPY was 
immobilized on micelles consisting of poly(ethylene glycol)-modified phospholipids 
(PEG-PE) as a model delivery system.  The targeted micelles were finally tested in 
cell culture using the human breast cancer cell-line MCF-7 which expresses the 
corresponding NPY Y1 receptor, to see whether GPCRs serve as a portal for micelle-
based cellular delivery. The results show that highly specific delivery of the peptide-
targeted micelles into cells is possible. By virtue of this targeting strategy it is obvious 
that these and similar constructs could be used to transport therapeutically relevant 
molecules into cells comprising of the respective GPCR of interest. 
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Introduction 
Targeted delivery of nanoparticles and other colloids to specific cells and tissues is of 
key interest in biomedical research [1-3]. Strategies in this field comprise of passive 
and active targeting principles. Though colloids can passively be accumulated in 
cancerous tissues due to their favored size, an effect also known as enhanced 
permeability and retention (EPR) [4], active targeting remains the more specific form 
of targeting. Here, cell-specific ligands mediate the binding of the nanoparticles to 
their target cells, preferably to cell-surface receptors, while binding to other cells that 
lack such receptors is ideally avoided [5,6]. Regarding such cell-surface receptors, 
only a few promising targets have been discussed so far, like the folic acid- [7], the 
transferrin- [8] or growth factor receptors [9]. However, all of these receptors are 
expressed in a variety of different tissues. Recent research has shown that G-protein 
coupled receptors (GPCRs) have high potential in mediating specific cellular uptake 
of nanoparticles [10].Since knowledge about the distribution of these receptors in the 
body is broad, this largest class of receptors with approx. 800 different members 
represents a highly interesting class of cell surface target [11]. Unfortunately, these 
studies were carried out using quantum dots that do not allow for incorporation of a 
drug substance. Therefore, we were looking for an alternate model carrier 
consequently we identified micellar systems [12,13]. They offer several advantages: 
their preparation is quite facile, their surface chemistry can easily be modified by their 
monomer composition and they exhibit small sizes, which is important for reaching 
the target tissues in vivo. Moreover, diagnostic as well as therapeutic active entities 
[14] can be incorporated into micelles, which allows for the handling of otherwise 
poorly deliverable drugs of unfavorable physico-chemical or toxic properties [15,16]. 
To prove the concept of intracellular delivery of polymeric micelles mediated by 
GPCRs, we conjugated an analog of the porcine neuropeptide Y (pNPY) to 
PEGylated phospholipid (PEG-phosphatidylethanolamine, PEG-PE) micelles. The 
corresponding GPCR – the human NPY Y1-receptor – exhibits an incidence of 85% 
in breast carcinoma and 100% of their lymph node metastases [17]. Therefore, a 
micelle-based delivery system targeting these receptors also exhibits a high 
therapeutic potential since micelles have already successfully been used for the 
incorporation of anti-tumor agents and showed a promising therapeutic profile 
[16,18]. In order to design targeted PEG-PE micelles, we established an effective 
Chapter 7 G-Protein Coupled Receptor Targeted Micelles   
 - 140 - 
protocol for the attachment of the peptidic ligand using specific conjugation chemistry 
based on the reaction of thiols with maleimides. Finally, we investigated whether 
labeled PEG-PE micelles were specifically delivered into human breast cancer cells 
expressing the NPY Y1-receptor by confocal laser scanning microscopy to examine 
the potential of such targeted micelles as a potential drug delivery system.   
  
Materials and Methods 
Materials 
The phospholipids used in this study consisted of 1,2-distearoyl-sn-glycero-3-
phosphatidylethanolamine which was covalently linked to poly(ethylene glycol) (PEG) 
of 2000 Da, and are referred to as PEG-PE. Two different kinds of PEG-PE were 
used, the first exhibited non-reactive methoxy-groups at the end of the PEG chain 
and was obtained from Lipoid (Ludwigshafen, Germany); the second class of PEG-
PE contained reactive amino-PEG and was purchased from Avanti Polar Lipids 
(Alabaster, AL) and is referred to as amino-PEG-PE. Acetone, 5(6)-
carboxytetramethylrhodamine N-succinimidyl ester (TAMRA-NHS), fluorescamine, 
cysteine, sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (sulfo-
SMCC) and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Acetonitrile (ACN) in HPLC grade was obtained from Merck (Darmstadt, 
Germany). For all reactions, water purified by a Millipore system was used.  
 
Peptide synthesis 
The peptide [Lys4(αN-Acetyl-Cys), Arg6, Pro34]-pNPY (Cys-NPY) was synthesized by 
standard automated solid phase synthesis and exhibited the sequence of the porcine 
neuropeptide Y (pNPY), with two amino acid exchanges in position 6 and 34 by Arg 
and Pro [19]. In position 4, an additional cysteine side-chain was introduced for the 
bioconjugation with the PEG-PE micelles. The sequence of the peptide was H-
YPSK(Ac-N-C)PRNPGEDAPAEDLARYYSALRHYINLITRPRY-NH2. The mass was 
confirmed by MALDI-Tof using an α-cyano-4-hydroxycinnamic acid (HCA) matrix 
(calculated mass: 4409 Da; found mass: 4412 Da). For a detailed synthesis protocol, 
see [10]. 
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Micelle preparation  
The micelles used in all of the studies were prepared by dissolving 6 parts of PEG-
PE and 1 part of amino-PEG-PE in the corresponding medium. All reactions were 
carried out in 1.5 ml standard reaction vessels (Eppendorf, Hamburg, Germany). For 
the establishment of the bioconjugation reaction, 2.3 mg of the lipid mixture 
(corresponding to 0.12 µmol amino-PEG-PE) and 0.15 mg of sulfo-SMCC (0.34 
µmol) were each dissolved in 50 µl of water and transferred into 100 µl of 50 mM 
phosphate buffered saline (PBS) at pH 7.2, 7.5 and 8.0, respectively, to yield a final 
buffer capacity of 50 mM. After 30 min of shaking, the reaction mixture was purified 
by gel filtration chromatography (GFC) as described below. The fraction containing 
the micelles was then collected and immediately frozen by submerging it into liquid 
nitrogen to avoid hydrolysis of the maleimides. Subsequently, the samples were 
freeze-dried using a Beta 2-16 lab-scale freeze-drier from Christ (Osterode am Harz, 
Germany) operating at -20 °C and 0.12 mbar overnight. After this, 1 mg of the 
samples (approx. 5.2 µM) was dissolved in 50 mM PBS, and a 3-fold molar excess of 
lysine (2.3 µmol, calculated for the theoretical number of maleimides) in the same 
buffer was added and reacted for 12h to investigate the reactivity of the maleimide-
modified micelles since the amino group of lysine is accessible for an amine group 
assay (see below). The final products were again purified by GFC and freeze-dried, 
as described above. 
For the conjugation of the micelles with the Cys-NPY, to yield NPY-PEG-PE, mixed 
PEG-PE micelles were reacted with sulfo-SMCC at pH 7.2 and purified as described 
above. Thereafter, the activated PEG-PEs were dissolved in 300 µl of PBS pH 7.2 
containing 30% acetonitrile to a concentration of 1 mg/ml, and an equimolar amount 
of the Cys-NPY dissolved in a small amount of the same buffer was added, followed 
by shaking of the mixture for 12 h. After incubation, the final product (Cys-NPY-PEG-
PE) was obtained after GFC and freeze-drying (see above).  
Dye-labeled PEG-PE (TAMRA-PEG-PE) was prepared by reacting 7 mg of mixed 
micelles (corresponding to 0.56 µmol amino-PEG-PE) in 500 µl PBS pH 7.4 with 0.5 
mg (0.95 µmol) TAMRA-NHS for 30 min. After this, the micelles were purified by GFC 
and freeze-dried as described above. 
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Gel filtration chromatography (GFC) 
Gel filtration was conducted using a Sephacryl S-100 resin packed into a Tricorn 
10/300 column (GE Healthcare, Chalfont St. Giles, UK). The column was coupled to 
standard HPLC equipment (Shimadzu, Duisburg, Germany) operating in the isocratic 
mode at a flow rate of 0.5 ml/min. The mobile phase consisted of 30% acetonitrile in 
water with the addition of 0.1% trifluoroacetic acid. A SPD-10 AV UV-detector 
(Shimadzu, Duisburg, Germany) recorded the absorbance at a wavelength of 220 
nm. 
  
Size determination 
PEG-PE micelles were imaged by cryo-transmission electron microscopy (cryo-
TEM). For sample preparation, a few microliters of a dilute solution of PEG-PE were 
transferred onto a 600 mesh copper grid (Plano, Wetzlar, Germany). After the 
removal of excess liquid by suction, the sample was quickly frozen in liquid ethane in 
a cryo-box. The sample was mounted on a cryo-transfer holder (CT 3500, Gatan, 
Munich) and measured using a Zeiss EM 922 EFTEM (ZeissNTS, Oberkochen, 
Germany), operated at 200 kV and around 90 K. 
The hydrodynamic diameter of the mixed PEG-PE micelles was determined by 
dynamic light scattering (DLS) using a ZetaSizer 3000 HSA (Malvern, 
Worcestershire, UK) at 20 °C and an angle of 90°. Data was processed using the 
CONTIN algorithm [20].  
 
Determination of amines 
The mixed PEG-PE micelles containing free primary amines were analyzed after 
preparation and went through the same GFC purification route like as the products. 
The colloid was also analyzed after the reaction with sulfo-SMCC and the coupling 
with lysine as well, in order to investigate the conversion. Therefore, the 
corresponding lipids, modified or unmodified, were dissolved at a concentration of 
approx. 7 mg/ml in water. 5 µl of the sample was added to 135 µl of 50 mM borate 
buffer pH 8.5 and 60 µl of a 1 mM solution of fluorescamine in acetone. Fluorescence 
was determined in 96 well-plates directly after the addition of the fluorescamine using 
a LS 55 fluorescence spectrometer from PerkinElmer (Waltham, MA) equipped with a 
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plate reader unit (excitation at 390nm, emission at 475nm). The fluorescence 
intensity was correlated to the theoretical mass of the lipids. 
  
Matrix assisted laser desorption ionization (MALDI) 
For the determination of the mass, equal volumes of the Cys-NPY-PEG-PE samples 
in a concentration of 4 mg/ml and a saturated matrix solution were cocrystallized. A 
matrix consisting of α-cyano-4-hydroxycinnamic acid (CHCA) in 50% acetonitrile with 
the addition of 0.1% TFA was used. The mass spectra were obtained using a 4700 
proteomics Analyzer MALDI-ToF/ToF mass spectrometer (Applied Biosystems, 
Foster City, CA), operating in the linear mode. 
 
Cell culture and cellular uptake studies 
The human breast cancer cell line MCF-7 was cultivated in Minimum Essential 
Medium containing Earl’s salts (EMEM) supplemented with 5% of foetal bovine 
serum (FBS) at 37 °C in an atmosphere of 95% humidity and 5% CO2.  
Before the observations by confocal laser scanning microscopy (CLSM), MCF-7 cells 
were seeded into 8-well µ-slides (Ibidi, Munich, Germany) in a density of 5000 cells / 
chamber and incubated for  48 h with the addition of 1 nM estradiol to increase the 
amount of Y1-receptors on the cells [21]. For the investigation of specific micelle 
uptake by the cells, TAMRA-labeled micelles were prepared by dissolving PEG-PE (1 
mg/ml) and TAMRA-PEG-PE (0.05 mg/ml) in water. Labeled micelles containing Cys-
NPY were prepared by adding 0.1 mg/ml of NPY-PEG-PE to the labeled micelles. 10 
µl of both kinds of labeled micelles was added to 150 µl of incubation medium 
containing EMEM medium supplemented with 1% BSA and 0.01% of bacitracin and 
incubated at 37 °C for 30 min. The cells were washed with PBS and again exposed 
to a sample-free incubation medium. The living cells were imaged at 37 °C using an 
Axiovert 200M inverted epifluorescence microscope coupled with a LSM 510 laser 
scanning device using Axiovert Software (Zeiss, Oberkochen, Germany), using a 
Plan-Apochromat X40 water-immersion objective with a numerical aperture of 1.2. 
The labeled micelles were excited at 543 nm and dye-emission was measured using 
a 560-615 nm band-pass filter. The thickness of the optical sections was below 1 µm. 
Image data was processed using ImageJ 1.42q [22].  
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Results and discussion 
In order to be used as an adequate delivery system for the delivery into specific cells, 
small sizes and uniform size-distributions are a crucial prerequisite [23]. To 
investigate this, the PEG-PE micelles were analyzed by TEM and DLS. The data 
suggests that PEG-PE micelles represent an almost ideal colloid due to their 
outstanding uniformity.  As depicted in fig. 1A, the micelles display a very uniform 
shape in TEM images. The micelles exhibit a diameter of approx. 13 nm which 
supports the results obtained by DLS which revealed an average size of 13.7 ± 
0.6 nm and a polydispersity index of  0.15 ± 0.03 (fig. 1B). This shows that the colloid 
should be small enough for entering cellular uptake pathways, like receptor-mediated 
endocytosis [24,25]. 
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Figure 1: Size analysis of PEG-PE micelles. (A) Cryo-TEM micrograph of PEG-PE 
in water showing uniform, spherical micelles. (B) Size distribution, determined by 
DLS (average size: 13.7 ± 0.6 nm; polydispersity: index 0.146 ± 0.024). 
 
Since the micelles are not only in pure water but also in various solvent mixtures as 
well as cell culture media for their preparation and their later biological testing, 
respectively, it was investigated whether the micelles show sufficient stability in 
various environments. Therefore, the micelles were exposed to aqueous solutions of 
ACN with and without addition of TFA, to PBS buffer (needed for the bioconjugation 
reaction later on), as well as to culture media lacking and containing serum proteins 
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and were analyzed by DLS (fig. 2). The results show sizes similar to the ones 
obtained in water and a moderate increase in polydispersity. Interestingly, when 
using ACN, the addition of TFA was necessary to keep the micellular structures 
needed for the GFC purification later on. The high stability in these different media, 
especially in the serum-containing medium, can be attributed to the PEG-shielding of 
the PEG-PE micelles which minimized the adsorption of proteins. Therefore, the 
colloid is suitable for modification under various conditions as well for the cellular 
drug targeting studies. 
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Figure 2: Formation of PEG-PE micelles in different media. The micelles show 
good stability under various conditions, like aqueous TFA / acetonitrile solutions, PBS 
buffer and also cell-culture medium. The colloid size (bars) remains constant. The 
polydispersity index (  ) decreases in solvents different from pure water but remains 
low. 
 
In the following approaches we investigated, how the PEG-PE micelles can be 
coupled effectively with a peptidic agonist of the Y1-receptor (Cys-NPY). The 
conjugation using maleimide-thiol couplings is especially favorable, since maleimides 
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react very selectively with thiols. Therefore, Cys-NPY could selectively be attached to 
the micelles at a position in the peptide sequence where modifications are well-
tolerated which was the lysine side-chain [10,26] that was acylated by an additional 
cysteine. Another advantage is the low size of the small-molecular thiol.reactive 
linkers, compared to bulky streptavidin molecules (over 60 kDa [27]).  Fig. 3 shows 
the reaction scheme of the conjugation of PEG-PE micelles (fig. 3, 1) to thiol-
containing molecules by using the hetero-bifunctional crosslinker sulfo-SMCC. In this 
two-step reaction, first the amine-containing micelles are activated by the crosslinker 
forming a stable amide bond. After purification by gel filtration to remove excess 
crosslinker and subsequent freeze drying, the activated PEG-PE (fig. 3, 2) is then 
reactive towards thiol groups yielding stable covalent conjugates (fig. 3, 3).  
 
O
O O P O
N
H
O
O H
O
O
O
(OCH2CH2)45NH2
N
O
O
O
O
N
O
O
S
HO
OO
O
O O P O
N
H
O
O H
O
O
O
(OCH2CH2)45NH
O
N
O
O
O
O O P O
N
H
O
O H
O
O
O
(OCH2CH2)45NH
O
N
O
O
HS-R
S-R
(1)
(2)
(3)
 
Figure 3: Reaction scheme of the bioconjugation of PEG-PE micelles with 
amino acids or peptides. The activation of the micelles containing amino-PEG with 
the crosslinker sulfo-SMCC to renders the colloid thiol-reactive (1). The activated 
PEG-PE then is reacted with thiol-containing molecules (cysteine or Cys-NPY) to 
form a stable covalent conjugate (2). 
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To obtain conditions that allow for an effective coupling, the conversion of each step 
of the reaction was analyzed by an amino-group assay. For this purpose, the 
micelles were activated by sulfo-SMCC at mild basic conditions (pH 7.2, 7.5, 8.0). 
Then the remaining amines of the micelles that had not reacted with the crosslinker 
were analyzed by the amino group assay using fluorescamine and by detecting the 
fluorescence of the product during GFC (fig. 4). As expected, the more basic the 
reaction medium the lower the amount of unreacted amines was. To investigate at 
which pH the maleimide of the thus activated micelles is kept most reactive, these 
micelles subsequently were reacted with cysteine and again assayed using 
fluorescamine and GFC. All of the three differently activated micelles had reacted 
with the thiol-containing amino acid as the fluorescence due to fluorescamine 
increased significantly. However, when the activation step was carried out at pH 7.2, 
the highest yields were obtained, though the yield of the first step was the lowest. 
The reason for this is the hydrolysis of the maleimide that increases at increasing pH. 
Thus, the optimal pH for the activation reaction was 7.2.  
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Figure 4: Observation of the efficacy of the bioconjugation at different pH 
values. The above reaction scheme shows how the amino-PEG containing PEG-PE 
micelles are activated using sulfo-SMCC and how the activated colloid then is 
conjugated to cysteine. Each species is converted with fluorescamine to determine 
the free amines. The graph shows the fluorescence intensity per mg of PEG-PE after 
conversion of the free amines with fluorescamine. After a decrease of the amines 
due to the conversion with sulfo-SMCC (more efficient at higher pH) the amines 
increase due to the reaction of the activated colloid with cysteine at pH 7.2. The 
highest overall conversion can be found when the colloid was activated at pH 7.2. 
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Subsequently, we investigated the conjugation of Cys-NPY under the optimized 
conjugation conditions. To this end, the PEG-PE micelles were activated with sulfo-
SMCC at pH 7.2 and the colloid was then purified by GFC. The corresponding 
chromatogram is shown in fig. 5. A very weak signal was recorded for the activated 
PEG-PE micelles. However, after the reaction with Cys-NPY, the corresponding GFC 
chromatogram shows a clear increase in absorbance at the first peak which 
represents the colloid (fig. 5). This clearly shows that the peptide was conjugated 
successfully to the PEG-PE micelles.  
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Figure 5: Gel filtration chromatograms of PEG-PE micelles before and after 
bioconjugation. The first chromatogram ( ) shows the PEG-PE micelles gained 
by UV-detection at 220 nm after activation with sulfo-SMCC (1st peak) and excess of 
the crosslinker (2nd peak). The second chromatogram ( ) represents the micelles 
after conjugation with the peptide. The signal of the 1st peak is clearly increased 
indicating a successful bioconjugation, while the second peak shows non-reacted 
peptide.  
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In order to investigate whether the association of the peptide with the PEG-PE is 
based on a covalent linkage and not only due to adsorption of the peptide to the 
micelles, mass analysis of the peak corresponding to the PEG-PE-peptide conjugate 
was performed. Mass analysis using MALDI-ToF was possible for the PEG-PE 
micelles, since the phospholipids form non-covalent micelles in aqueous 
environments. The mass spectrum in fig. 6 shows the unmodified PEG-PE (left) 
exhibiting a molar mass of around 2600. The broad peak corresponds to the mass 
distribution caused by the different molecular mass distribution of the PEG chains. 
The same pattern can be found for the conjugate. Here, the mass corresponding to 
the sum of PEG-PE, the linker part and the peptide was found to be around 7400 Da. 
Therefore, it is evident that the bioconjugation reaction between the colloid and the 
peptide yielded a covalent product.  
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Figure 6: Mass spectrogram of the PEG-PE micelles conjugated to the Cys-
NPY. The lower masses at 2600 Da represent the non-functionalzed part of the 
micelles (left) while the higher masses at a mean of approx 7400 Da are due to the 
bioconjugate (right). 
 
In order to investigate the specific uptake of the NPY-PEG-PE micelles by cells 
expressing the NPY Y1-receptor, the NPY-PEG-PE micelles were labeled by 
integrating TAMRA-labeled PEG-PE molecules into the micelles. To follow cellular 
uptake, the Y1-receptor positive human breast cancer cell line MCF-7 was imaged 
after incubation with the labeled micelles. The TAMRA-labeled micelles without the 
targeting ligand Cys-NPY showed no affinity towards the target cells under the 
confocal fluorescence microscope. Non-specific uptake was effectively reduced, due 
to the PEG-shielding of the micelles (fig. 7A). In contrast, when the micelles 
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contained NPY-PEG-PE, delivery into the target cells took place. As can be seen in 
fig. 7B, the cells then showed fluorescence due to the uptake of the fluorescent 
micelles. As expected, fluorescence is concentrated in vesicular structures, typical for 
receptor-mediated endocytosis [24,25]. However, except for the cell nuclei, 
fluorescence was also located throughout the cells indicating that escape from the 
endosomal structures into the cytoplasm may take place (fig. 7B).  
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Figure 7: Specific cellular uptake of PEG-PE micelles at Y1-receptor positive 
MCF-7 breast cancer cells investigated by CLSM. (A) Non-targeted TAMRA-
labeled (represented by the orange hexagons in the scheme) PEG-PE micelles are 
not taken-up as no signal appears in the confocal micrograph. (B) In contrast, the 
TAMRA-PEG-PE micelles modified by the ligand Cys-NPY (represented by the ball-
chain) are taken up by the cells. The micelles are accumulated in vesicular structures 
as well as they are distributed into the cytosol. Dark circles correspond to the cell 
nuclei where the colloid was not delivered to. (Scale bar = 20 µm) 
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Since the endosomal escape is a crucial prerequisite for intracellular targeting, the 
delivery of micelles for cellular targeting may be favorable compared to solid 
nanoparticles. The data demonstrates that the introduction of Cys-NPY as a targeting 
ligand for Y1-receptors effectively renders the colloid affine to cells expressing the 
receptor. Moreover, the micelles or seem to be delivered into the cytoplasm of the 
target cells. These findings make GPCR-targeted micelles interesting for further 
diagnostic and therapeutic purposes.  
    
Summary and conclusion 
In conclusion, we showed that polymeric PEG-PE micelles are potent candidates for 
a GPCR-targeted drug delivery system. After precisely modifying these micelles with 
specific ligands for GPCRs using site-specific peptide-attachment by thiol-maleimide-
interaction, the micelles are effectively delivered into human breast cancer cells 
expressing the NPY Y1-receptor, whereas in the absence of the targeting peptide, no 
delivery takes place. Moreover, the micelles are not only internalized, they also seem 
to be delivered into the cytoplasm after endosomal escape, a decisive step in 
intracellular drug targeting. Therefore, the combination of PEG-PE micelles as drug 
carrier and GPCRs as selective portal into cells is a promising candidate for future 
targeted drug delivery. 
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Abstract 
Improving the selectivity of interactions between nanoparticles and cells would 
substantially increase the potential for nanoparticle diagnostic and therapeutic 
applications. Thus it is desirable not only that nanoparticles be targeted to any cell 
with high specificity and affinity, but also that one be able to unequivocally determine 
whether they rest immobilized on the cell surface (as a diagnostic tag) or are 
internalized (to serve as a drug delivery vehicle). To date no class of targets is known 
that would allow one to direct nanoparticle interactions with cells alternatively into 
one of these mutually exclusive events. Using MCF-7 breast cancer cells expressing 
the human Y1-receptor we demonstrate that G-protein coupled receptors (GPCRs) 
provide us with this ability. We show that quantum dots carrying a surface-
immobilized antagonist remain with nanomolar affinity on the cell surface, while 
particles carrying an agonist are internalized upon receptor binding. We found that 
agonist- and antagonist-modified nanoparticles bind to several receptor molecules 
simultaneously. This multiligand binding leads to an increase of 5 orders of 
magnitude in the receptor affinities (compared to free ligand). The fact that there are 
more than 800 GPCRs in humans provides us with the possibility of targeting of a 
plethora of cells. This work demonstrates that switching from cell recognition to cell 
uptake is simply a matter of modifying the nanoparticle surface with the appropriate 
choice of ligand type. 
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Introduction 
A major goal of biomedical targeting is the selective delivery of nanoparticles to a 
specific mammalian tissue for diagnostic or therapeutic purposes [1-3]. Current 
strategies for guiding nanoparticles to their target have focused mainly on 
immobilizing either antibodies against cell surface proteins [4-6] or natural ligands for 
cell surface receptors [7] on particle surfaces. The substantial molecular mass and 
size added to the nanoparticles decreases the utility of attached antibodies, and 
receptor ligands have not provided us with the necessary versatility to date. Only a 
few receptors, such as the transferrin receptor or the epidermal growth factor 
receptor, have emerged as targeting sites [4,7]; these are unfortunately expressed in 
a multitude of tissues and are therefore rather unspecific.  
In addition to these severe limitations, a problem of paramount significance is the 
loss of control over such particles’ fate once they bind to their target. To date no 
mechanism is known that would allow one to design particles destined for a single 
target structure such that they are addressed exclusively to the cell surface or to the 
cell interior. The former would allow the use of particles for diagnostic purposes 
without interfering with intracellular processes, while the latter would allow one to 
elicit a cellular response in cells identified by nanoparticles. Despite the tremendous 
progress towards a better understanding of factors having an impact on particle 
uptake by cells, such as size and surface charge [8-10], a fundamentally new 
strategy to control nanoparticle trafficking has yet to be developed.  
To develop this strategy, it was necessary to utilize a new family of targets for which 
ligands are available that are highly tissue-type specific and allow ‘sorting’ of particles 
after binding. The family of G-protein coupled receptors (GPCRs), which exhibit high 
tissue-specificity and represent the largest class of receptors in the human genome 
[11], appeared to be a promising choice. High affinity ligands for GPCRs of moderate 
molecular mass exist, and early reports have indicated that ligand-decorated 
nanoparticles still interact with the receptor [12,13]. Most importantly, however, two 
classes of GPCR ligands exist: agonists that lead to receptor internalization upon 
binding and antagonists that do not [14].  
Having identified this potential ‘molecular switch’ for controlling the gateway into 
cells, we hypothesized that the immobilization of an agonist on a nanoparticle surface 
would cause cellular uptake, while the immobilization of an antagonist to a particle 
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would result in arrest on the cell surface. Furthermore, we believed that such 
nanoparticles would preserve their high cell affinity and target specificity by attaching 
to cell surface receptors via a multi-ligand binding mode.  
To investigate the validity of both hypotheses, we selected the human neuropeptide 
Y (NPY) Y1-receptor as a model receptor. This receptor has an incidence of 85% in 
breast carcinoma and 100% in lymph node metastases [15]. We used quantum dots 
(QDs) [16] to which peptidic agonists of a few kDa in molecular mass or a small-
molecule antagonist were attached to examine if GPCR trafficking upon ligand 
binding [17] can be exploited as a selective nanoparticle gateway into cells. 
 
Materials and Methods 
Buffers and reagents 
All chemicals were obtained from Sigma (St. Louis, MO) in the highest purity 
available, unless stated differently. Activation buffer consisted of 50 mM sodium 
tetraborate buffer, pH 7.2. Purification buffer I consisted of activation buffer, 
supplemented with 150 mM sodium chloride and 10 mM ethylenediaminetetraacetic 
acid (EDTA) disodium salt. Conjugation buffer contained two parts of purification 
buffer I and one part of dimethylformamide (DMF), whereas purification buffer II 
contained dimethylsulfoxide (DMSO) instead of DMF and 0.01% sodium azide. The 
ultrafiltration units had a 100 kDa cut-off membrane (Amicon Ultra-4, Millipore, 
Billerica, MA). Incubation medium consisted of phenol red-free Leibovitz F-15 
medium (Invitrogen, Carlsbad, CA), 1% of bovine serum albumin and 0.01% of 
Bacitracin (Invitrogen). 
 
Synthesis of pNPY analogs 
Three analogs of the porcine neuropeptide Y (pNPY) were synthesized by standard 
automated solid phase synthesis. Lysine in position 4 was modified by side chain 
attachment of an additional cysteine residue for the bioconjugation with the QDs. The 
sequences of the peptides are given in tab. 1. The mass was confirmed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF-
MS) using α-cyano-4-hydroxycinnamic acid (HCA) matrix (for details see SI 
methods). 
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Synthesis of BIBP3226 and SH-BIBP 
BIBP3226 and (R)-Nα-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)-Nω-(6-sulfanyl-
hexanoyl)-argininamide, in this article referred to as SH-BIPB, were synthesized 
based on a procedure which was published previously for other NG-substituted 
derivatives of BIBP3226 [21] (for details see SI methods and SI fig. 1). 
 
Conjugation of Y1-receptor ligands to QDs 
1 nmol of Qdot 655 IT amino (PEG) quantum dot (Invitrogen) was transferred into 
200 µl of activation buffer by buffer exchange using ultrafiltration (Amicon Ultra-4, 
100K MWCO, GE Healthcare, Chalfont St. Giles, UK). The QDs were subsequently 
activated by a 500-fold molar excess of sulfosuccinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (sulfo-SMCC) dissolved in activation buffer to yield a final 
volume of 250 µl. After 30 min of gentle shaking at room temperature, the activated 
QDs were purified by gel filtration chromatography (GFC) using purification buffer I 
as mobile phase (for details see SI methods and SI fig. 2). After buffer exchange to 
conjugation buffer, removal of the excess conjugation buffer by ultrafiltration and 
concentration to a volume of 100 µl, QDs were incubated with a 30-fold excess of the 
respective NPY-analog or a 100-fold excess of SH-BIBP for 12 h at 4° C. Thereafter, 
a 100-fold molar excess of 2-mercaptoethanol was added to quench unreacted 
maleimides. After 30 min, the obtained bioconjugate was purified again by GFC using 
purification buffer II. Subsequently, the conjugate was concentrated by ultrafiltration 
to a final concentration of 3 µM that was used for the biological studies. 
 
Cell culture 
The human breast cancer cell line MCF-7 and the human neuroblastoma cell line SK-
N-MC were maintained in Minimum Essential Medium containing Earl’s salts (EMEM) 
supplemented with 5% fetal bovine serum (FBS). 48 h before the experiments MCF-7 
cells were seeded in the same medium supplemented with 1 nM estradiol (Sigma). 
SK-N-MC cells were cultured in the absence of estradiol. MDA cells were kept in 
McCoy`s medium supplemented with 5% FBS and seeded 24 h before the 
experiments. 
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Imaging: Confocal laser scanning microscopy (CLSM) 
Two days before the experiments, cells were seeded in 8-well µ-slides (Ibidi, Munich, 
Germany). All experiments were conducted in incubation medium at 37 °C. Cells 
were observed using a Zeiss Axiovert 200M inverted epifluorescence microscope 
coupled with a LSM 510 laser scanning device, using a 40x Plan-Apochromat water-
immersion objective (NA 1.2). QDs and QD/ligand-conjugates were excited using the 
488 nm line of an Ar-laser. Emission was measured using a 650 nm long pass filter. 
For the investigation of agonist- and antagonist-modified QDs interactions with MCF-
7 cells by z-stack images we used as slice thickness of 1.1 µm for agonist-modified 
QDs, and 1.8 µm for antagonist-modified QDs. 
 
Binding and displacement studies 
Cells were seeded in 24-well plates at a density of 130,000 (MCF-7) and 80,000 
(MDA) cells per well. For the studies, the medium was removed, cells were washed 
with phosphate buffered saline (PBS) and incubated with the QD dilutions for 2 h at 
23 °C. After incubation, the QDs were removed, and the cells were washed with PBS 
and trypsinized. After centrifugation at 200 RCF at 4 °C, the cells were washed twice 
with cold PBS and used for FACS analysis. For association curves, the respective 
amount of the testing substance was diluted in incubation medium. For displacement 
studies, all ligand-modified QDs were used at a concentration of 1 nM. The 
incubation medium contained the respective amount of BIBP3226 and 7.5% DMSO 
to increase the solubility of the antagonist. Cells were analyzed on a FACSCalibur 
(BD Biosciences, San Jose, CA). QDs were excited at 633 nm via a diode laser and 
emission was measured using a 661/16 nm bandpass filter. Data was analyzed by 
using the WinMDI 2.8 software. The population representing whole cells (on average 
20,000 cells) was gated and the fluorescence was plotted in a histogram. All values 
were corrected for the background signal obtained in absence of QDs. For binding 
studies, the intensities of the geometric mean of the histogram were plotted. For 
displacement studies, the intensity of the geometric mean obtained for 1 nM of the 
respective QD sample without antagonist was set to 100%, and all other samples 
were calculated proportional to this value. Each data point represents the mean of 3 
independent measurements (± SEM). All data to be fitted were processed with 
SigmaPlot 8.0. Data from binding experiments were evaluated by one-site saturation 
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fits. Data from displacement experiments were analyzed by four-parameter sigmoidal 
fits. 
 
Results and discussion 
Different peptidic agonists of the Y1-receptor, analogs of porcine NPY (pNPY) 
exhibiting different receptor affinities and molecular masses (tab. 1A-C), were 
synthesized (for details see Supporting Information (SI)). The introduction of a 
cysteine residue by side-chain modification of a lysine found in the selected agonists 
[18-20] provided a specific reaction site for the stable covalent linkage to the QDs.  
 
  Name 
(abbreviation) 
Sequence / structure Ligand type Lit* 
a 
 
[Lys4(Nα-Acetyl-Cys)]-
pNPY 
 
H-YPSK(Ac-N-C)PDNPGEDAPAEDLA
RYYSALRHYINLITRQRY-NH2 
 
peptidic agonist 18 
b 
 
[Lys4(Nα-Acetyl-Cys), 
Arg6, Pro34]-pNPY  
H-YPSK(Ac-N-C)PRNPGEDAPAEDLA
RYYSALRHYINLITRPRY-NH2 
peptidic agonist 19 
c 
 
 
[Lys4(Nα-Acetyl-Cys), 
Ahx9-17]-pNPY [Ahx = 6-
aminohexanoyl] 
 
H-YPSK(Ac-N-C)PDNP-Ahx-
ARYYSALRHYINLITRQRY-NH2 
peptidic agonist 20 
d SH-BIBP 
 
H
N
N
HO
O
OH
NH
H2N N
O
SH
 
 
non-peptidic 
antagonist 
21 
 
Table 1: Overview of ligands used in the study. Structures and names of the NPY-
analogs (A-C) and non-peptidic Y1-receptor antagonist (D) used for bioconjugation 
with the QDs. (*Literature refers to the cysteine-free peptide and the non-acylated 
BIBP3226.) 
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As shown in fig. 1A, amino-PEG coated QDs were rendered thiol-reactive upon 
treatment with sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate 
(sulfo-SMCC), subsequently reacted with the peptides and purified by gel filtration 
chromatography (details of the conjugation and purification procedure can be found 
in SI). Transmission electron microscopy images confirmed that this strategy yielded 
monodisperse (see SI methods and SI fig. 1), peptide-modified (see SI fig. 2) QDs, a 
schematic illustration of which is shown in fig. 1B. Similarly, QDs decorated with a 
low molecular mass, non-peptidic antagonist were prepared. For the attachment to 
the QDs, a thiol was introduced into the antagonist BIBP3226 by acylation with 6-
mercaptohexanoic acid to obtain (R)-Nα-(2,2-diphenylacetyl)-N-(4-hydroxybenzyl)-Nω-
(6-sulfanylhexanoyl)-argininamide, referred to as SH-BIPB (tab. 1D) (for details of 
BIBP and SH-BIBP synthesis see SI and SI fig. 3). 
BA
O
NH2
n
O
N
H
O
N
O
O
n
N
O
O
O
O
N
O
O
S
HO
OO
O
N
H
O
N
O
O
n S R
SH R
2
1
3
 
Figure 1: Method of Y1-receptor ligand conjugation to QDs. (A) Scheme of the 
bioconjugation reaction. After activation of the amino-PEG QDs (1) with sulfo-SMCC, 
the resulting thiol-reactive nanoparticles (2) were connected with either the peptidic 
agonistic analogs of pNPY or the non-peptidic antagonist SH-BIBP to yield the 
ligand-modified QDs (3). R-SH refers to the structures A-D depicted in tab. 1. 
(B) Schematic illustration of NPY-modified QDs. The nanoparticles consist of 
polymer-coated CdSe/ZnS QDs, decorated with amine PEGs and the attached NPY 
analog. 
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Both agonist- and antagonist-modified QDs were investigated by confocal laser 
scanning microscopy (CLSM) to observe binding to the human breast cancer cell-line 
MCF-7, which expresses the Y1-receptor (cell culture conditions and details of CLSM 
investigations are provided in SI methods). Both QD types exhibited highly specific 
binding (fig. 2 and 3). To assure that ligand-free QDs are not internalized by any 
unspecific uptake mechanism, NPY Y1-receptor positive MCF-7 cells were incubated 
under the conditions described for ligand-modified nanoparticles. Fig. 4 shows that 
there is no significant uptake of the particles.  
 
flu
o
re
sc
e
n
ce
br
ig
ht
fie
ld
MCF-7 (Y1+) MCF-7 (Y1+),
BIBP3226
MDA (Y1-)
 
Figure 2: Specific binding and uptake of agonist-modified QDs. Confocal 
fluorescence micrographs and corresponding brightfield images of cell clusters after 
incubation with [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-pNPY-QDs (10 nM). The 
nanoparticles are delivered into living MCF-7 cells in vesicular structures. Except for 
the cell nuclei, the particles are located throughout the cellbodies. After blocking 
receptors with the soluble antagonist BIBP3226 (10 mM) or when using MDA cells 
(Y1-), no internalization can be observed (scale bars = 20 µm). 
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Figure 3: Cell-binding of antagonist-modified QDs. Confocal fluorescence 
micrographs and corresponding brightfield images of cells incubated with 10 nM of 
SH-BIBP-QDs. The particles exhibit binding to the cell surfaces of living MCF-7 cells, 
whereas upon displacement with 10 mM of the antagonist BIBP3226 or for MDA cells 
(Y1-) no binding occurs (scale bars = 20 µm). 
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Figure 4: Cell binding of ligand-free QDs. 100 nM of QDs lacking ligands show no 
binding and uptake after incubation with MCF-7 cells (scale bars = 20 µm). 
 
The control experiments (fig. 2 and 3) showed that binding is specific to the Y1-
receptor since no binding was observed either to MCF-7 cells in the presence of free 
antagonist BIBP3226 or when conducting the experiment with MDA cells lacking the 
receptor. Both agonist- and antagonist-modified QDs exhibited specific cell binding, 
but there was a tremendous difference with respect to cellular uptake. Only agonist-
modified QDs were internalized. The cells formed vesicular structures containing 
agonist-modified QDs which indicate that the nanoparticles had been transported into 
the cells (fig. 2). The internalization of these particles was corroborated by confocal 
z-stack images. To further elucidate the location of agonist-modified particles after 
their interaction with cells, images representing optical sections through the cells 
were taken from MCF-7 cells after incubation with [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-
pNPY-QDs. As depicted in fig. 5, strong fluorescence due to the QDs can be found 
throughout the cells, except for the cell nuclei. This supports the concept that the 
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particles were effectively delivered into the target cells. The cells show spots in the 
cytoplasm that are typical of endocytotic vesicles formed upon receptor-mediated 
endocytosis.  
0 µm 1.1 µm 2.1 µm 3.2 µm
4.3 µm 5.3 µm 6.4 µm 7.5 µm
 
Figure 5: CLSM investigation of agonist-modified QDs’ interactions with cells. The z-
stack images shows MCF-7 cells incubated with 10 nM of [Lys4(Nα-Acetyl-Cys), Arg6, 
Pro34]-pNPY-QDs. In every optical section, QD-fluorescence is located throughout 
the cells, except for the nuclei (scale bar = 20 µm). The numbers in µm indicate the 
distance of the focal plane to the surface of the cell culture plate. 
 
In the case of antagonist-modified particles, the fluorescence was strictly limited to 
the cell membrane, indicating that particles were located on the cell surfaces only 
(fig. 6).  
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0 µm 1.8 µm 3.5 µm 5.3 µm
7.1 µm 8.8 µm 10.6 µm
 
Figure 6: CLSM investigation of antagonist-modified QDs’ interactions with 
cells. The stack of images shows MCF-7 cells incubated with 10 nM of SH-BIBP-
QDs. In every optical section, QD-fluorescence is located on the cell surface only 
(scale bar = 20 µm). The numbers in µm indicate the distance of the focal plane to 
the surface of the cell culture plate. 
 
Similar results concerning binding and internalization were obtained when repeating 
the experiment with SK-N-MC cells, another Y1-receptor positive cell line derived 
from the central nervous system (SI fig. 4). This clearly demonstrates that the 
findings are neither dependent upon the cell type nor the receptor density (SK-N-MC 
cells – approx. 60,000 receptors/cell [21]; MCF-7 cells – approx. 300,000 
receptors/cell [21]). In summary, our results show that GPCRs can be used to target 
nanoparticles specifically either to the target cell’s surface or to its intracellular 
compartment by simply attaching an antagonist or an agonist, respectively, to the 
particle surface.  
After demonstrating that GPCRs can function as selective gateways, we investigated 
if tagged nanoparticles still exhibited a sufficiently high affinity towards their receptor. 
This is of concern for future in vivo applications, which demand that particles 
accumulate reliably at the target site in the presence of competing unspecific binding 
sites that may exist. Binding curves of QDs modified with the agonist [Lys4(Nα-Acetyl-
Cys), Arg6, Pro34]-pNPY (fig. 7A) and the antagonist SH-BIBP respectively (fig. 7B) 
were recorded for Y1-receptor positive MCF-7 cells using MDA cells as a negative 
Chapter 8 GPCR Targeted Nanoparticles 
 - 168 - 
control (for details of binding and displacement studies see SI methods). The 
resulting saturation of binding sites and the low non-specific binding indicate that the 
particles bind specifically to the receptor. Similar results were obtained for the other 
two agonistic peptides (SI fig. 5). When we calculated the concentrations at which 
50% of the binding sites are occupied (the dissociation constant, Kd), the values were 
approximately 21 nM for agonist-modified and approx. 30 nM for antagonist-modified 
QDs (SI tab. 1). These values reflect that the nanoparticles, even though their ligands 
were chemically altered, still possess a superb affinity for the receptor. To further 
confirm the specificity of the interaction with cells, we investigated the binding 
behavior of particles in a competitive binding assay with unbound Y1-receptor 
antagonist BIBP3226. As expected, both agonist- and antagonist-modified QDs can 
be displaced from the receptors 5 almost completely (fig. 7C and D). However, we 
found that very high amounts of BIBP3226 were needed to displace the 
nanoparticles from the receptor. For 1 nM agonist-modified particles, the inhibitory 
constant (IC50, reflecting the concentration at which BIBP3226 displaces 50% of the 
particles) ranged from 640 to 1550 µM (SI, fig. 5 and tab. 1). This is approx. 5 orders 
of magnitude higher than values usually obtained for the free agonist according to the 
literature [22]. The results were similarly striking for the antagonist-modified QDs. For 
the half-maximum displacement of 1 nM of antagonist-modified (i.e. BIBP3226-
modified) QDs, again a 5 order of magnitude excess of free BIBP3226 was needed.  
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Figure 7: Cell-binding and displacement curves for agonist- and antagonist 
modified QDs. (A, B). Binding curves of ‘agonistic’ [Lys4(Nα-Acetyl-Cys), Arg6, 
Pro34]-pNPY-QDs and ‘antagonistic’ SH-BIBP-QDs. For the determination of the total 
binding MCF-7 cells (Y1+) were used (filled circles) while MDA cells (Y1-) served as 
a control to assess non-specific binding (open circles). The resulting specific binding 
curve is indicative of receptor saturation beyond 100 nM for both species. (C, D) 
Displacement of [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-pNPY-QDs and SH-BIBP-QDs 
from MCF-7 cells by the Y1-receptor antagonist BIBP3226, determined by flow 
cytometry. At high concentrations of the competitive antagonist, both types of 
particles can be displaced from the receptor almost completely. Error bars, ± SEM 
(n = 3). 
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We hypothesize that such a tremendously high affinity of the agonist- and antagonist-
modified particles compared to the free antagonist is attributed to the fact that 
nanoparticles can bind to several receptors at a time, a phenomenon that is referred 
to as ‘multiligand binding’ [23-25]. This is strongly supported by other examples in the 
literature in which monovalent ligands were found to poorly displace multivalent 
particles or molecules subject to multiligand binding [25,26]. 
The results that we obtained have a number of significant implications for the delivery 
of nanoparticles to cells. GPCRs provide us with a tool that allows us to target a 
multitude of cells in an organism with exceptionally high specificity. Currently there 
are more than 800 receptors known for humans and approx. 1800 in rats and mice 
[27]. This suggests that, if we want to direct nanoparticles to a certain tissue, we only 
have to pick the appropriate GPCR for the respective tissue from a database [28], 
choose the appropriate ligand for this GPCR and tether it to the nanoparticles surface 
as an ‘address label’ - a “building block” strategy. In addition to high target specificity, 
a significant advantage of GPCR-targeting is that we can control the particles´ fate 
after binding to the cell surface: by choosing an agonist for the interaction with the 
receptor we open the gate into cells or by selecting an antagonistic ligand we leave it 
closed. This strategy improves upon other sophisticated approaches with antibodies 
that also demonstrate highly specific binding [29], but are associated with accepting 
the subsequent fate of the particle as it is. In the future our technique could lead to 
applications in which antagonistic nanoparticles first identify cells inside a tissue or 
an organism and then agonistic particles are used for therapeutic purposes to deliver 
nanoparticles via the same target structure into the same cell type.  
In addition, our results have implications beyond the fact that we can reproducibly 
target particles either to the cytosol or the cell surface. The findings reported here 
may represent the first step to granting us access to a toolbox currently only 
employed by viruses that allows them to achieve outstanding target cell specificity. 
By binding to several different cell surface proteins at the same time, viruses 
unequivocally identify their target cell and make use of a single additional interaction 
to trigger cell internalization [30,31]. If we would like to mimic this strategy using 
nanoparticles, we would have to design multiligand binding particles that allow for 
target identification by tagging the cell surface in a first step followed by triggering cell 
entry. Our results have shown that GPCRs would be ideal target candidates. GPCR 
binding nanoparticles can thus be used as a tool to
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of particles in vivo. Simultaneously they provide us with a mechanism for a multitude 
of biotechnological applications, such as receptor mediated siRNA delivery into cells 
(for which we recently developed a new type of carrier [32]). While more research is 
necessary to further tailor the targeting and uptake events for specific tissues, the 
remarkable biological and pharmaceutical implications of such “dual-action” 
nanoparticles indicates this is an exciting line of future inquiry with broad-ranging 
applications. 
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Transmission electron microscopy (TEM) investigation of ligand-conjugated QDs 
The QD-bioconjugates were imaged using a Philips CM12 transmission electron 
microscope (FEI Co., Eindhoven, The Netherlands). Therefore, 5 µl of a 30 nM 
aqueous dilution of the sample were transferred onto a carbon-coated, glow-
discarged copper grid. Excess liquid was removed by blotting with filter paper. A 
typical micrograph is shown in Supplementary Information (SI) fig. 1. 
 
Synthesis of [Lys4(Nα-Acetyl-Cys)]- (1), [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]- (2) and  
[Lys4(Nα-Acetyl-Cys), Ahx9-17]-pNPY (3) 
Solid-phase peptide-chain assembly was performed on the synthesizer Syro-1 
(MultiSynTech, Witten, Germany) by using the Rink amide 4-methylbenzhydrylamine 
resin (loading: 0.6 mmol·g−1). All amino acids were Nα-(9-fluorenylmethoxycarbonyl, 
Fmoc)-protected, with the exception of Tyr1 that was introduced as Nα-(tert-butyloxy-
carbonyl, Boc)-amino acid. The following side-chain protecting groups were used: 4-
methyltrityl (Mtt) for Lys; tert-butyl for Asp, Glu, Ser, Thr and Tyr; trityl for Asn, Gln, 
Cys and His; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg. Double 
couplings (2 x 40 min) were performed with amino acids (5 equivalents) activated in 
situ with O-(1-benzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU, 5 equiv.), 1-hydroxybenzotriazole (HOBt, 5 equiv.) and N,N- diisopropyl-
ethylamine (DIPEA, 10 equiv.). Fmoc cleavage was accomplished by first treating 
with 40% piperidine in N,N-dimethylformamide (DMF)/Nmethylpyrrolidone (NMP) (4:1 
vol./vol.) for 3 min, followed by a second treatment with 20% piperidine for 10 min. 
After coupling of Boc-Tyr1(tert-butyl) the Mtt group was selectively removed by 
washing (30 x 1 min) the peptidyl-resins with trifluoroacetic acid (TFA) / triisopropyl-
silane (TIS) / dichloromethane (DCM) (1:1:98 vol./vol.), followed by washings with 
DCM, DIPEA (1.2 equiv. in NMP), and DMF. The free Lys4 side chain was acylated 
by performing a first coupling overnight with Fmoc-Cys(trityl)-OH / N,N’-dicyclohexyl-
carbodiimide / HOBt/DIPEA (6:6:6:3 equiv.), followed by a second coupling with 
Fmoc-Cys(trityl)-OH / HBTU / HOBt / DIPEA (5:5:5:10 equiv.) for two hours. After 
removal of the Fmoc group with 20% piperidine in DMF (2 x 25 min) the free α-amino 
group of Cys(trityl) was acetylated by using acetic anhydride / DIPEA (10:0.1 equiv.) 
for one hour. The completed peptides were cleaved from the resin with simultaneous 
side-chain deprotection by a three-hour treatment with the mixture TFA / TIS / 
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ethanedithiol / water (90:4:3:3 vol./vol.). The crude peptides were recovered by 
precipitation from ice-cold diethylether and centrifugation at 3 °C for 8 min. After 
several ether-washing / centrifugation cycles, the crude peptides were purified by 
preparative RP-HPLC (Agilent equipment) using the Phenomenex (Aschaffenburg, 
Germany) C18(2) column Luna (10 µm, 100 Å, 21.2 mm x 250 mm) and the following 
binary elution system: (A) 0.004% (vol./vol.) TFA in water and (B) acetonitrile. The 
peptide purity was > 90%, as determined by analytical RP-HPLC (L-6200A Intelligent 
Pump from Merck, HP detector Series 1050 from Agilent) with the Phenomenex 
C18(2) column Luna (3 µm, 100 Å, 4.60 mm x 150 mm) and the following elution 
system: (A) 0.012% (vol./vol.) TFA in water and (B) 0.01% (vol./vol.) TFA in 
acetonitrile. Analytical RPHPLC: tR of 17 min. for 1, 17.5 min. for 2, and 15 min. for 3 
(gradient: 10% B for 3 min., 10-70% B over 40 min.; UV-detection at 220 nm; flow of 
1 ml/min). MALDI-TOF-MS (Future GSG spectrometer, Bruchsal, Germany): 
MWcalcd./MWfound (Da): 4398.92/4400 for 1, 4409.01 / 4410 for 2, and 3614.18 / 
3614 for 3. 
 
Purification of nanoparticles after ligand coupling by gel filtration chromatography 
Gel filtration was conducted using a Sephacryl S-100 resin packed into a Tricorn 
10/300 column (GE Healthcare, Chalfont St. Giles, UK). The column was coupled to 
standard HPLC equipment (Shimadzu, Duisburg, Germany) operating in the isocratic 
mode with the respective eluent and a flow rate of 0.5 ml/min. A UV-detector (SPD-
10 AV, Shimadzu) operating at 635 nm was used for the determination of the QD 
concentrations. The peptides were detected by a fluorescence detector (RF-551) with 
excitation at 275 nm and emission at 310 nm. All QD concentrations were deter-
mined using the UV-detector signal together with a standard curve obtained from the 
areas under the curve for different QD concentrations. A typical chromatogram is 
show in SI Figure 2. The fluorescence (area under curve) of the peptides occurring at 
18 minutes, which corresponds to the conjugated fraction, was obtained after 
reaction and compared to the background measured for the activated QDs, 
normalized respective to the QD-concentrations obtained by UV-detection. The 
strong increase in the peak area of the fluorescence signal after bioconjugation to the 
particles indicated the successful linkage. 
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Synthesis of BIBP3226 and SH-BIBP 
BIBP3226 and SH-BIBP were obtained by conversion of the NG-Boc-O-tert-butyl 
protected analog of BIBP3226 (SI fig. 3) as published by Keller et al. (J. Med. Chem. 
51, 8168-81724 (2008)). BIBP3226 was obtained by deprotection in DCM / TFA (1:1) 
at room temperature for 3 h. SH-BIBP was synthesized under Ar atmosphere at room 
temperature using degassed solvents. Mass analysis results were obtained by 
electrospray ionization mass spectrometry (ESI-MS). First, 0.310 mmol of 6-acetyl-
thiohexanoic acid was activated with 0.357 mmol carbonyldiimidazole in 3 ml DCM 
for 30 min. Then, 0.238 mmol of 1 and 0.119 mmol of triethylamine were added to 
the solution and left to react for 12 h. After solvent reduction under reduced pressure, 
2 was purified by column chromatography using a preparative silica column and 
DCM / EE (5-3:1) as eluent. After solvent reduction, 2 was deprotected in 5 ml of 
DCM / TFA (2:3) with addition of 50 µl of water for 2 h. After removing DCM and TFA 
under reduced pressure and re-suspension in 25 ml water, 3 was obtained after 
freeze-drying (MH+=646.3). The acetyl group of 3 was hydrolyzed by 1 N aqueous 
NaOH for 30 min at room temperature. After purification by preparative HPLC and 
the removal of the eluent under reduced pressure, Thiol-BIBP (4) was obtained. The 
product was lyophilized after resuspension in water (MH+=604.3). For more detailed 
information on the HPLC method see Keller et al. (J. Med. Chem. 51, 8168-8172 
(2008)). 
 
Binding and uptake of ligand-modified nanoparticles using NPY Y1-receptor positive  
SK-N-MC neuroblastoma cells 
The results of the confocal fluorescence microscopy studies using the human 
neuroblastoma cell line SK-N-MC were similar to those for the MCF-7 cells. As 
shown in SI fig. 4, the [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-pNPY-QDs strongly 
associate with the cells (SI fig. 4A). The QDs can be found on the cell surfaces as 
well as internalized inside vesicular structures. Since the number of Y1-receptors on 
SK-N-MC cells is lower as compared to MCF-7 cells, the internalized particles are 
even more clearly visible, since the fluorescence signal here is less dominated by the 
particles located near the cell surface. In contrast, the SH-BIBP-QDs can mainly be 
found on the cell surface and no internalization is visible (SI fig. 4B). The pictures (SI 
fig. 4C) and (SI fig. 4D) show the corresponding brightfield images. 
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Figure 1: TEM micrograph of peptide-modified QDs. QDs were conjugated with 
[Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-pNPY and imaged after purification. The particles 
are monodisperse, evenly distributed and show no sign of aggregation. The QD-
cores are visible by TEM, due to their inherent contrast, while the polymer coating 
and the peptide show no contrast. 
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Figure 2: Chromatogram recorded during quantum dot purification after bio-
conjugation. Chromatogram, showing the peptide fluorescence signal, of QDs after 
activation with sulfo-SMCC (solid line) and after incubation with [Lys4(Nα-Acetyl-Cys), 
Arg6, Pro34]-pNPY(dashed line), normalized to the QD-concentration obtained by the 
UV-signal (not shown). The first peak corresponds to the size-excluded fraction 
(QDs), the second peak is due to the excess of non-bound peptide. The strong 
increase of the fluorescence signal after bioconjugation shows the success of the 
reaction. 
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Figure 3: Synthesis scheme of thiolated-BIBP (4). Starting from the NG-Boc-O-
tert-butyl protected analog of BIBP3226 (1), the guanidino group was acylated with 6- 
acetylthiohexanoic acid after activation of the carboxylic acid group using 
carbodiimidazole (CDI). After complete deprotection by TFA and NaOH, 4 was 
obtained. 
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Figure 4: Selective binding and uptake of QDs by SK-N-MC cells. Confocal 
fluorescence micrographs showing the interaction of Y1-receptor positive SK-N-MC 
cells with 10 nM of agonist-modified [Lys4(Nα-Acetyl-Cys), Arg6, Pro34]-pNPY-QDs 
and antagonist-modified SH-BIBP-QDs. Both species associate with the cells. The 
fluorescence images (upper row) confirm that antagonist-modified QDs are only 
visible on the cell surfaces, whereas the agonist-modified particles are internalized 
into the cells in vesicular structures (scale bars = 20 µm). 
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Figure 5: Overview over the binding and displacement curves for the three 
different types of agonist-modified QDs. (A) Specific binding curves normalized to 
the respective maximum binding. The binding behavior of the three peptides 
conjugated to the QDs is similar, each reaching saturation at approx. 100 nM. (B) 
Displacement curves were obtained by displacement of the QDs (1 nM) from MCF-7 
cells by BIBP3226. All particles could be displaced from the receptors almost 
completely by millimolar amounts of the antagonist. (error bars represent SEM for 
n = 3). 
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 Kd  ± SD 
 [nM] 
IC50 ± SD 
[µM] 
 
[Lys4(Nα-Acetyl-Cys)]-pNPY-
QDs 
 
6.92 ± 2.10 641 ± 61.1 
 
[Lys4(Nα-Acetyl-Cys), Arg6, 
Pro34]-pNPY-QDs 
 
12.3 ± 2.60 696 ± 34.6 
 
[Lys4(Nα-Acetyl-Cys), Ahx9-17]-
pNPY-QDs 
 
20.7 ± 6.49 1555 ± 127 
 
SH-BIBP-QDs 
 
31.3 ± 5.66 822 ± 53.8 
 
Table 1: Comparison of binding- and inhibitory constants of different 
multiligand QDs and the monovalent antagonist BIBP3226. Dissociation 
constants (Kd) of the three agonist-modified QDs and SH-BIBP antagonist-modified 
QDs obtained from the binding curves and half maximal inhibitory concentrations 
(IC50) of BIBP3226 (using MCF-7 cells) determined in displacement studies. 
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Abstract 
The targeting of G-protein coupled receptors (GPCRs) represents a promising 
strategy for addressing nanoparticles to most types of cells in the human organism, 
since this receptor family is the largest, with over 800 different specific receptor 
subtypes. Being able to access these receptors for the delivery of nanoparticles 
carrying active substances directly to as well as into the target cells would 
substantially increase diagnostic and therapeutic possibilities. 
It has been shown that the neuropeptide Y (NPY) Y1-receptor can be selectively and 
very effectively targeted with nanoparticles that bind to the receptor-positive cells in 
high affinity. Moreover, the receptor mediated uptake of nanoparticles carries 
agonists for the receptor on the surface. However, there is almost no knowledge 
about the mechanism of this internalization of nanoparticles today. In this study, the 
uptake of quantum dots (QDs) modified with a peptidic Y1-receptor agonist was 
analyzed using endosome markers and was compared to the uptake of the natural 
dye-labeled ligand. In addition, the specific uptake was compared to non-specific 
uptake of QDs modified with poly(ethyleneimine). 
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Introduction 
G-protein coupled receptors are the largest class of receptors in humans, with 
approx. 800 different subtypes and represent the most important class of targets in 
pharmacotherapy [1-3]. Besides their physiological function, i.e. signal transduction 
and mediation of sensoric impressions [4], these receptors also mediate specific 
interactions with nanoparticles. [5]. 
Neuropeptide Y (NPY) Y1-receptors play an important role in signal transduction in 
the central nervous system and mediate effects like vasoconstriction and anxiolysis 
[6]. Moreover, these receptors are overexpressed in cancerous tissues, such as 
breast carcinoma and neuroblastoma [7-10], which renders these receptors 
interesting candidates for drug targeting. Y1-receptors have been shown to rapidly 
internalize after agonist binding [11,12]. However, besides the internalization of 
natural ligands, these receptors have also been proven to mediate strong and very 
specific interactions between cells expressing the receptor and nanoparticles, more 
precisely quantum dots (QDs), which carry ligands for the receptor on their surface. 
Via these GPCRs, selective uptake of the QDs was observed (see chapter 8). 
However, the mechanism of internalization of the nanoparticles by these receptors 
has not been elucidated so far. Thus, it is not clear whether the particles are 
internalized by the route commonly taken by GPCRs after activation by their natural 
ligands, clathrin-mediated endocytosis [13,14]. It is possible that although this binding 
is highly receptor-specific, the appearance of the uptake could be via a route other 
than receptor-mediated endocytosis. To make a step towards the mechanism of the 
particle uptake by GPCRs, in this study the internalization of QDs modified with an 
agonistic peptide-ligand for the Y1-receptor was investigated using dye-labeled 
transferrin, a marker for clathrin-mediated endocytosis [15]. The uptake of the 
peptide-modified agonistic QDs also was compared to the uptake of dye-labeled free 
ligand and QDs modified with a custom-designed poly(ethyleneimine) (PEI). While 
the former allows for comparison with the physiological uptake, the latter is typically 
bound and internalized non-specifically and thus is frequently used for nucleic acid 
delivery [16-18]. Thus, QDs modified with PEI represent a model for non-specific 
particle uptake. Using these tools, we were hopeful that new insights into the cellular 
delivery of nanoparticles mediated by GPCRs could be obtained. 
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Materials and methods 
6-acetylthiohexanoic acid (97%), 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride (DMTMM) (purum, ≥96%), 5,5′-dithiobis(2-nitrobenzoic 
acid) (DTNB) (99%), 2-mercaptoethanol (≥99%), 3-mercaptopropionic acid (≥99%), 
ninhydrin reagent (2% solution), poly(ethyleneimine) 50% solution (average 
molecular weight 1200 Da) (PEI) and sulfosuccinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (sulfo-SMCC) were obtained from Sigma-Aldrich (St. 
Louis, MO). S0536-NPY was synthesized as published before [19] and was a 
generous gift of Prof. Buschauer, Department of Medicinal Chemistry, University of 
Regensburg. QDs (Qdot 655 IT amino (PEG) quantum dot), SYTO 13 and Alexa fluor 
488 conjugated with human transferrin (Alexa488-Tf) were obtained from Invitrogen 
(Karlsruhe, Germany). Activation buffer consisted of 50 mM sodium tetraborate 
buffer, pH 7.2. Purification buffer I consisted of activation buffer, supplemented with 
150 mM sodium chloride and 10 mM ethylenediaminetetraacetic acid (EDTA) 
disodium salt. Conjugation buffer contained two parts of purification buffer I and one 
part of dimethylformamide (DMF), whereas purification buffer II contained 
dimethylsulfoxide (DMSO) instead of DMF and 0.01% sodium azide. The 
ultrafiltration units had a 100 kDa cut-off membrane (Amicon Ultra-4, Millipore, 
Billerica, MA). Incubation medium consisted of phenol red-free Leibovitz F-15 
Medium (Invitrogen), 1% of bovine serum albumin and 0.01% of Bacitracin 
(Invitrogen). All other cell-culture media as well as fetal calf serum (FCS) were 
obtained from Sigma-Aldrich. 
 
Peptide synthesis 
The peptidic Y1-receptor agonist [Lys4(αN-Acetyl-Cys), Arg6, Pro34]-pNPY was 
synthesized by standard automated solid phase synthesis and exhibited the 
sequence of the porcine neuropeptide Y (pNPY), with two amino acid exchanges in 
position 6 and 34 by Arg and Pro [20] and an additional cysteine side-chain in 
position 4 for the bioconjugation with the QDs. The sequence of the peptide was H-
YPSK(Ac-N-C)PRNPGEDAPAEDLARYYSALRHYINLITRPRY-NH2. The mass was 
confirmed by MALDI-Tof using α-cyano-4-hydroxycinnamic acid (HCA) matrix 
(calculated mass: 4409 Da; found mass: 4412 Da). For a detailed synthesis protocol 
see [21].  
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Synthesis of thiol-modified poly(ethylene imine) (SH-PEI) 
The water of the PEI solution was removed by distillation with ethanol. For the 
reaction, 0.8 mmol of polymer dissolved in ethanol was reacted with 1.6 mmol of 6-
acetylthiohexanoic acid and 6.4 mmol of DMTMM for 24 h at 40 °C. The solvent was 
removed under reduced pressure and the residue was dissolved in 0.1 N NaOH. 
After 1 h of stirring, the polymer was purified by a gravity PD-10 desalting column 
containing Sephadex G-25 (GE Healthcare, Chalfont St. Giles, UK), using 50 mM 
phosphate buffer at pH 7.0 as mobile phase. At every 0.5 ml, fractions were collected 
and analyzed for PEI and thiol content. The amount of PEI was determined by using 
the ninhydrin reaction [22]. The colored product was determined spectro-
photometrically by measuring the absorbance at 570 nm and using unmodified PEI 
as the standard substance. Samples and the standard curve were prepared together 
by heating to 60 °C for 1h before measurement. The thiols were determined by 
means of the Ellman reagent. The reagent consisted of 50 mM sodium acetate and 2 
mM DTNB. For the measurement, 50 µl of this solution and 100 ml of Tris buffer pH 8 
were diluted with 849 ml of water. 10 ml of the sample was added and the sample 
was measured spectro-photometrically detecting the emerging thionitrobenzoic acid 
at 417 nm. A standard curve was obtained using mercaptopropionic acid. All UV 
absorbance measurements were recorded using an Uvikon 941 (Kontron 
Instruments, UK) and 10 cm polystyrol cuvettes. 
  
Conjugation of SH-PEI and [Lys4(αN-Acetyl-Cys)]- pNPY to quantum dots 
1 nmol of the QDs was transferred into 200 µl of activation buffer by buffer exchange 
using ultrafiltration. The QDs were subsequently activated using a 500-fold molar 
excess of sulfo-SMCC dissolved in activation buffer to yield a final volume of 250 µl. 
After 30 mins of gentle shaking at room temperature, the activated QDs were purified 
by gel filtration chromatography (see below) using purification buffer I as eluent.  
After buffer exchange by conjugation, buffer by ultrafiltration and concentration to a 
volume of 100 µl, the QDs were incubated with a 30 fold excess of [Lys4(αN-Acetyl-
Cys), Arg6, Pro34]-pNPY or of the SH-PEI for 12 h at 4° C. Thereafter, a 100-fold 
molar excess of 2-mercaptoethanol was added to quench unreacted maleimides and 
after 30 mins the bioconjugate was purified by GFC using purification buffer II. 
Subsequently, the bioconjugate was concentrated by ultrafiltration to a final 
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concentration of 3 µM and used for the biological studies. QDs covalently linked to 
[Lys4(αN-Acetyl-Cys), Arg6, Pro34]-pNPY or to SH-PEI are denoted NPY-QDs and 
PEI-QDs, respectively. 
 
Gel filtration chromatography 
Gel filtration of the QDs was conducted using a Sephacryl S-100 resin packed into a 
Tricorn 10/300 column (GE Healthcare, Chalfont St. Giles, UK). The column was 
coupled to standard HPLC equipment (Shimadzu, Duisburg, Germany) operating in 
isocratic mode with the respective eluent and a flow rate of 0.5 ml/min. The peptides 
were detected by a fluorescence detector (RF-551) with an excitation at 275 nm and 
emission at 310 nm. All concentrations were determined using the UV-detector 
(SPD-10 AV, Shimadzu) operating at 635 nm and a standard curve of the QDs by 
determination of the areas under the curve of the particle fraction of the 
chromatograms. 
 
Cell culture 
The human breast cancer cell line MCF-7 and the human neuroblastoma cell line SK-
N-MC were grown in Minimum Essential Medium containing Earl’s salts (EMEM) and 
supplemented with 110 mg of pyruvate and 2.2 g of sodium bicarbonate per litre. The 
medium contained 5 and 10% of FCS for MCF-7 and SK-N-MC cells, respectively. 
The human breast cancer cell line MDA was maintained in McCoy’s 5A medium 
supplemented with 2.2 g sodium bicarbonate per litre and 10% of FCS. For 
microscopic investigations, 5000 cells were seeded into 8-well µ slides (Ibidi, Munich, 
Germany) one day before being placed in the corresponding medium. MCF-7 cells 
were grown with the addition of 1 nM estradiol to increase the Y1-receptor density 
[23].  
 
Confocal laser scanning microscopy 
All investigations were carried out in incubation medium at 37 °C. The samples were 
imaged using a Zeiss Axiovert 200M inverted epifluorescence microscope coupled 
with an LSM 510 laser scanning device using Axiovert Software (Zeiss, Oberkochen, 
Germany) and using a Plan-Apochromat X40 water-immersion objective (NA 1.2). 
The QDs were excited using a 488 nm Ar laser and fluorescence was collected using 
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a 650 nm longpass filter. SYTO 13 nucleic acid stain was excited at 543 nm and 
fluorescence was collected using a 505-550 nm bandpass filter. QDs and SYTO 
were imaged together in multi-track mode. Alexa488-Tf was excited at 488 nm and 
fluorescence was collected using a 505-530 nm band pass filter and was imaged 
together with the QDs in single-track mode. S0536-NPY was excited at 633 nm and 
emission was filtered using a 650 nm longpass filter. 
 
 
Results and discussion 
In order to characterize the uptake of NPY-QDs by cells expressing the human NPY 
Y1-receptor, MCF-7 cells were counterstained and investigated by CLSM. In fig. 1, it 
can clearly be seen that the QDs, visualized in red, are bound to the cell membranes 
and are also entering the cells but cannot pass the nuclear membrane, since QDs 
cannot be found inside the nuclei, which were stained blue.  
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Figure 1: Cellular uptake of NPY-QDs. Cell nuclei of the MCF-7 cells are 
counterstained by SYTO 13 and visualized in blue. Binding of the QDs to the cell 
membranes and internalization is clearly visible. QDs do not enter the nuclei.  Scale 
bar: 20 µm. 
 
It is known that after agonist binding, GPCRs are internalized into cells via clatrhin 
coated pits and are subsequently present inside cells in endosomes [24]. Therefore, 
it was investigated whether QDs targeted towards these receptors take a similar 
route. Since transferrin is internalized into cells via receptor-mediated endocytosis as 
well, dye-labeled transferrin has become a frequently used marker of endosomes 
[15]. In fig. 2, green fluorescence is caused by Alexa488-Tf (green) which could be 
separated spectrally very well from the signal of the NPY-QDs which are shown in 
red. Both species are internalized into cells, since vesicular structures are visible 
throughout the cells, again with the exception of the nuclei which remain unstained. 
However, almost no colocalization of the NPY-QDs and Alexa488-Tf in endosomes 
was found which is indicated by the yellow color. Since transferrin and QDs seem to 
remain separated, this could suggest that the uptake of NPY-QDs would follow a 
route different from clathrin-mediated endocytosis. Moreover, the confocal 
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micrograph unambiguously proves that the NPY-QDs are taken up by the cells since 
they are localized on the same optical plane as the endosomes containing Alexa488-
Tf. 
 
Figure 2: NPY-QDs (red) and Alexa488-Tf labeled endosomes (green). Though 
partially present in intracellular vesicles, the QDs are not colocalized in endosomes 
together with the labeled transferrin. Scale bar: 20 µm. 
 
For further characterization of the cellular uptake mechanism, the uptake of NPY-
QDs was compared with that of the free ligand and QDs coated with PEI. This highly 
positively charged polymer is known for mediating cellular uptake without 
discriminating between cells. Therefore, this polymer has become a standard tool for 
cell transfect ion with nucleic acids [25]. While S0536-labeled pNPY has already 
been synthesized by Schneider et al. [19], the preparation of PEI-QDs had to be 
established. In order to bind the polymer to the QDs, PEI of a molecular weight of 
1200 Da was modified with a thiolcarboxylic acid to introduce a thiol group. The 
reaction scheme is depicted in figure 3. After amide coupling of the PEI with the S-
acetyl protected ε-mercaptohexanoic acid, mediated by the coupling reagent 
DMTMM, the acetyl group was removed by basic hydrolysis to yield SH-PEI. 
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Figure 3: Synthesis scheme of SH-PEI. PEI (1200 Da) is acylated by S-
acetylthiohexanoic acid mediated by the coupling reagent DMTMM. After this, 
deacetylation was obtained by basic hydrolysis to yield SH-PEI. 
 
Fig. 4 shows the chromatogram of SH-PEI in the last purification step. The 
chromatogram shows a main peak at 3.5 ml representing the PEI. While the amount 
of thiols is depicted by the blue circles, the PEI content is shown by the red squares. 
Correlating both signals results in approx. 1.3 thiol groups per PEI molecule on 
average.  By varying the ratio of 6-acetylthiohexanoic acid to PEI, the degree of thiol 
modification could be changed (not shown). The SH-PEI was subsequently bound to 
QDs. 
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Figure 4: Purification and characterization of SH-PEI by size exclusion 
chromatography. Fractions concerning the PEI-content ( 
 
 ) and the thiol-content  
( 
 
 ) were analyzed. The calculated number of thiols per PEI molecule was 1.3. 
 
To see whether the PEI-QDs prepared do indeed mediate non-specific cell binding 
and uptake, the interactions with the Y1-receptor free human breast cancer cell line 
MDA were compared to their interactions of the NPY-QDs with the cells. In fig. 5, the 
PEI-QDs show strong binding to the cell surfaces and are also partially internalized 
into the cells. In contrast, no non-specific interactions of the NPY-QDs with the MDA 
cells can be seen.  
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Figure 5: Binding and internalization of non-specific PEI-QDs and Y1-receptor 
targeted NPY-QDs at Y1-receptor negative MDA cells. While the PEI-QDs are 
bound and internalized, the NPY-QDs specifically targeted towards Y1-receptors 
show no interaction with the cells. Scale bar: 20 µm. 
 
In fig. 6, the uptake of NPY-QDs by Y1-receptor positive MCF-7 cells is compared to 
the uptake of S0536-NPY and PEI-QDs. As for S0536-NPY, the NPY-QDs are found 
in vesicular structures inside the MCF-7 cells. However, the QDs seem to have 
accumulated at the cell membranes too while the S0536-NPY shows slightly lower 
concentration at the cell membranes. In contrast, the PEI-QDs are highly dispersed 
at the cell membranes, though diffuse fluorescence appears in the cytoplasm. Here, 
the tendency to form vesicular structures is lower than for the two GPCR-targeted 
species. This shows that the specific uptake of ligands and nanoparticles has a 
different appearance than non-specific uptake. When comparing PEI-QDs with NPY-
QDs, it was found that the intensity of the first species was tremendously higher than 
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the NPY-QDs. This is because PEI-QDs, in contrast to the NPY-QDs, can only bind 
to a limited number of receptors. 
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Figure 6: Comparison of the binding and internalization of NPY-QDs, S0536-
labeled pNPY and PEI-QDs by Y1-receptor positive MCF-7 cells. The Y1-receptor 
targeted QDs and the dye-labeled agonist S0536-pNPY show similar internalization 
behavior and are localized in vesicles. In contrast, the PEI-QDs are mainly localized 
on the cell membranes. Scale bar: 20 µm. 
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Similar findings were made when using SK-N-MC cells also expressing the Y1-
receptor (fig. 7). While the NPY-QDs are found inside intracellular vesicles, the PEI-
QDs are found in large amounts on the cell membranes. However, internalization 
seems to take place as well. Again, the intensity of the fluorescence when regarding 
the cells was much higher than for the NPY-QDs. 
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Figure 7:  Comparison of the binding and internalization of NPY-QDs and PEI-
QDs at Y1-receptor positive SK-N-MC cells. While the majority of the PEI-QDs 
stick to the cell membranes and only a few substances are internalized, the NPY-
QDs can be found inside the cells in higher amounts inside vesicular structures. 
Scale bar: 20 µm. 
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Summary and conclusion 
In summary, the specific uptake of QDs via NPY Y1-receptors was studied by CLSM 
using endosome markers and free dye-labeled ligand as well as QDs modified with a 
custom-designed PEI. It was found that after endocytosis, the QDs modified with the 
GPCR-ligand are localized inside cells but not together with transferrin, a commonly 
used endosome marker. However, the appearance of the endosomes derived from 
QDs internalized by Y1-receptors looks very similar to the ones obtained after uptake 
of the free dye-labeled agonist S0536-pNPY. These findings again make clear that 
endocytosis can occur in various forms, dependent upon the substance to be 
internalized. Since the pathway of internalization directly influences the fate of 
nanoparticles inside the cells, further investigations will be helpful to further elucidate 
the pathway of cellular uptake by GPCRs. 
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Summary 
Targeted delivery of nanoparticles to specific cells has great potential to optimize 
drug therapy. Through this method, drawbacks in contemporary drug therapy could 
be overcome. Active substances would no longer be distributed to all regions in the 
body and thus the side-effects and toxic reactions could be decreased significantly. 
Moreover, such a delivery of nanoparticles would highly support new therapy 
strategies which need to be directed to specific cells, like gene therapy of diseased 
cells [1,2]. Though the idea of drug targeting has been existing for more than 100 
years [3] and though promising nanoparticulate drug carriers have been developed 
[4,5], still the question has to be solved how to deliver these particles effectively to 
specific target cells.  
For the investigation of the delivery of nanoparticles to specific kinds of cells, 
quantum dots (QDs), semiconductor nanocrystals, were reported to be promising 
tracers. QDs offer small and well-defined sizes and outstanding fluorescence 
properties. Due to these properties numerous studies enlightened the more or less 
specific delivery of QDs to cells by different cellular targets. In this context, the 
receptor-mediated endocytosis by distinct cell surface receptors was the most 
promising pathway for the delivery of nanoparticles into specific cells (chapter 1).  
However, the largest class of receptors in the human genome [6], the G-protein 
coupled receptors (GPCRs), has only barely been investigated for their potential for 
being a specific portal into specific cells. Having access to this class of receptors for 
nanoparticle targeting would substantially increase the number of possible targets. 
Therefore, the main goal of this thesis was the development of ligand-modified QDs 
targeted to cells expressing a specific GPCR, the human neuropeptide Y (NPY) Y1-
receptor which served as model receptor the class of GPCRs (chapter 2).  
For this purpose, practical protocols for the synthesis of QDs were developed, based 
on their fabrication in non-coordinating and coordinating solvents. It turned out that 
QDs synthesized in the latter exhibited higher fluorescence quantum yields, which 
increases the sensitivity for their detection in biological studies (chapter 3). 
In order to use these tracers as model colloids in biological systems, it was 
necessary to modify the particle surfaces to render the particles water-soluble. The 
investigations showed that introducing poly(ethylene glycol) (PEG) in the coating 
yielded highly stable QD-dispersions. A very convenient coating strategy was to use 
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PEG-modified phosphatidylethanolamines (PEG-PEs), as besides simple preparation 
of PEG-PE-QDs, the functionalization of the particles is very flexible, as PEG-PEs 
are available with numerous functional groups (chapter 4). 
Having established the fabrication of stable PEGylated QDs, the exact 
characterization of the size-distribution of QDs for biological applications was of 
major interest, since the sizes of nanoparticles substantially influence their 
interactions with biological systems [7]. For this purpose, asymmetrical flow field-flow 
fractionation (AF4) was used. With this technique, a robust method for the separation 
of QDs as well as size-analysis was available. Moreover, for the first time, an 
estimation of the masses of QDs was presented, showing that QDs had molar 
masses of 300 kDa and higher (chapter 5). 
The as-developed QDs subsequently had to prove their potential for use in cellular 
uptake studies in order to be an adequate model nanoparticle system. After 
microinjection it was found that the QDs could easily be detected inside living cells. 
The non-specific interactions with cells were extremely low, which was a decisive 
prerequisite for their use in studying specific interactions with cells. Additionally, the 
cytotoxicity of QDs was investigated, with the result that the toxic effects of the QDs 
were of minor significance when using the particles in concentrations up to 500 nM 
(chapter 6). 
In order to explore whether QDs can be delivered into specific cells as model 
nanoparticles, the particles were modified with agonists or an antagonist of the 
human neuropeptide Y (NPY) Y1-receptor. Interestingly, the particles showed 
extremely high affinity towards cells expressing the receptor, which was 5 orders of 
magnitude higher than the affinity of the free ligands. The nanoparticles were 
delivered into the cells by endocytosis when the ligand was an agonist. In the case of 
an antagonist, the particles remained on the cell surface. These findings successfully 
proved the enormous potential of GPCRs for targeted nanoparticles delivery (chapter 
8). 
The bioconjugation between the peptidic Y1-receptor ligand and the nanoparticles is 
a decisive step, since in this step the specific targeting properties are bestowed upon 
the nanoparticles. The bioconjugation reaction was optimized using PEG-PE micelles 
and different pH values and the success of the coupling reaction was unequivocally 
proven by gel filtration chromatography and mass spectrometry. Through this, the 
first step towards a drug delivery system was taken, since micelles have already 
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been described as drug delivery vehicles [8,9]. The Y1-receptor agonist-modified 
micelles exhibited specific delivery into the target cells by the GPCR (chapter 7). 
Finally, the mechanism of QD-internalization by Y1-receptor positive cells was 
investigated. It was found that there are several similarities between agonist-modified 
QDs and the free dye-labeled pNPY. Both were internalized and could be found 
inside intracellular vesicles. However, in contrast to the free ligand, the QDs were not 
colocalized with the endosome-marker transferrin. Comparison with non-specifically 
binding poly(ethyleneimine)-modified QDs (PEI-QDs) revealed that the specifically 
binding QDs are found inside the cells and yielded different characteristics in the 
fluorescence microscope (chapter 9). 
 
Conclusions 
In conclusion, this thesis has successfully demonstrated that GPCRs are far more 
than just important targets in drug therapy – they also bear high potential for the 
targeted delivery of nanoparticles into specific cells. The results showed how to build 
stable QD-based model colloids that can be used for cellular uptake studies. Using 
bioconjugates between QDs and ligands of the human NPY Y1-receptor, highly affine 
nanoparticle targeting and the delivery into cells expressing the GPCR were 
obtained. 
The results have several implications that must be considered in future 
investigations.  First of all, by introducing GPCRs into the field of nanoparticle 
targeting, a class of more than 800 candidates is accessible for specific targeting. 
Moreover, since the receptors discriminate between agonists and antagonists, it is 
possible to choose whether the particles are delivered into the cells for therapeutic 
purposes (agonist-conjugated nanoparticles) or whether they remain on the cell 
surfaces as diagnostic tag (antagonist-conjugated nanoparticles). The demonstrated 
multiligand-binding can be used for the combination of several different GPCR-
ligands on one particle. This would open up the possibility of creating nanoparticles 
that fit to a very distinct receptor-pattern and would increase the cell-type selectivity 
enormously. Multiligand binding could also create a new class of receptor ligands, for 
‘conventional’ therapeutic purposes, binding several orders of magnitude stronger 
than the ligands known up to now. 
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Abbreviations 
1H-NMR Proton nuclear magnetic resonance spectroscopy 
5HT 5-hydroxytryptamine 
AFM atomic force microscopy 
Alexa488-Tf Alexa Fluor 488-labeled human transferrin 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid 
ANG II angiotensin II 
AT angiotensin receptor 
BIBP3226 selective NPY Y1-receptor antagonist 
CCV clathrin coated vesicle 
Cd Cadmium 
CdO cadmium oxide 
CdSe cadmium selenide 
CHO chinese hamster ovary 
CHO chinese hamster ovary cell line 
CL-MUA-QDs MUA-QDs exhibiting a surface crosslinked with lysine 
CLSM confocal laser scanning microscopy 
CME clathrin mediated endocytosis 
CO2 carbon dioxide 
CPP cell penetrating peptide 
cryo-TEM Kryo-Transmissionselektronenmikroskopie 
Cys-NPY [Lys4(αN-Acetyl-Cys), Arg6, Pro34]-pNPY 
Da Dalton 
DCC N,N’-dicyclohexylcarbodiimide 
DHLA dihydrolipoic acid 
DLS dynamic light scattering 
DLS dynamic light scattering 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DMTMM 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride 
DNA desoxyribunucleic acid 
DTNB 5,5′-dithiobis(2-nitrobenzoic acid) 
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EDC 1-ethyl-3-3(3-dimethylaminopropyl) carbodiimide 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
EMEM minimum essential medium containing Earl’s salts 
EPR enanced permeability and retention 
erbB1 Epidermal growth factor subtype 
FACS fluorescence activated cell sorting 
FCS Fetal calf serum 
FR folate receptor 
FWHM full width at half maximum  
GFC gel filtration chromatography 
GPCR G-protein coupled receptor 
HDA hexadecylamine 
HEK human embryonic kidney 
Her2 human epidermal growth factor receptor 2 
HIV human immunodeficiency virus 
HIV TAT human immunodeficiency virus transactivator protein 
IL-2 interleukin-2 
K2CO3 potassium carbonate 
LDL low-density lipoprotein 
MALDI-ToF matrix assisted laser desorption/ionization time of flight mass 
spectrometry 
MCF-7 human breast cancer cell line 
MDA human breast cancer cell line 
MLS mitochondrial localization signal 
MMP matrix metalloprotease 
MRI magnetic resonance imaging 
MUA 11-mercaptoundecanoic acid 
MUA-QDs quantum dots hydrohilized by mercaptoundecanoic acid 
NGF nerve growth factor 
NHS N-hydroxysuccinimide 
NIR near infrared 
NLS nuclear localization signal 
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NMR nuclear magnetic resonance 
NPY neuropeptide Y 
OA oleic acid 
PEG poly(ethylene glycol) 
PEG polyethylene glycol 
PEG-PE PEGylated phosphatidylethanolamine 
PEG-PE-QDs quantum dots hydrophilized by PEG-PE 
PEI poly(ethyleneimine) 
PET positron emission tomography 
PL photoluminescence 
pNPY porcine neuropeptide Y 
PO-PEG phosphine oxide-modified PEG 
PO-PEG-QDs quantum dots hydrophilized by phosphine oxide-modified PEG 
PSMA prostate specific membrane antigen 
PTD protein transduction domain 
QD quantum dot 
RES reticulo endothelial system 
ROS reactive oxygen species 
S sulfur 
SERT serotonin transporter protein 
SH-PEI thiol-modified PEI 
SK-N-MC human neuroblastoma cell line 
SNAC serotonin-labeled CdSe nanocrystals  
SPECT single photon emission computerized tomography 
SPION superparamagnetic iron oxide nanoparticle 
sulfo-SMCC sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-
carboxylate 
SV40 simian virus 40 
TAMRA 5(6)-carboxytetramethylrhodamine 
TAMRA-PEG-PE 5(6)-carboxytetramethylrhodamine-labeled PEGylated 
phosphatidylethanolamine 
TEM transmission electron microscopy 
Tf  transferrin   
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TfR transferrin receptor 
THF tetrahydrofurane 
TOP trioctylphosphine 
TOPO trioctylphosphine oxide 
TOPS trioctylphosphine sulfide 
TOPSe trioctylphosphine selenide 
tris Tris(hydroxymethyl)aminomethane 
TRK receptor tyrosine kinase 
UV ultraviolett light or irradiation 
Zn zink 
ZnS zinc sulfide 
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